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 viii Abstract 
Abstract 
 
The establishment and maintenance of cell polarity constitutes the basis for the morphological and 
functional diversity of metazoan cells. Intracellular vesicle transport processes mediate the delivery 
of cell surface receptors, adhesion proteins and other components to the desired locales, in order to 
define the polarised higher eukaryotic nature of cells. Members of the Rab family of small GTPases 
thereby act as master regulators for the complex network of trafficking routes, as they specifically 
attach to intracellular membranes and recruit distinct effector proteins, including motor proteins, in 
order to facilitate directed transport along microtubule networks and actin tracks. The Rab11 GTPase 
is critical for exocytic and recycling pathways and has been shown before to recruit the processive 
actin motor protein myosin V (MyoV) to vesicle surfaces to drive specific cellular functions. 
Furthermore, there is growing evidence for a coupling of actin assembly by actin nucleation and 
elongation factors, and myosin motor activity in eukaryotic cells. However, the mechanisms for 
recruitment of actin nucleators and motor proteins to specific membrane compartments remain 
unclear. By a set of protein interaction studies, this thesis unravelled a direct physical interaction of 
the Spir actin nucleators and myosin V motors. The interaction was shown to be mediated by the 
MyoV globular tail domain (GTD) and a newly identified highly conserved sequence motif (GTBM) in 
the central Spir linker region and the crystal structure of the Spir-2-GTBM:MyoVa-GTD complex was 
solved. By means of fluorescence microscopy and FLIM-FRET analysis, the Spir/MyoV interaction was 
observed in living cells at vesicle membranes as well, proving its biological significance. Further, a 
regulatory mechanism was revealed in which the Spir-2 protein is able to bind to the back-folded, 
auto-inhibited MyoV protein and targets it from a cytoplasmic state towards vesicle surfaces. 
Spir proteins have been shown before to functionally overlap with Rab11 in exocytic and recycling 
pathways, although a direct Rab11/Spir interaction has never been revealed. The direct interaction of 
myosin V motors and Spir proteins identified here enables the formation of a tripartite 
Rab11:MyoV:Spir protein complex at vesicle surfaces in which the MyoV protein acts as a linker 
between Rab11 and Spir, as was shown by in vitro interaction studies and fluorescence microscopy. 
The ternary complex architecture would explain how Rab11 vesicles support coordinated F-actin 
nucleation and myosin force generation for vesicle transport and tethering. Considering the large 
diversity of MyoV cooperation with Rab family members, the coordinated recruitment of actin 
nucleators and actin motors to vesicle surfaces could provide a common mechanism to control force 
generation and motility of vesicles and organelles in different cellular processes.  
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Zusammenfassung 
 
Zur Gewährleistung der ordentlichen Entwicklung einer Zelle und deren Funktionen, und um deren 
Überleben zu sichern, ist die Ausbildung und Aufrechterhaltung einer Zellpolarität entscheidend. 
Diese wird maßgeblich durch eine differentielle Zusammensetzung der Plasmamembran beeinflusst. 
Für die Bereitstellung bestimmter Zelloberflächen-Rezeptoren, Anheftungsproteine und weiterer 
Membranbestandteile an den jeweiligen Membranbereichen sind intrazelluläre, Membranvesikel-
getriebene Transportprozesse verantwortlich. Die kleinen Rab GTPasen werden als Hauptregulatoren 
der diversen, miteinander verknüpften Transportwege angesehen. Diese binden spezifisch an 
intrazelluläre Membranen und rekrutieren anschließend bestimmte Effektorproteine, wie 
beispielsweise Motorproteine, welche daraufhin den gerichteten Transport entlang von Mikrotubuli-
Netzwerken und Aktinfasern umsetzen. Das Rab11 Protein ist hierbei speziell für den nach außen 
gerichteten, exozytotischen, und den wieder verwendenden, rückführenden Transport wichtig. In 
vorherigen Studien wurde bereits gezeigt, dass das Rab11 Protein in der Lage ist, das kontinuierlich 
laufende Aktin-Motorprotein Myosin V (MyoV) an die Vesikeloberfläche zu ziehen um damit 
bestimmte Zellfunktionen zu regulieren. 
Des Weiteren gibt es vermehrt Hinweise darauf, dass an bestimmten Membrankompartimenten der 
Aufbau von Aktinfasern mittels Aktin-Nukleations- und Aktin-Polymerisierungs-Proteinen mit der 
Funktion von Motorproteinen verknüpft ist, wobei der genaue Mechanismus bisher unbekannt ist. 
Mit Hilfe einer Reihe von Protein-Interaktions-Studien gelang es nun hier, eine direkte, unmittelbare 
Bindung des Aktin-Nukleations-Proteins Spir-2 an das Myosin V Motorprotein aufzudecken. An dieser 
direkten Bindung ist zum einen die kompakt gefaltete Endstruktur des MyoV Proteins (globular tail 
domain, GTD) und zum anderen ein hierbei neu entdecktes, hoch konserviertes Sequenzmotiv 
(globular tail domain binding motif, GTBM) in der Mitte des Spir Proteins beteiligt. Zudem wurde die 
Kristallstruktur für diesen Proteinkomplex gelöst. Mittels Fluoreszenz-Mikroskopie und FLIM-FRET 
Untersuchungen konnte die Interaktion von Spir und MyoV Proteinen auch an Membranvesikeln 
lebender Zellen beobachtet werden, wodurch letztendlich eine biologische Bedeutung dieser 
Komplexbildung abzuleiten ist. Außerdem wurde eine regulatorische Funktion des Spir-2 Proteins 
entdeckt, indem es in der Lage ist, an ein in sich gefaltetes und dadurch selbst-inaktiviertes MyoV-
Dimer zu binden und es folglich aus dem Zytoplasma an die Oberfläche bestimmter Vesikel zu 
bringen.  
Obwohl eine direkte Bindung von Spir Proteinen an Rab11 GTPasen nie gezeigt wurde, gibt es einen 
funktionellen Zusammenhang beider Proteine im exozytotischen und rückführenden Transport. Die 
im Rahmen dieser Arbeit identifizierte direkte Bindung von Myosin V Motorproteinen an Spir 
 x Zusammenfassung 
Proteine ebnet allerdings den Weg für die Zusammensetzung eines aus drei Komponenten 
bestehenden Rab11:MyoV:Spir Proteinkomplex direkt an der Vesikeloberfläche. Wie mittels in vitro 
Interaktions-Studien und Fluoreszenz-Mikroskopie abgeleitet wurde, fungiert das MyoV Protein 
hierbei als ein verknüpfendes Protein, das die Funktionen von Rab11 und Spir miteinander verbindet. 
Der Aufbau dieses dreiteiligen Komplexes würde die koordinierte Bildung von Aktinfasern und 
Myosin-vermittelter Krafterzeugung erklären, die beide über das Rab11 Protein an die 
Vesikelmembran lokalisiert werden und die letztendlich den Vesikeltransport und die 
Vesikelanheftung steuern. Bedenkt man die Vielzahl möglicher Interaktionen von MyoV Proteinen 
und Rab GTPasen für unterschiedliche Zwecke in verschiedenen Bereichen der Zelle, könnte die 
genau koordinierte Verknüpfung von Aktin-Nukleatoren und Aktin-Motorproteinen an der 
Vesikeloberfläche einen möglichen generellen Mechanismus der Krafterzeugung an Vesikeln und 
anderen Zellorganellen darstellen, um folglich deren Bewegung während verschiedener zellulärer 
Prozesse zu steuern. 
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1 Introduction 
 
1.1 Cell polarisation as a prerequisite for cellular and organismic function 
A common feature of eukaryotic cells is their polarised morphological and functional organisation. 
The establishment of cellular polarity is indispensable for developmental processes, such as 
asymmetric oocyte division, formation of epithelial tissues and the development of the central 
nervous system. Highly polarised cells undergo complex cellular rearrangements during their 
development in order to generate cells in which different cellular regions with different properties 
mediate different functions. Neuronal cells, being one of the most polarised cell types in vertebrate 
organisms, require a proper formation of morphological and thus functional polarity during 
development in order to fulfil their purpose to propagate excitation signals from the environment to 
the central nervous system and back to executing organs for reflexes and fine-tuned reactions (Figure 
1A). Epithelial cells, lining the cavities and inner surfaces of organs and vessels in higher order 
organisms, demand a strong apical to basal polarity in order to fulfil their functions in secretion, 
absorption and transcellular transport, protection and sensing. Other cell types, such as immune 
cells, fibroblasts and, although not desired, cancer cells require fast and rather short-lasting 
polarisation processes as the base for cell migration (Figure 1B). 
 
 
Figure 1 | Highly polarised eukaryotic cells. (A) Neuronal cells show a highly polarised morphology, forming branched 
dendrites for input and axons for output processing. The specified neuronal cell structure is required to enable efficient 
signal transduction within the nervous system. (B) Migrating cells adopt a highly polarised morphology, forming a leading 
edge with membrane protrusions and a retracting trailing edge. Both, persistent (A) and short-lasting or adaptive (B) cell 
polarisation, require the polarised expression of cell surface proteins mediated by intracellular transport. Images are 
adapted and modified from Chavarría and Cárdenas, 2013 (1) and Le Clainche and Carlier, 2008 (2). 
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The establishment of cell polarity is largely mediated by changes in the composition of the plasma 
membrane, therefore affecting how cells might act or react on their environment. Differential 
abundance of plasma membrane receptors, such as growth factor receptors, allows that one region 
of the cell is able to sense and respond to external signals in a different way than other regions of the 
cell do. The timely and spatially regulated presence (and absence) of cell adhesion proteins, such as 
integrin receptors, at the cell surface allows directed cell migration. Here, the adhesion receptors are 
constantly internalised at former adhesion sites and transported towards newly established adhesion 
sites. The insulin dependent insertion of glucose transporters provides the base for efficient glucose 
uptake from the intestinal tract and also other nutrients get internalised for breakdown and energy 
consumption. As another example, melanin, a natural pigment required for skin and hair colouration, 
needs to be transported from the centre towards the periphery of specialised cells, the melanocytes, 
to finally reach keratinocytes in the outer epidermal regions. 
The cellular polarity is primarily mediated by intracellular transport processes in which highly 
sophisticated and highly regulated transport machineries deliver different cargoes, especially 
membrane vesicles, but also organelles, proteins, signalling peptides or RNAs to the demanding 
cellular regions. Different kinds of vesicle transport processes exist which are distinct in respect of 
contribution of specific proteins and co-factors, but which are also interconnected to generate a 
continuous flow of membrane trafficking inside the cell, thereby requiring complex regulatory 
mechanisms. Proteins considered for directed transport are newly synthesised at endoplasmatic 
reticulum (ER) associated ribosomes, delivered to the Golgi system where they undergo sorting for 
subsequent transport towards the desired target sites, for instance for exocytic transport through 
the trans-Golgi-network (TGN) towards the plasma membrane. Extracellular particles, nutrients, 
plasma membrane receptors but also other membrane components undergo endocytosis for 
sequential transport towards the cell interior and for subsequent degradation or reuse via recycling 
pathways. In this case, the endocytosed membrane components are sorted to specific membrane 
compartments, including the recycling endosome, from which they are transported back to the 
plasma membrane. 
The aspects of intracellular vesicle transport are widely described by the so called highways and local 
roads model (Figure 2) (3–6), which includes  a fast and long-range transport mediated by a complex 
and highly polarised microtubule network in order to quickly, but rather coarsely, transport cargo to 
distinct cellular regions. Arrived there, a more slowly, but also more flexible cargo trafficking system 
takes over which is mediated by the highly dynamic actin cytoskeleton that allows transport beyond 
the microtubule network to precisely reach outlying regions of the cell and to provide the delivery at 
the desired subcellular locales (7). 
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1.2 Motor proteins as force generators for vesicle transport 
Microtubule networks and actin filaments, spanning the cell with different characteristics, serve as 
tracks for specific motor proteins which act as molecular motors that produce the force necessary for 
cargo movement. Motor proteins are ATPases, i.e. they hydrolyse ATP to produce energy and force, 
and are thus commonly referred to as mechanoenzymes (8). There are three major groups of motor 
proteins. Kinesin motors move along microtubules towards their plus ends, whereas dynein motors 
move in the opposite direction towards the microtubule minus end. The third major group comprises 
the myosin motor proteins which generate forces on actin filaments. 
 
1.2.1 Kinesins and dyneins transport cargo along microtubule networks 
There two major groups of microtubule associated motor proteins which are responsible for cargo 
movement. The kinesin motors comprise a large group of motor proteins, devided into 14 classes so 
far identified, including ~40 human genes (9–12). Kinesin motors move unidirectionally towards the 
microtubule plus end (13) with few exceptions (kinesins-14, e.g. Drosophila Ncd (nonclaret 
disjunctional), move minus end directed and kinesins-13 might not move at all) (9, 12). Most kinesins 
are heavy chain dimers and function as processive motors, i.e. they move continuously along 
microtubules due to their two motor heads binding in a sequential fashion to the microtubule tracks, 
finally allowing efficient cargo transport. One of those processive kinesins is the family of classical 
kinesins (kinesins-1). Kinesin-1 family members are capable to move over long distances with a 
velocity of ~0.8 µ𝑚/𝑠. Considering a step size of 8 nm (distance between two consecutive tubulin 
dimers), the motor takes a step every 10 ms (14, 15). 
Dyneins belong to the AAA family of ATPases (ATPases Associated with Diverse Activities) and have a 
distinct evolutionary origin compared to kinesin and myosin motors (16). There are two classes of 
Figure 2 | Schematic overview on intracellular vesicle transport 
processes. Membrane vesicles (green) containing proteins, membrane 
components and other material, are transported along microtubules 
(blue) for fast and long-range transport towards the cell periphery 
(microtubule plus end) and also towards the cell centre (microtubule 
minus end), as indicated by arrows. F-actin tracks (orange) are located 
in more peripheral regions of the cell and mediate rather slow but 
more flexible transport due to the highly dynamic character of actin 
filaments, in order to reach more outlying subcellular regions. 
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dyneins: the axonemal dynein and the cytoplasmic dynein (17). The axonemal dynein is important for 
the sliding of microtubules within the axonemes of cilia and flagella and thus for the beating 
movement of those. The cytoplasmic dynein motors transport diverse cargo towards the microtubule 
minus end and are thus involved in different cellular functions (18–21). Cytoplasmic dynein 1 
transports cargo towards the cell centre and is essentially involved in mitosis, asymmetric cell 
division and developmental processes (22–31), whereas cytoplasmic dynein 2 has only transport 
functions within cilia (17). The cytoplasmic dynein comprises are large, 1.6 MDa motor complex 
formed by two heavy chains, including 6 AAA ATPase modules, and additional intermediate and light 
chains (16, 18). Not least owing their large size, dynein motor complexes are hard to handle in terms 
of recombinant expression and purification for subsequent analysis. In combination with the multiple 
ATPase domains within the heavy chain dimer the knowledge on the mechanism of dynein motors 
movement is limited compared to what is known for kinesin and myosin motors. Recent advances in 
the structural determination of dyneins allowed a better understanding of its motility mechanism, 
although it is still not completely clear how the specific minus end directed movement is mediated 
(17). A mechanism is proposed in which the two motor domains of the dynein dimer rather move in 
an inch-worm step manner, in which the leading head takes a step forward and is followed by the 
trailing head, in combination with other movement patterns, including eventual hand-over-hand 
steps, backward steps and steps with different step sizes (17, 32). By time-lapse fluorescence 
microscopy employing an intermediate chain-GFP fusion protein, the minus end directed movement 
velocities of cytoplasmic dynein have been measured ranging from ~1.4 to 2.8 µ𝑚/𝑠 (33). 
In many cell types the microtubule network is organised by the microtubule-organising centre 
(MTOC), located next to the nucleus, leading to a polarised microtubule network in that the minus 
ends are trapped within the MTOC in the cell centre and the plus ends protrude towards the cell 
periphery. Therefore, kinesins are generally considered as motors driving outward directed 
movement towards the cell cortex, whereas dyneins are inward-directed motors to transport cargo 
towards the cell centre (13, 18). 
 
1.2.2 Myosin actin motor proteins 
Myosin motor proteins are molecular motors that associate with actin filaments. Myosin motors are 
involved in a multitude of cellular and sub-cellular processes, including cell adhesion and migration, 
cell division and transport of cargo, including vesicles, to drive endocytic and exocytic trafficking 
events. Myosin motors are ATPases which hydrolyse ATP induced by actin filament binding in order 
to generate forces which are subsequently used to either modulate the actin cytoskeleton leading to 
morphological changes, or to move along actin tracks to transport cellular components. 
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The myosin superfamily consists of 35 classes (34) and 40 myosin genes have been identified in 
humans which are grouped into 13 classes. Myosin heavy chains are generally composed of three 
domains (35).  A large motor domain, also referred to as head, is usually located at the N-terminus of 
the protein, harbours the ATPase activity and binds to F-actin. The motor is followed by a neck region 
containing a variable number of IQ motifs required for binding of calmodulin light chains or 
calmodulin related light chains. The neck region is also termed lever arm because of its structural 
rigidity that is utilized for the power stroke in consequence of conformational changes of the motor 
domain during the ATP hydrolysis cycle (see below) (36–39). The C-terminal part of myosin heavy 
chains comprises the tail domain which represents the highest diversity across different myosin 
classes in order to ensure the diversity of subcellular myosin functions. 
The first myosin class discovered was the class II myosins, therefore named conventional myosins 
(40). All ensuing myosin classes discovered have been named accordingly unconventional myosins. 
The most prominent member of conventional myosins is the sarcomeric myosin II which is primarily 
expressed in the striated skeletal muscle and cardiac muscle (8).  Additionally, non-muscle myosin II 
and smooth muscle myosin II are found in vertebrates (8, 41). All class II myosins share the ability to 
form bipolar filaments of varying length wherein their motor heads are oriented in opposite 
directions to mediate the movement of complementary actin filaments towards each other. These 
characteristics enable sarcomeric myosin II to generate forces for muscle contraction by forming 
large bipolar filaments (8). Non-muscle myosin II forms shorter bipolar filaments and also generates 
forces on actin filaments, and is involved in cell adhesion and migration, protrusion formation and 
cytokinesis (8, 41–45). Myosin II family members also work to crosslink actin filaments (8). 
 
 
1.3 Class V myosin motor proteins 
One member of the unconventional myosin motors comprises the class V myosins. In contrast to 
class II myosins which exert forces on actin to rather induce structural alterations, class V myosins 
work as molecular motors to transport a diversity of cargo along actin filaments (35, 46). The ability 
of class V myosins to function as a transporting motor is achieved by their specific structural 
organisation (Figure 3). Class V myosin proteins contain an N-terminal motor domain, an elongated 
neck with six IQ motifs and the C-terminal tail which is further subdivided into a coiled-coil region 
that mediates the dimerisation of two myosin V heavy chains and a globular tail domain (GTD) at the 
very C-terminus which serves as the cargo binding domain (8, 47). Myosin V motors move towards 
the actin filaments barbed end (plus end) and its gliding velocities are in the order of a magnitude 
slower than that of kinesins or dyneins and have been reported roughly between 0.2 and 0.8 µ𝑚/
𝑠𝑠𝑠, although exceptions exist towards slower and faster movements (48–50). 
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Figure 3 | Structural organisation of class V myosins exemplified by the vertebrate myosin V (MyoV). (A) MyoV proteins 
contain an N-terminal motor domain (also called head) which binds to actin filaments and mediates the actin dependent 
ATPase activity. Six IQ motifs each bind calmodulin light chains and are also referred to as neck and forming the lever arm 
required for forward movement. The C-terminal tail is divided into a coiled-coil region which is periodically interrupted and 
required for heavy chain dimerisation, and the very C-terminal globular tail domain (GTD) which is the cargo binding 
domain, e.g. by binding to specific membrane receptors, and a major protein interaction site. (B) Schematic overview of the 
myosin Va and myosin Vb domain organisation. IQ, isoleucine/glutamine; GTD, globular tail domain; aa, amino acids. 
 
1.3.1 Vertebrate myosin V 
Class V myosins are conserved across almost all eukaryotic species (34). Three myosin V genes can be 
found in humans: MYO5A, MYO5B and MYO5C, encoding the myosin Va (MyoVa), myosin Vb 
(MyoVb) and myosin Vc (MyoVc) proteins, respectively (51–54). MyoVa and MyoVb proteins are 
expressed throughout the body (55) and can also be found in the brain, in contrast to myosin Vc (8, 
54, 56–59). In the brain, MyoVb is strongly expressed in the hippocampus (57), whereas MyoVa is 
more widely distributed to other brain regions (58). Within neuronal cells, both isoforms are localised 
to dendritic spines and the postsynaptic densities (57, 60–62). Myosin Vc is highly abundant in 
epithelial and glandular tissues, such as pancreas, prostate, mammary, stomach, colon and lung, and 
is mainly expressed in epithelial cells (54). Different splice variants of all three  MyoV isoforms exist, 
which are differentially expressed and which mediate specific interactions and functions (see below) 
(53, 55, 63–67). The vertebrate myosin Va protein has been first described in vitro to processively 
move along actin filaments, i.e. it moves processively as an isolated dimer on actin tracks in a step-
wise, hand-over-hand fashion (8, 48, 68, 69). This characteristic is suggested to be demanded for an 
efficient actin dependent transport of cargo in living cells (69, 70). The vertebrate MyoV feature of 
processive movement is in contrast to other myosin classes and is even not conserved within the 
myosin V family (myosin Vc and Drosphila myosin V; see below). 
 
The base for efficient MyoVa movement along F-actin is provided by its specific structural 
organisation and adaptation. The myosin Va heavy chain dimer binds to actin filaments by its motor 
domains forming a leading and a trailing head each time (Figure 4). At the point the trailing head 
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detaches from the filament, the leading head undergoes a slight conformational change, referred to 
as the power stroke, bringing the trailing head in front to become the new leading head, i.e. the 
motor takes one step (35, 71). The step size of myosin motors largely depends on the length of the 
neck region/lever arm. The two heads of the MyoVa dimer bind to the actin filament within a 
distance (step size) of 36 𝑛𝑚 which is facilitated by the elongated neck region containing six IQ 
motifs (69). In comparison, the step size of the conventional myosin II is only about 7 𝑛𝑚 due to the 
shorter neck (72). The large step size of myosin Va perfectly fits to the double helical actin filament 
organisation with consecutive actin monomers every 36 𝑛𝑚 on the short pitch helix. Thus, MyoVa is 
able to walk along actin filaments in a linear, step-like fashion instead of spiralling around the 
filament by following the long pitch helix, which would strongly impede transport through the 
cytoplasm (71, 73–77). Another structural feature facilitating continuous transport of cargo along 
actin tracks is the flexibility of the tail domain induced by interruptions in between the coiled-coil 
regions (78, 79). Finally, myosin Va proteins adapted to intracellular transport in terms of binding to 
specific cargoes in distinct ways therefore allowing to specifically switch between different cargoes 
for different transport routes. Although the cargo binding is mainly mediated by the globular tail 
domain which interacts with specific membrane associated proteins, such as Rab GTPases or their 
respective adaptors (80–84), the ability to select between different cargoes is further supported by 
other parts of the protein, for instance the flexible regions within the coiled-coil domains, and cell 
type specific alternative splicing events (66, 67, 80). The elongated neck of MyoVa also enables the 
motor to switch from one actin filament to another one allowing transport of cargo across a complex 
network of actin filaments or along branched filaments (6, 85). 
The kinetic properties of myosin Va motors are another rationale for its processive movement (Figure 
4). In general, there are four kinetic states of the motor domain influencing the actin binding capacity 
and strength. The motor alone or the motor binding ADP shows high affinity for F-actin, whereas the 
motor binding ADP and inorganic phosphate (Pi) or the motor binding ATP shows low affinity for F-
actin. As the hydrolysis of ATP to ADP and Pi and the subsequent release of Pi are rather fast 
processes,  the dissociation of ADP from the motor domain is considered to be the rate-limiting step 
in the ATPase cycle of the myosin V motor domain (86, 87). Considerng that, the motor domain is 
most of the cycle time tightly bound to the actin filament (it has a high duty ratio), which is reported 
to be demanded for processive movement along actin tracks (8, 35, 68). As a final requirement for 
the continuous movement, the ATP hydrolysis cycles within the two motor domains of the dimer 
need to be tightly regulated in a way, that only one of the motors can detach from the filament at a 
given time (68, 88–91). 
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Among the vertebrate class V myosins, myosin Vb is very similar to myosin Va in terms of structure 
and kinetics and is also reported to be a processive actin motor at single dimer level (48). The third 
vertebrate MyoV isoform, myosin Vc, is also similar in terms of structure (~50% overall identity to 
both MyoVa and MyoVb) (54), but has not been considered to be a processive motor as a single 
dimer. That is reasoned by the ADP release being not the rate-limiting step within the ATP hydrolysis 
cycle of myosin Vc (92, 93). Nevertheless, specific conditions are discussed in which myosin Vc might 
act as processive motor or that multiple MyoVc proteins assemble to a large motor complex to 
efficiently transport cargo (94). 
Figure 4 | Processive movement of MyoVa along 
actin filaments. (1) Both motor heads of the MyoVa 
dimer bind ADP and are strongly attached to the 
actin track. (2) Due to an intramolecular strain, ADP 
is released first from the trailing head. (3) The trailing 
head binds ATP and subsequently dissociates from 
the actin track. (4) The still attached leading head 
undergoes a conformational change (power stroke) 
to bring the former trailing head in front to become 
the new leading head. ATP bound to the new leading 
head gets hydrolysed to ADP and Pi and by a 
thermally driven search the new leading head finds a 
binding site. (5) The new leading head binds to actin 
inducing the fast release of Pi followed by strong 
binding of the head to the actin track. The cycle is 
completed and the MyoVa dimer moved 36 nm (step 
size) towards the F-actin barbed end. Adapted and 
modified from Hammer and Sellers, 2012 (35). 
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1.3.2 Insect and yeast class V myosin motors 
The Drosophila melanogaster myosin V (Dm-MyoV)  is a well-characterised example for class V 
myosin members significantly differing from vertebrate MyoVa and MyoVb (49). As it is true for 
vertebrate MyoVc, the structural organisation of Dm-MyoV is similar to that of vertebrate MyoV 
proteins, besides their distinct evolutionary origin. Although the velocity of Dm-MyoV is nearly 
identical to that of vertebrate MyoV processive motors, major alterations can be found in respect to 
the kinetic cycle. Dm-MyoV is considered to be a low duty ratio myosin, i.e. the motor is most of the 
time of the ATP hydrolysis cycle detached from F-actin (in contrast to vertebrate MyoV), which 
prevents its function as a processive motor at the single molecule level. To overcome these intrinsic 
deficits, multiple motor proteins cluster at the potential cargo to form a processive motor unit which 
ultimately drives the processive transport (49). 
In line with that, the two class V myosin members found in yeast, Myo2p and Myo4p, also act 
differently compared to vertebrate MyoV (95–97). Myo2p is structurally similar to vertebrate MyoV 
but does not function as a processive motor as a single dimeric molecule (95). Myo4p is even more 
different as it has a distinct structural organisation by forming a heterodimeric complex with the 
Swi5-dependent HO expression 3 protein (She3). Thus, Myo4p is a single-headed motor which does 
not move processively along F-actin alone but only by clustering into motor units, similar to Dm-
MyoV (95, 97). 
 
1.3.3 Regulation of myosin V activity and function 
The property of myosin V motor proteins being processive motors on actin tracks demand regulatory 
mechanisms that prevent its activity and movement on F-actin when not required, e.g. when not 
attached to cargo. The full-length myosin V motor exists in two distinct states. There is an auto-
inhibited, inactive state in which the MyoV dimer is back-folded in a way that its globular tail 
domains (GTD) bind to its motor domains (Figure 5) (98–100). In this state, the ATPase activity is 
inhibited and the motor binds only weakly to actin filaments (101, 102). Furthermore, the auto-
inhibited motor shows a cytoplasmic localisation and is therefore not attached to vesicles or other 
cargo (103). Activatory mechanisms release the inhibiting GTD/motor domain interactions and 
enable MyoV to adopt an open and extended conformation that resembles the active state at which 
it binds to cargo and F-actin. Increased concentrations of intracellular Ca2+ ions induce the MyoV 
dimer opening and activate the ATPase activity in vitro (104). At the same time, excessive Ca2+ 
concentrations ultimately lead to the dissociation of calmodulin light chains from the neck region 
thereby making it very flexible and thus not suited to drive the motor movement, which finally 
results in the inability of MyoVa to move on F-actin tracks (102, 105, 106). The binding of cargo to the 
globular tail domains might be ultimately the more physiologically relevant opening mechanism for 
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MyoV proteins. A perfect example in that respect is the melanophilin (MLPH or Slac-2a) protein (see 
below) which binds to the GTD of MyoVa, activates its ATPase activity and facilitates its movement 
on actin filaments in vitro (107, 108). Furthermore, it has been demonstrated very recently by means 
of electron microscopy, that MLPH is able to bind to the purified full-length back-folded MyoVa 
dimer and induces its opening into the extended conformation (109). 
 
 
 
Besides the regulated opening and activation mechanisms for myosin V dimers, myosin motors also 
undergo a fine-tuned regulation at their active state, at least in some cases. Although, generally, 
myosin V proteins (e.g. the mammalian MyoVa and MyoVb) are processive actin-based motors as 
dimeric molecules, it has been repeatedly observed that myosin V proteins cluster at the cargo 
surface to form motor units (110–112), in a similar way as was described for the Drosophila MyoV or 
mammalian MyoVc. This mechanistic behaviour increases the run length of the motors on actin 
tracks but also reduces their velocities compared to single dimeric molecules (113–120). This 
phenomenon might be explained by a hindrance due to asynchronous movement of the different 
motors (119) and by a load dependence of the motor kinetics, meaning that the cargo itself can 
influence the motors walking behaviour, at least to some extent (88, 121–123). Even the lipid 
composition of the vesicular cargo can influence the myosin movement (50). A more fluid vesicle 
nature thereby induces walking velocities higher than those at the single dimeric molecule level even 
measuring up to velocities of unloaded motors. Contrary, more gel-like vesicle compositions reduced 
the walking velocity. These findings are further supported by a mechanism in which the melanophilin 
protein has also been demonstrated to slow myosin Va movement (~4-fold), but, on the other hand, 
increases the length of processive walks (~2-fold) compared to the single dimeric motor. Altogether, 
the time the motor is attached to actin tracks is significantly increased, therefore facilitating 
melanosome trafficking in melanocytes (124). A suitable explanation for these observations might be 
Figure 5 | Model of the back-folded auto-inhibited state 
of the full-length myosin V motor. The two globular tail 
domains (GTD 1, 2) of the heavy chain dimer interact with 
the two motor domains to adopt a back-folded state in 
which the ATPase activity of the motor is inhibited and only 
weak F-actin binding is obtained. Increased concentrations 
of Ca2+ ions induce MyoV opening and ATPase activity of the 
motor but do not promote efficient processive movement 
due to the release of calmodulin from the neck region. 
Cargo binding to the GTDs induces MyoV unfolding, 
activates ATPase activity and allows efficient MyoV driven 
cargo transport. The MyoVa-GTD Rab11 binding site is 
highlighted in blue. The model was generated from a partial 
electron microscopy model (PDB ID 2DFS) (99), mutational 
analysis data on residues participating in the GTD/motor 
interactions (109) and the crystal structures of the MyoVb 
GTD (210). Image provided by Olena Pylypenko. 
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that electrostatic interactions between MLPH and actin filaments make MLPH to act as a tether for 
the myosin Va motor to stay longer attached to the actin tracks. 
Furthermore, an interconnectivity has been revealed in which motor proteins of different families 
cooperate to influence each other’s processivity (125). One example here is the cooperation of 
myosin V and kinesin family motors in the periphery-directed transport. In this process, myosin V 
performs a diffusional search along microtubules which in turn prolongs the run length of the kinesin 
motor attached to the same cargo. The same effects occur the other way around for myosin V 
motors on actin tracks. The proposed mechanism for a mutual run length enhancement might be 
explained (in similarity to the aforementioned MLPH effects on myosin Va processivity) by 
electrostatic interactions within the non-specific motor-cytoskeleton connections, which possibly 
have a tethering character that reduces the diffusion rate of the cytoskeleton specific motor. 
 
 
1.4 The Ras superfamily of small GTPases 
Kinesin, dynein and myosin motor proteins were introduced as the molecular motors that provide 
the forces required for movement of cargo on cytoskeletal tracks. The delivery of the highly diverse 
set of intracellular membrane vesicles to their respective destinations requires to be coordinated in a 
timely and spatially regulated manner. Members of the Rab family of small GTPases, being a family of 
the Ras superfamily of small GTPases, act here as master regulators as they control the membrane 
identity in order to provide the basis for a proper sequence of vesicle budding, movement and fusion 
by recruiting specific adaptor and effector proteins to intracellular membranes (126). 
 
1.4.1 The Ras superfamily includes five families of small GTPases 
The Ras superfamily comprises a very large and diverse set of small GTP binding proteins and is 
subdivided into five major families (127). The Rab (Ras-like in brain) family comprises the largest 
group of small GTPases (126, 127), next to the other four major families of Ras, Rho, Arf/Sar and Ran 
GTPases all of which serve different functions (127). Shortly, the Ras (Rat sarcoma) family members 
act as signalling molecules, integrating extracellular stimuli to activate intracellular signalling 
cascades (for instance the mitogen activated protein kinase cascade) to control gene transcription. 
The most prominent members of the Ras family might be the oncogenic Ras proteins. Members of 
the Rho (Ras homology) family are well known for their function in the regulation of actin dynamics 
(128, 129), cell polarity (130), cell cycle progression and gene expression (127). The Ran (Ras-like 
nuclear) family of small GTPases contains only one member in eukaryotic cells, except plants having 
multiple members, and are involved in nuclear transport across the nuclear envelop (127). The Arf 
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(ADP-ribosylation factor) family is the most divergent family of the Ras superfamily and is also 
involved in vesicle transport (131). 
The structural organisation that is shared by Ras superfamily small GTPases includes a large (~170 
amino acids) G domain which mediates the GTP binding and hydrolysis, and the interaction with 
different effectors (131, 132). The G domain itself contains five G-boxes (G1 to G5) with conserved 
residues. The switch I and switch II regions as part of the G domain are particularly involved in 
effector binding and undergo a conformational change upon GTP binding, especially Switch I located 
around G2 (133). 
 
1.4.2 The Ras cycle 
A common feature of most Ras superfamily small GTPases is their function as molecular switches by 
alternating between two distinct conformational states: the GTP bound active state and the GDP 
bound inactive state. The conversion between the two states is mediated by a Ras GDP-GTP cycle 
(Figure 6). GDP in the inactive Ras protein is exchanged by GTP under support of guanine nucleotide 
exchange factors (GEFs) which facilitate the release of GDP and favour fast GTP loading due to the 
high abundance of GTP in the cytoplasm (~1 mM) (126). GTPase activating proteins (GAPs) stimulate 
the hydrolysis of GTP to GDP and inorganic phosphate (Pi) within the GTPase which is necessary given 
the relatively poor intrinsic GTP hydrolysis activity of the GTPase itself (132, 134). This is also the 
reason for the term GTPase being not completely precise, as GTP hydrolysis needs the support by 
GAPs, and therefore the term small G-protein might be more suited for these kinds of proteins. 
However, to stay with the literature I will keep to the term small GTPase throughout this thesis. 
Generally, GEFs and GAPs are essential factors determining small GTPase activity in time and space 
as they integrate a wide range of cellular inputs coming from different signal sources, such as binding 
of signalling proteins, second messengers like cAMP, or structural proteins (134). 
 
Most family members of the Ras superfamily of small GTPases are specifically targeted to distinct 
subcellular compartments, such as membrane vesicles or larger organelles, either by membrane-
targeting protein sequences or by post-translational lipid modifications inserting into the membrane 
lipid bilayer (132). Members of the Ras, Rho and Rab families are typically modified via isoprenylation 
at the C-terminus. Farnesyl, geranylgeranyl or palmitoyl lipid groups are here covalently linked to 
cysteine residues of common sequence motifs, including the Caax (cysteine-aliphatic-aliphatic-
arbitrary) motif (131, 132, 135). Within the large and diverse family of Rab GTPases isoprenylation 
motifs were found with C-terminal cysteine residues involving the motifs: xxxCC, xxCxC, xxCCx, xCCcc 
and CCxxx which are modified by geranylgeranylation (135, 136). To ensure efficient isoprenylation, 
members of the Rab family need the assistance of a helper protein, the Rab escort protein (REP) 
 13 1 Introduction 
(137). REP binds to newly synthesised Rab proteins and presents them to geranylgeranyl 
transferases, thus allowing efficient geranylgeranylation of both C-terminal cysteins (138–140). Arf 
family members are typically N-terminally myristoylated and Ran family members are not modified 
(131, 132, 141). In providing a strong and specific subcellular localisation of small GTPases to distinct 
vesicle pools and/or organelles, the post-translational modification is only one part of the truth; the 
target membrane composition, electrostatic properties of both membrane and protein, and the 
support by chaperones must act together in order to achieve selectivity and specificity in membrane 
targeting of Ras small GTPases (132). 
The eventual presence of lipid modifications require a further regulatory feature for small GTPases 
involving the guanine nucleotide dissociation inhibitors (GDIs) (142). GDIs have a high affinity for the 
inactive, GDP bound and lipid modified GTPases and serve first, to prevent the release of GDP in 
order to stabilise the inactive form (143) and second, as a shield for the hydrophobic lipid modified 
part against the hydrophilic cytoplasm when being transported to destined locales (132, 144–149). 
 
 
 
 
1.5 Rab family GTPases 
The Rab family of small GTPases comprises the largest group within the Ras superfamily. Rab proteins 
are considered as being the master regulators of intracellular vesicle transport processes as they 
tightly coordinate all stages of a membrane vesicles lifecycle, including  vesicle budding from the 
donor compartment, vesicle uncoating, vesicle transport, vesicle docking at the acceptor 
compartment and subsequent membrane fusion (Figure 7) (7, 126, 127). So far, 65 members of the 
Rab family have been identified in the human genome, which are divided into 9 functional groups. 
The large diversity of this family is mainly explained by gene duplications during evolution. Each 
member of the Rab family is localised to specific intracellular membrane compartments (126, 127, 
150–153). Rab proteins decide on the membrane identity and mediate their functions in membrane 
Figure 6 | Activity cycle of Ras superfamily small 
GTPases. Ras small GTPases exist in to distinct 
states: the GDP bound inactive state (yellow) and 
GTP bound active state (red). Ras-GDP is bound by 
guanine nucleotide dissociation inhibitors (GDI, 
brown) to prevent GDP dissociation and shielding 
lipid modifications. Guanine nucleotide exchange 
factors (GEF, green) mediate the exchange of GDP 
by GTP inducing Ras GTPase activation and enabling 
its interaction with a wide range of effector and 
adaptor proteins. GTPase activating proteins (GAP, 
pink) support the intrinsic GTP hydrolysis activity of 
Ras proteins to hydrolyse GTP to GDP and inorganic 
phosphate (Pi), and finally inactivate the GTPase to 
complete the activity cycle. 
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transport by recruiting specific adaptor and effector proteins towards the membrane surface. To do 
so, they interact with a wide range of membrane associated proteins, such as vesicle coat proteins, 
motor proteins, tethering factors, signalling proteins and SNARE (SNAP (Soluble NSF Attachment 
Protein) Receptor) complex proteins (126). 
 
1.5.1 Regulation of Rab GTPase activity and its impact on intracellular membrane cycling 
The aforementioned cycling between the active, GTP bound and inactive, GDP bound Rab GTPase 
states induces major conformational changes in the switch I and switch II regions (154). Rab GEFs 
specifically recognise distinct residues in these switch regions to induce GDP release and GTP 
binding. Following the GTP-binding induced conformational change, adaptor and effector proteins 
bind to both switch and interswitch regions of the active Rab-GTP (155). GTP hydrolysis of Rab 
proteins is supported by Rab GAPs. Rab GAPs contain a conserved catalytic TBC domain 
(Tre2/Bub2/Cdc16) (156–158) promoting GTP hydrolysis by a dual arginine-glutamine-finger 
mechanism (157, 159, 160). There are at least 40 Rab GAPs in humans, suggesting specific 
interactions of individual GAPs with their respective Rab proteins (161, 162). 
A well-regulated interplay between Rab GEFs and Rab GAPs wit h specific Rab GDIs, the Rab escort 
protein REP, and membrane bound GDI displacement factors (GDFs), last of which recognise 
cytoplasmic Rab-GDI complexes and induce GDI release, is proposed to be the driving force for 
specific targeting of distinct geranylgeranylated Rab GTPases to their desired membrane 
compartments, finally enabling the directed transport from donor to acceptor compartments (Figure 
7) (126, 163). The whole membrane transfer procedure can be divided into five major steps (126): 
vesicle budding and sorting of target proteins to the budding vesicle, potentially accompanied by 
vesicle coating with stabilising coat proteins (i), vesicle uncoating (ii), vesicle transport through the 
cytoplasm along cytoskeletal tracks (iii), vesicle tethering at target membrane compartments, 
supported by tethering factors and SNARE complex proteins (iv), and vesicle fusion with the destined 
compartment (v). 
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Figure 7 | Schematic overview 
on vesicle transport from a 
donor towards an acceptor 
membrane compartment and 
the involvement of Rab small 
GTPases. Vesicle budding starts 
from the donor membrane 
compartment. This step 
requires active, GTP bound Rab 
GTPases located at the future 
bud site and recruiting different 
adaptor and effector proteins. 
Cargo destined to undergo 
trafficking is sorted into the 
vesicle bud. Potentially, vesicle 
formation involves clathrin 
coating of the membrane for 
clathrin mediated endocytosis. 
Following contingent uncoating, 
membrane vesicles are 
transported in a Rab-GTP and 
motor protein dependent 
fashion along microtubule and 
actin tracks. When reaching the 
acceptor compartment, vesicle 
docking and subsequent vesicle 
fusion is facilitated by tethering 
factors located at the target 
membrane and SNARE proteins 
on both vesicle and target 
membrane. In succession of 
vesicle fusion with the target Rab GAPs bind to Rab-GTP and support GTP hydrolysis to GDP and the release of inorganic 
phosphate (Pi), leading to Rab GTPase inactivation and subsequent Rab-GDP liberation from the membrane. Rab-GDIs bind 
to cytosolic Rab-GDP to prevent GDP dissociation and to shield hydrophobic lipid tails. Rab-GDP is recycled and eventually 
returned to membrane compartments. Here, Rab-GDFs target cytosolic Rab-GDP:GDI complexes, facilitate GDI release from 
Rab-GDP thus retargeting Rab proteins to membranes. Rab-GEFs mediate the exchange of GDP by GTP therefore activating 
Rab GTPases and start the cycle from the beginning. GAP, GTPase activating protein; GDI, guanine nucleotide dissociation 
inhibitor; GDF, GDI displacement factor; GEF, guanine nucleotide exchange factor. 
 
1.5.2 Rab GTPases as master regulators of intracellular transport 
Intracellular membrane trafficking comprises a large array of different types of membrane vesicles, 
transported between different types of donor and acceptor compartments, organelles and other 
cargo. Specific Rab GTPases are associated with distinct membraneous compartments and are 
therefore involved in particular transport processes. These have been reviewed in detail by Harald 
Stenmark (Figure 8) (126) and are shortly summarised here. Rab1 is involved in trafficking from the 
endoplasmatic reticulum (ER) to the Golgi as it is localised to the ER and pre-Golgi intermediate 
compartment (IC). Rab2 might have similar functions. Trafficking within the Golgi system is mediated 
by Rab6, Rab33 and Rab40. Rab8 is a major regulator of exocytic transport from the trans-Golgi 
network (TGN) to the plasma membrane, e.g. it supports the transport of GLUT4 vesicles, together 
with Rab10 and Rab14. Different types of exocytic transport are further mediated by Rab3, Rab26, 
Rab27 and Rab37. Rab27a is particularly important for the periphery directed transport of 
melanosomes in melanocytes as an essential mechanism in skin and hair pigmentation, and Rab32 
and Rab38 participate in the biogenesis of melanosomes, as do Rab7 and Rab8. Rab32 is furthermore 
 16 1 Introduction 
crucial for mitochondria fission. Rab22 is required for trafficking between the TGN and the early 
endosomes. Rab5 is potentially the most important regulator of endocytosis as it is localised to 
endocytic sites at the plasma membrane and to early endosomes and phagosomes as well. Rab5 
functions in mediating endocytic events, for instance by inducing the formation of clathrin-coated 
pits and clathrin-mediated endocytosis, and macropinocytosis, and is also involved in subsequent 
endocytic pathways, such as the fusion of clathrin-coated vesicles with the early endosome and the 
maturation of early phagosomes, often together with other Rab proteins. Rab21, for instance, 
participates in integrin receptor re-uptake. Recycling pathways are used to return endocytosed 
receptors, signalling molecules and other membrane components back to the plasma membrane. 
Fast recycling only involves the early endosome and is mediated by Rab4. In contrast, a more slowly 
recycling traverses the recycling endosome and requires function of Rab11 and Rab35. In this process 
also Rab15 plays a role in trafficking from the early endosome towards the recycling endosome. 
Despite its role in exocytosis, Rab8 is also involved in endocytic and recycling events. Together with 
the Arf family member Arf6, Rab8 induces macropinosome formation, subsequent tubulation of 
those and final recycling of receptors, signalling molecules and membrane components (164). Rab7a 
and Rab7b are structurally very similar but contribute to different endosomal transport steps (165, 
166). Rab7a is localised to the early endosome and mediates transport towards the late endosome 
and lysosome, therefore playing a role in protein degradation (165). In contrast, Rab7b is additionally 
localised to the TGN and Golgi and rather mediates retrograde trafficking from the late endosome 
towards the TGN (167). Similar functions are described for Rab9. 
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1.5.3 Rab GTPases form complexes with motor proteins 
In order to achieve vesicle transport along cytoskeletal tracks, motor proteins need to associate with 
vesicle membranes in a highly specific and well-regulated fashion. Rab family GTPases specifically 
recruit motor proteins directly or indirectly to the respective vesicle surface. This mechanism is well 
described for class V myosin actin motors which have been shown to associate with Rab GTPases at 
vesicle membranes in both, in yeast and higher order eukaryotic cells. The yeast Rab GTPase Ypt11p 
has been shown to interact with the class V myosin member Myo2p in transporting the Golgi into a 
growing bud (168). Furthermore, a cooperation of Ypt11p and Myo2p has been implicated in the 
transport and inheritance of mitochondria (169, 170), and the yeast Rab GTPase Sec4p (the 
mammalian homolog is Rab8) has been demonstrated to recruit Myo2p to secretory vesicles (169, 
171).  
The well-studied role of Rab27a in melanosome transport in melanocytes is another example for the 
formation of Rab GTPase myosin V motor protein complexes (80, 124, 169, 172–174). Here, Rab27a 
forms a tripartite complex with myosin Va and the melanophilin protein (MLPH). MLPH functions to 
connect the myosin Va actin motor with the melanosome associated Rab27a small GTPase (83). The 
formation of this tripartite complex is essential for the transport of melanosomes to the periphery of 
Figure 8 | Localisation 
and function of Rab 
GTPases at intracellular 
membranes. Members of 
the large family of Rab 
GTPases regulate 
different steps of 
intracellular trafficking, 
including exocytosis, 
endocytosis and recycling 
transport, pathways for 
degradation of cellular 
content, organelle 
transport and dynamics, 
and cell morphological 
alterations, such as cilia 
formation and cell 
adhesion. Adapted from 
Harald Stenmark, 2009 
(126).  
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melanocytes for subsequent transfer to keratinocytes, an important process for skin and hair 
pigmentation (80, 175). Mutation of either of the complex partners underlies the manifestation of a 
disease called Griscelli syndrome (GS) (174, 176–180). There are three types of disease presentation 
all of which have in common a skin and hair hypopigmentation (176). Griscelli syndrome type 1 
further includes severe neurological impairments and is caused by mutations in the MYO5A gene 
(176, 180). GS type 2 is based on mutations in the RAB27A gene and presents with misfunctions of 
the immune system and increased infection susceptibility (174, 176, 177). GS type 3 is related to 
mutations in the MLPH gene and here patients only show the phenotype of partial albinism (176, 
178, 179). 
The Myosin and Rab interacting protein (MyRIP or Slac-2c) is another Rab27a binding protein which 
has been shown to form a similar tripartite complex with myosin VIIa.  The Drosophila myosin VIIa 
protein has been shown to function as a processive motor on actin filaments and the mammalian 
homolog is supposed to act in a similar way  (181–183). Myosin VIIa plays a crucial role in the retina 
and in the inner ear as it is localised to photoreceptor cells and pigmented epithelial cells of the 
retina, and to the pericuticular necklace of sensory hair cells (181, 184–186), where it functions as a 
molecular transporter (187, 188). In particular, a Rab27a:MyRIP:myosin VIIa complex is required for 
melanosome motility in the retinal pigment epithelium (189). Mutations of the MYO7A gene have 
been shown to cause the human Usher syndrome type 1B (184). Usher syndrome type 1 is the most 
frequent cause for inherited deaf-blindness in humans (190), presenting sensorineural hearing loss, 
vestibular dysfunctions and early-onset retinis pigmentosa (184, 191), and underlies mutations in 
multiple loci leading to different disease subtypes (myosin VIIa is encoded by the USH1B locus) (184, 
190). 
This mechanism of differential targeting of distinct motor proteins to Rab27a vesicles by co-
recruitment of specific adaptor proteins (MLPH vs. MyRIP) nicely shows the fine-tuned regulation of 
vesicle associated protein complex formation, depending on cell type and cargo. In accordance, 
Rab27a has been shown to functionally correlate with myosin Va in the transport of dense core 
secretory granules to the plasma membrane of pancreatic beta-cells (192). Here, Rab27a and myosin 
Va form a tripartite complex with the adaptors granuphilin-a, granuphilin-b and rabphilin-3A, 
respectively. 
The small GTPase Rab3A, being the most abundant Rab family member in the brain (193), has been 
shown to directly interact with myosin Va at synaptic vesicles to facilitate the transport of these 
vesicles in neuronal cells (194), as has also been shown for Rab27b (195). Rab8a directly interacts 
with myosin Vb at the aforementioned tubular recycling network containing Eps-15-homology 
domain-containing proteins EHD1 and EHD3 (196). Rab8a, in conjunction with Rab11a, interacts with 
myosin Vb in the regulation of enterocyte polarity by driving apical transport processes, and regulate 
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enterocytic microvilli growth (197). Mis-regulation of these Rab motor complexes has a major impact 
on the pathogenesis of microvillus inclusion disease, in which impaired interactions of MyoVb and 
Rab8a induce microvilli loss and uncoupling of MyoVb and Rab11a lead to microvilli inclusions. Rab8a 
also interacts with myosin Va in the insulin triggered transport of GLUT4 (glucose transporter type 4) 
vesicles towards the plasma membrane of rat muscle cells (198–200). A similar mechanism has been 
proposed for the cooperation of Rab10 and MyoVa in adipocytes (201). These studies nicely show the 
interconnection of stimuli induced intracellular signalling (e.g. phosphorylation events following 
insulin receptor activation) and vesicle transport processes (Rab GTPase activity). Rab8a is 
furthermore suggested to interact with the epithelial-related myosin Vc in the transferrin receptor 
transport in epithelial cells (54). Rab10, which is related to Rab8a and localises to the same tubular 
network (196), has also been shown to interact with myosin Va, Vb and Vc in vivo and is thus 
proposed to be involved in similar recycling functions (55, 202–206). Vertebrate myosin Vc directly 
interacts with Rab38 and the closely related Rab32 to cooperate in the biogenesis and secretion of 
melanosomes (207). Here, the myosin Vc motor is required to transport distinct melanosome 
biogenesis factors, such as the tyrosinase-related proteins Tyrp1 and Tyrp2, and the SNARE protein 
Vamp7, from the early and recycling endosomes towards maturing melanosomes. Interestingly, 
Rab32 and Rab38 interact specifically with MyoVc, but neither with MyoVa nor with MyoVb. In the 
following melanosome maturation process, MyoVc also interacts with Rab7a and Rab8a. 
 
Alternatively spliced exons within the C-terminal regions between the neck and the globular tail 
domain  in myosin Va, myosin Vb and myosin Vc specifically determine the interaction of the motor 
proteins with distinct Rab GTPases (Figure 9) (55). Myosin Va has six alternatively spliced exons: 
exons A, B, C, D, E and F, whereas myosin Vb has only five as it misses exon F. Particularly, the three 
exons B, D and F undergo alternative splicing in myosin Va (53, 63, 64). Exon F supports the 
association of myosin Va with melanophilin to form a functional complex with Rab27a (80, 83, 208, 
209). Exon B has been demonstrated to play a role in the interaction of myosin Va with dynein light 
chain 2 (DLC2), which, however, has not been resembled for the exon B of myosin Vb (66, 67). Exon D 
is required for MyoVa binding to Rab8a and Rab10. For MyoVb the exon D is also essential for Rab10 
interaction, but, in contrast to MyoVa, inhibits binding to Rab8a (55). Rab11a interacts with both, 
myosin Va and myosin Vb, in an exon independent fashion (55, 210, 211). Myosin Vc also expresses 
an alternatively spliced exon F which determines its interaction with Rab32 and Rab38 (207). 
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Figure 9 | Schematic representation of alternatively spliced exons of mammalian MyoVa and MyoVb proteins. 
Alternatively spliced exons are located within the coiled-coil regions of the MyoV-tail (exons A, B, C, D, E and F for MyoVa, 
and exons A, B, C, D and E for MyoVb). (A) Three exons are particularly subjected to alternative splicing in MyoVa: exons B, 
D and F (drawn in red). Exon B mediates interaction with dynein light chain 2 (DLC2). Exon D is essential for MyoVa 
interaction with Rab8a and Rab10. The melanocyte specific exon F is required for efficient interaction with melanophilin 
(MLPH). (B) Only two exons in particular undergo alternative splicing in MyoVb: exons B and D (drawn in red). A specific 
function for exon B has not been demonstrated so far. Exon D mediates MyoVb interaction with Rab10, similar to MyoVa, 
but, in contrast, inhibits its interaction with Rab8a, which binds to the same region in absence of exon D. There is no exon F 
present in MyoVb. Numbers on the protein domains indicate amino acids for mouse (Mm) MyoVa and human (Hs) MyoVb; 
aa, amino acids. 
 
 
1.6 The Rab11 GTPase 
Of special interest for this thesis is the Rab11 subfamily of Rab small GTPases. Rab11 proteins 
regulate exocytic and recycling processes following plasma membrane internalisation by clathrin-
mediated endocytosis and subsequent recycling towards the cell surface (7, 196). Rab11 proteins 
localise to the trans-Golgi network (TGN) and post-Golgi vesicles to support secretory pathways 
(212), and to the pericentriolar recycling endosome, therefore participating in later recycling steps, 
but not in early endosomal recycling (Figure 10) (213, 214). As an example, Rab11 has been observed 
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to function in the establishment and maintenance of epithelial polarity being localised to the 
pericentriolar recycling compartments (215, 216). E-cadherin, a cell surface protein that mediates 
cell-cell contacts, continuously undergoes recycling, after internalisation from the cell surface, via 
recycling endosomes. The importance of Rab11 in the process of E-cadherin recycling has been 
described during all stages of epithelial polarity formation (217, 218). Furthermore, Rab11 has been 
implicated in the transport of several other cargoes, especially cell surface receptors and adhesion 
proteins, in different cell types. Some of those are the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor in dendritic spines of neuronal cells, rhodopsin in 
photoreceptor cells, epidermal growth factor (EGF) receptor, Toll-like receptor 4 (TLR4), and other 
adhesion proteins besides cadherins, such as integrin receptors (219). Considering that, Rab11 is 
involved in multiple cellular functions depending on proper secretory vesicle transport which 
comprise, besides others, ciliogenesis, neuritogenesis, oogenesis, and the establishment and 
maintenance of epithelial polarity (Figure 10) (215, 217, 220–226). Furthermore, Rab11 drives 
endosomal membrane organisation, contributes to phagocytosis and is involved in cytokinesis (213, 
227–229). 
 
 
 
In mammals, three Rab11 isoforms exist: Rab11a, Rab11b and Rab11c, which is also termed Rab25 
(7). The overall sequence homology between the three isoforms is considerably high, but the tissue 
expression varies. Rab11a shows a wide expression pattern (7, 230), whereas the Rab11b expression 
is rather restricted to brain, testis and heart (231). Also the Rab11c expression shows a restricted 
pattern, with lung, kidney and gastric tract being the major expressing tissues (232). The Rab11 
Figure 10 | Overview on Rab11 
functions in intracellular transport 
and cellular processes. Rab11 small 
GTPases are localised to the trans-
Golgi network, post-Golgi vesicles and 
the recycling endosome (green 
membrane compartments) to mediate 
secretory and recycling transport of 
diverse cargo towards the plasma 
membrane. A Rab11 function has been 
described for diverse cellular 
processes, including membrane 
receptor transport, such as rhodopsins 
in photoreceptor cells, adhesion 
proteins or AMPA receptor subunits in 
dendritic spines, ciliogenesis, 
cytokinesis, neuritogenesis and vesicle 
transport in metaphase oocytes 
required for proper oogenesis. 
Adapted from Welz, Wellbourne-Wood 
and Kerkhoff, 2014 (7). 
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isoforms typically have two lipid modifications at their C-termini as they contain the CCxxx 
isoprenylation motif (see above). Both cysteine residues get geranylgeranylated to facilitate 
membrane association (135). 
 
1.6.1 Regulation of Rab11 activity 
Rab11 specific GTPase activating proteins (GAPs) belong to the TBC domain containing proteins. So 
far, three distinct Rab11 GAPs have been identified: TBC1D11, TBC1D15 and the ecotropic viral 
integration site 5 protein (Evi5) (233–235). Evi5 has been investigated in terms of Drosophila border 
cell migration during which the protein is critical to drive the Rab11 dependent localisation of 
receptor tyrosine kinases to the leading edge cell surface to initiate collective cell migration (236, 
237). Furthermore, Evi5 negatively regulates the localisation of Rab11 to the centrosome (238). In 
contrast to Evi5, not much is known about the other two Rab11-GAPs, TBC1D11 and TBC1D15, and 
their role in regulating Rab11 dependent processes. Both GAPs are also not specific to Rab11 as they 
also regulate the activity of Rab7 and Rab4 (233, 235). 
The knowledge about Rab11 specific guanine nucleotide exchange factors (GEFs) is by now very 
limited. In Drosophila, a Rab11-GEF has been identified recently: the calmodulin-binding protein 
related to a Rab3 GDP/GTP exchange protein (Crag) which interacts with Rab11 during light induced 
rhodopsin transport in photoreceptor cells (239). The Crag protein belongs to the DENN 
(differentially expressed in normal and neoplastic cells) domain proteins  which have been shown to 
be able to activate human Rab proteins including Rab10 and Rab11, but not Rab5 (239, 240). 
Interestingly, the Rab-GEF activity of Crag is increased in presence of Ca2+ and calmodulin which 
opens the opportunity of Ca2+ regulated mechanisms for Rab11 activation and Rab11 dependent 
processes (239). Very recently, a novel Rab11-GEF has been identified in Caenorhabditis elegans, the 
RAB-11-interacting protein-1 (REI-1), which was proposed to regulate Rab11 activity in early C. 
elegans embryos (241). The human homolog of REI-1, SH3BP5, also showed a strong GEF activity for 
the human Rab11 protein. Before that, no mammalian Rab11-GEF has been undoubtedly identified. 
Intriguingly, the mammalian genome encodes for three homologs of the Drosophila Crag protein: 
DENND4A, DENND4B and DENND4C, which might point towards a conserved role for these proteins 
in Rab11 activation (7). The huntingtin protein has also been described to mediate Rab11 GEF activity 
(242, 243). Huntingtin colocalises with Rab11 at endosomal membranes and the Rab11 mediated 
recycling transport is impaired in cells from Huntington’s disease patients and from Huntington’s 
disease mouse models. A GEF activity for Rab11 has been demonstrated for co-precipitates from 
brain lysates, but a direct interaction of Rab11 and huntingtin has not been revealed. Thus, 
huntingtin might affect Rab11 activity rather as part of a protein complex containing a discrete 
Rab11-GEF than solely by itself. 
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1.6.2 Rab11 family-interacting proteins act as Rab11 specific adaptor proteins 
Rab11 family-interacting proteins (Rab11-FIPs) resemble a well-characterised group of Rab11 
interacting adaptor proteins (7, 244–247). Five members of Rab11-FIPs are known, Rab11-FIP1-5, 
separated into two classes, which all share a C-terminal Rab11-binding domain mediating a specific 
interaction with Rab11-GTP. Class I FIPs include Rab11-FIP1 (also termed Rab coupling protein; RCP), 
Rab11-FIP2 and Rab11-FIP5 (also termed Rab11-interacting protein; Rip11). Members of the class I 
FIPs contain an N-terminal C2 membrane binding motif which mediates phospholipid binding and 
potentially supports the membrane association of Rab11/effector protein complexes (244, 247). 
Class II FIPs include Rab11-FIP3 and Rab11-FIP4. 
 
1.6.3 Rab11 motor protein complexes 
Rab11 specifically recruits effector and adaptor proteins to vesicle surfaces to mediate their 
functionality. Motor proteins of the kinesin, dynein and myosin families have been repeatedly 
reported as being direct or indirect Rab11 effector proteins to mediate vesicle transport along 
microtubules (kinesins and dyneins) and F-actin tracks (myosins) and thus a number of Rab11 motor 
protein complexes have been described so far (Figure 11). 
 
 
Figure 11 | Rab11 motor protein complexes. Rab11 directly and indirectly forms protein complexes with both microtubule 
and actin associated motor proteins depending on its activity state and distinct adaptor proteins. Rab11-GTP interacts via 
the Rab11 family-interacting protein Rab11-FIP3 with the microtubule minus end directed dynein motor. In contrast, 
Rab11-GDP interacts with the adaptor protein protrudin and the microtubule plus end directed kinesin motor KIF5 (kinesin-
1). Interactions of Rab11-GTP with the actin motor protein myosin Vb (MyoVb) are either direct or indirect via the Rab11 
family-interacting protein Rab11-FIP2 in order to drive plus end (barbed end) directed transport along F-actin tracks. 
Adapted and modified from Welz, Wellbourne-Wood and Kerkhoff, 2014 (7). 
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The first of those identified was the Rab11/myosin Vb complex (248) and also myosin Va has been 
described to interact directly with Rab11 (Table 1). By now, the crystal structures of both, the 
MyoVb-GTD:Rab11 complex (PDB ID: 4LX0) (210) and the MyoVa-GTD:Rab11 complex (PDB ID: 5JCZ) 
(211), have been solved. Long-term-potentiation (LTP) within neuronal networks is the activity 
dependent strengthening of synaptic connections, inducing synaptic plasticity important for learning 
and memory. As a molecular base for LTP establishment, GluA1 AMPA receptor subunits are 
delivered from the recycling endosome located at the spine base and dendritic shaft towards the 
plasma membrane and postsynaptic densities (249, 250). Rab11 and myosin Vb have been shown to 
interact in the transport of AMPA receptor subunit containing recycling endosomes towards the 
postsynaptic densities of hippocampal neurons (251). Myosin Vb is here actively recruited to the 
recycling endosome by Rab11 and the Rab11 family-interacting protein 2 (Rab11-FIP2). This complex 
is required to pull the recycling endosomal membranes from the spine base towards the postsynaptic 
densities along F-actin tracks, and thus for exocytic events within the dendritic spine. The whole 
process is strongly Ca2+ dependent. It has been suggested that increased Ca2+ concentrations 
following synaptic activity lead to the opening of the back-folded MyoVb motor and to a local 
reduction of the motors walking ability (see above) (252). This is thought to promote myosin Vb 
recruitment at the spine base, and the local rise in Ca2+ concentrations would subsequently allow 
myosin Vb to pull the recycling endosome into the spine heads. Myosin Va as well has been 
demonstrated to associate with Rab11 and GluA1 (55, 253). However, the existing data about the 
essential involvement and a potential underlying mechanism for myosin Va function in hippocampal 
synaptic plasticity diverges and needs to be further investigated (251, 253–255). 
Rab11 and myosin Vb have been implicated in the transport of membrane vesicles towards the 
cortex of mouse metaphase oocytes by actin dependent long-range transport (222). These Rab11- 
and myosin Vb-positive vesicles directly modulate the density of the actin network which is crucial 
for the proper asymmetric spindle positioning in mouse oocytes (see below) (256). 
As already mentioned, Rab11 is involved in the proper functioning of the Drosophila eye. Rab11 
forms a tripartite complex with myosin V (Dm-MyoV) and the Rab11-interacting protein RIP11 to 
mediate the transport of rhodopsin containing post-Golgi secretory vesicles towards the developing 
rhabdomere membrane of photoreceptor cells (257).  
The Rab11 and myosin Vb interaction is crucial for the apical constriction during Xenopus 
gastrulation. Furthermore, both proteins potentially mediate the trafficking of the planar cell polarity 
protein Vangl2 to the cell surface (258).  
A complex formed by Rab11a, myosin Vb and Rab11-FIP2 at the endosomal recycling compartment 
and at vesicle docking and tethering sites participates in the transport of the C type lectin receptor 
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langerin being an important cell surface receptor of Langerhans cells within the epidermis, which 
undergoes continuous endocytosis and recycling (259). 
By regulating the recycling transport of distinct kinases towards the apical surface of enterocytes, 
Rab11a and myosin Vb are crucial determinants for the proper development of microvilli required for 
the absorption of nutrients within the intestinal tract (260). Interference with either Rab11a or 
MyoVb, as it is the case in microvillus inclusion disease (already described earlier), leads to mis-
regulated trafficking of kinases and reduced phosphorylation of ezrin, a member of the ezrin-radixin-
moesin (ERM) family which are essential factors for the development and organisation of the apical 
plasma membrane and microvilli of epithelial cells (261–263). 
 
MyoV protein (adaptor) Cell type Function/Mechanism 
MyoVa Hippocampal neurons Hippocampal synaptic plasticity 
MyoVb (FIP2) Hippocampal neurons Hippocampal synaptic plasticity; transport of 
AMPA receptor subunits from recycling 
endosomes to postsynaptic densities 
MyoVb Metaphase oocytes Transport of vesicles towards oocyte cortex, 
asymmetric spindle positioning 
MyoVb Xenopus oocytes Apical constriction; transport of Vangl2 
towards the cell surface 
MyoVb (FIP2) Langerhans cells Cell surface transport of langerin receptors 
MyoVb  Intestinal tract 
(enterocytes) 
Development of microvilli; apical transport 
of kinases, phosphorylation of ezrin 
Dm-MyoV (RIP11) Drosophila 
photoreceptor cells 
Transport of rhodopsin containing secretory 
vesicles to rhabdomer membranes 
Table 1 | Rab11 interactions with MyoV proteins. 
 
Rab11 GTPases also functionally interact with microtubule associated motors of the dynein and 
kinesin families. Class II Rab11-FIP3 mediates the interaction between Rab11 and the microtubule 
minus end directed cytoplasmic dynein motors by forming a tripartite complex with the dynein light 
intermediate chains (DLIC-1 and DLIC-2) (264–266). A function of this complex has been proposed for 
transport processes from the peripheral sorting endosome to centrally located recycling endosome 
compartments (265), for instance for the transport of membrane containing vesicles towards the 
recycling endosome which are further delivered to the cleavage furrow during cytokinesis (267, 268). 
Rab11-FIP5 facilitates the formation of a complex containing Rab11 and the microtubule plus end 
directed kinesin family member kinesin-2 (also known as KIF3), which is involved in the regulation of 
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protein recycling at the perinuclear recycling endosome (269). Another Rab11-interacting protein, 
protrudin, mediates the interaction of Rab11 and kinesin-1a (also known as KIF5A) (13). This 
tripartite complex has been revealed to play a role in neuronal process formation (13, 270). 
Interestingly, and in contrast to what is found normally, the protrudin protein interacts with Rab11-
GDP and not with Rab11-GTP. Its Rab11-GDP binding site is similar to that of the Rab11-GDP 
dissociation inhibitors Rab-GDIα and Rab-GDIβ and differs from other Rab11-binding domains (221, 
271). This opens the possibility that the conversion of Rab11 from the GDP bound state to the GTP 
bound state could switch the direction of microtubule dependent transport (FIP3-dynein vs. 
protrudin-kinesin-1a) or between transport mechanism (microtubule vs. actin). 
 
 
1.7 Myosin motors and actin nucleators and elongators cooperate at intracellular membranes 
The actin cytoskeleton is involved in a wide range of cellular processes, such as the establishment 
and maintenance of cell shape and polarity, critical as the base for cell adhesion and cell motility, and 
intracellular transport, including endocytosis and exocytosis (272–275). Actin filaments, or 
filamentous actin (F-actin), comprise a right-handed double helical filament generated by the 
assembly of monomeric or globular actin (G-actin), which is polarised throughout the filament with a 
fast-growing barbed end (or plus end) and a pointed end (or minus end) (Figure 12) (276). Actin 
monomers bind and hydrolyse ATP. The ATPase activity of actin monomers mainly decides on the 
transition between G-actin and F-actin as ATP-actin preferably binds to the barbed end, ATP-
hydrolysis occurs within the filament and ADP-actin is released from the pointed end. The 
depolymerisation from the filaments pointed end is enhanced by actin depolymerising factors 
(ADF)/cofilin proteins, which bind to ADP-actin rich regions of the filament and increase the actin 
monomer dissociation rate by filament severing (277–281). The whole process of actin 
polymerisation and depolymerisation is considered as the actin treadmilling.  
The dynamics of actin networks needs to be tightly regulated. The well-controlled formation of new 
actin filaments from free actin monomers, filament stabilisation and crosslinking, but also the 
regulated capping and depolymerisation, as well as filament severing and actin monomer 
sequestering, is required to temporally and spatially coordinate actin network functions (276). The 
control of actin dynamics is thereby executed by a large and very diverse set of G- and F-actin binding 
proteins, as well as signalling and scaffolding proteins (272, 276). 
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Figure 12 | Principles of actin nucleation, polymerisation and depolymerisation. Spontaneous actin polymerisation from 
free actin monomers is inhibited due to the high dissociation constants for small actin oligomers. After the formation of an 
actin nucleus, polymerisation of ATP-actin starts to form an actin-filament with barbed end (+) and pointed end (-). ATP 
hydrolysis takes place within the filament in a way that ATP-actin is found rather at the barbed end and ADP-actin at the 
pointed end. A treadmilling process occurs in which new ATP-actin binds to the barbed end and ADP-actin is released from 
the pointed end. ADF/cofilin binds to ADP-actin rich regions and induces filament severing to increase the depolymerisation 
rate. 
 
1.7.1 Actin nucleation factors 
Actin nucleation factors include proteins that bind actin monomers to form and stabilise an actin 
nucleus from which further actin polymerisation starts to generate new actin filaments. The cellular 
concentrations of actin monomers, being the most abundant proteins in most eukaryotic cells, range 
from 100-500 µM and are much higher than the critical concentrations for the addition of monomers 
to barbed end (0.1 µM) and pointed end (0.7 µM) (272, 276). In order to prevent exceeding 
spontaneous actin polymerisation, two mechanisms developed. First, a diverse set of actin monomer 
binding proteins exist, which reduce the pool of free actin monomers available for filament 
formation. Second, the formation of small actin oligomers, like dimers and trimers, required as a 
seed for filament elongation, is an energetically unfavourable process (276, 282). The function of 
actin nucleators warrants a very tight temporal and spatial regulation of F-actin generation as they 
help to overcome the kinetic barrier of oligomer formation when desired. 
There are three major groups of actin nucleation factors (283). The Arp (actin-related protein) 2/3 
complex is the best studied actin nucleator and is composed of seven subunits, including Arp2 and 
Arp3 and the Arp complex proteins ARPC1 to ARPC5 (284). The Arp2/3 complex binds to pre-existing 
filaments to generate branched actin networks, with an angle of 70° between two filaments, which 
have major contributions in determining cell shape and enabling cell migration (272, 285, 286). The 
complex by itself has only weak actin nucleation capacities (287). Thus, it requires the support by 
nucleation promoting factors (NPFs), including, besides others, the Wiskott-Aldrich syndrome protein 
(WASP) family and WASP-family verprolin homology (WAVE) family members (286, 288–291). NPFs 
are tightly regulated by diverse signalling mechanisms, for instance by the activity of Rho family 
GTPases, and act by recruiting one to three actin monomers to the Arp2/3 complex, and by inducing 
a conformational change of the complex (276, 292–296). 
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Formin proteins, as the second major group of actin nucleators, are large modular proteins which 
share the two formin-homology domains FH1 and FH2 (297). Formin proteins dimerise to form a 
dimeric ring of FH2 domains in which each FH2 binds two actin monomers to form the nucleus. The 
ring subsequently moves processively with the fast-growing barbed end to elongate the filament and 
prevent access of capping proteins (298–300). The FH1 domain is a proline rich region which is able 
to bind profilin-actin complexes, the main source of ATP-actin monomers in the cell (301). FH1 is 
suggested to enhance both, the nucleation and elongation activity of the FH2 domain by recruiting 
and pre-orienting the actin monomers towards the FH2 domains (299, 302–306). 
The third major group of actin nucleation factors comprise the Wiskott-Aldrich syndrome protein 
homology 2 (WH2) domain containing actin nucleators. This group includes the Cordon-bleu protein 
(Cobl), Leiomodin (Lmod), the Junction-mediating and regulatory protein (JMY) and the Spir proteins 
which all have in common the presence of one or multiple WH2 domains used for actin binding and 
nucleation (307). Cobl is described as a vertebrate specific actin nucleator, with major expression in 
the brain, and contains three WH2 domains for highly efficient actin nucleation (307). A role for Cobl 
has been suggested in vertebrate axis formation (308) and midbrain neural tube closure (309), and 
proven in neuromorphogenesis by neurite induction and branching, related to Cobl mediated actin 
polymerisation and generation of unbranched actin filaments (310). Leiomodin is a heart, skeletal 
and smooth muscle related actin nucleator, with three so far identified isoforms that show strong 
actin nucleation activity to generate unbranched filaments (307, 311). JMY was added to that group 
recently and is considered as a transcriptional co-activator of the tumour suppressor p53. It is 
furthermore suggested to function both, as a NPF for the Arp2/3 complex and as an independent 
actin nucleator (312). 
 
1.7.2 Spir actin nucleators 
Spir proteins were first identified in Drosophila as the protein product of the spire gene and as a Jun 
N-terminal kinase (JNK)-interacting protein (313–315). Spir proteins have been identified only in 
metazoans (283, 316). Besides Ciona savignyi PEM-5 (posterior end mark-5) and Drosophila dSpir 
(p150-Spir), there are two spir genes in vertebrates: spir-1 and spir-2 (317). The respective gene 
products, Spir-1 and Spir-2 proteins, are highly similar with an identity of 37% and a similarity of 50% 
for the mouse proteins (283). It has been proposed first that Spir proteins act as nucleation 
promoting factors for the Arp2/3 complex due to their WH2 domains (314, 315). Subsequent 
experiments did not reveal any interaction of Spir proteins and Arp2/3, but rather showed that the 
WH2 domains of Spir are sufficient to nucleate actin polymerisation (318). It has been shown that 
Spir proteins not only function in actin nucleation but also in sequestering of actin monomers and 
severing of actin filaments (319–321). 
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Both, spir-1 and spir-2 genes are highly expressed in the central nervous system (322, 323). In situ 
hybridisations in mice demonstrated strong spir-1 expression in the developing nervous system and 
in the adult brain (322) with highest expression levels observed in hippocampus, dentate gyrus and 
cerebellum, especially in Purkinje cells. The spir-1 gene was also expressed in the thalamus, the 
lateral septal nucleus and the cerebral cortex (323). Similarly, spir-2 is also strongly expressed in the 
murine central nervous system, both, during development and in adulthood (323). During 
embryogenesis, a high expression of spir-2 was detected throughout the whole brain and in the 
spinal cord, as well as in the peripheral nervous system. Interesting to note is that the specific 
expression patterns of both spir genes during development indicate a high spatial regulation of spir 
gene expression. In early developmental stages both spir genes are differentially expressed and 
might therefore have distinct functions. However, in later stages of development a rather 
overlapping expression pattern was observed which indicates a redundant function of both genes 
during this developmental stage. In the adult mouse brain, spir-2 expression was enriched in 
thalamus, inferior colliculus, cerebral cortex and in particular in the cerebellum (323). The spir-2 gene 
is also expressed in the digestive tract within intestinal and colonic epithelial cells along villi and 
crypts, in the seminiferous tubules and spermatocytes of testis, and kidney (323). 
 
The spir gene products are modular proteins containing multiple domains (Figure 13) (283). The N-
terminal KIND (kinase non-catalytic C-lobe domain) resembles the organisation of a protein kinase C-
lobe without catalytic kinase activity and developed into a protein interaction domain (316). KIND 
mediates the interaction with Formin (FMN) family formin proteins (324). A cluster of four WH2 
domains binds actin monomers and is necessary and sufficient to nucleate actin polymerisation, 
potentially by forming a longitudinal tetrameric actin nucleus (318). At the C-terminal end of Spir 
proteins, the Spir-box and the FYVE-type zinc-finger are located. The specific function of the Spir-box 
is still not revealed. The short region is highly conserved across species and shares sequence 
homology to an α-helical region within the Rab3A effector protein rabphilin-3A mediating its 
interaction with Rab3A (325, 326). This opens the opportunity that the C-terminal Spir-box mediates 
the interaction of Spir proteins with Rab family GTPases, potentially Rab3A or the related Rab27a. 
The FYVE-type zinc-finger (after Fab1, YOTB/ZK632.12, VAC1, EEA1; the proteins in which the domain 
was first discovered) at the very C-terminus mediates membrane targeting of Spir proteins to 
intracellular membranes (325, 327). The zinc-finger comprises eight cysteine residues which together 
bind two zinc ions (328, 329). Membrane association is enabled by the formation of a hydrophobic 
turret loop that penetrates the membrane (330, 331). In contrast to canonical FYVE domains, which 
can be found for instance in the Early Endosome Antigen 1 (EEA1) protein, the Spir FYVE-type zinc-
finger binds rather non-specifically to negatively charged membranes in an phosphatidylinositol-3-
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phosphate independent manner (327). Within the central Spir linker region, connecting the WH2 
domains and the Spir-box, a highly conserved short sequence motif (globular tail domain binding 
motif, GTBM) was discovered, which will be of major interest in this thesis (see results). 
 
 
Figure 13 | Domain organisation of vertebrate Spir-1 and Spir-2 proteins. The N-terminal KIND (kinase non-catalytic C-lobe 
domain) mediates interaction with Formin (FMN) family formins and intramolecularly with the Spir-FYVE-type. A cluster of 
four Wiskott-Aldrich syndrome protein homology 2 (WH2) domains binds monomeric actin and serves actin filament 
nucleation. The central Spir linker region contains the newly identified globular tail domain binding motif (GTBM) for 
myosin V interaction (see results for more detail). Within the vertebrate Spir-1 proteins, two alternatively spliced exons, 
exon B and exon C, have been identified. The function of exon B is so far unknown and exon C mediates Spir-1 targeting to 
mitochondria membranes. The C-terminal Spir-box (SB) has yet unknown functions but is potentially involved in binding to 
distinct Rab GTPases. The FYVE-type zinc-finger (after Fab1, YOTB/ZK632.12, VAC1, EEA1) mediates targeting of Spir 
proteins to negatively charged intracellular membranes. 
 
Although Spir proteins are capable to nucleate actin polymerisation in vitro due to their four WH2 
domains, they are not able to bind and nucleate profilin-actin, the major source of monomeric actin 
in living cells, in vivo (285, 318, 332). The physical and functional interaction of Spir and FMN family 
formins is meanwhile well established, in which both proteins are suggested to form a 
heterotetrameric complex at intracellular membranes  (317) and regulate each other’s nucleation 
activity, thus being a highly efficient actin nucleator complex for profilin-actin (332, 333) (Figure 14). 
The Spir/FMN cooperativity has been demonstrated to be essential in oocyte development both, in 
mouse (FMN-2) (222, 334) and in Drosophila (335, 336). Spir and FMN-2 work together to generate a 
vesicle originating actin meshwork in metaphase mouse oocytes which is not formed by either of the 
two nucleators alone (222, 334). This mechanism is conserved as the Drosophila Spir protein (p150-
Spir) also interacts with the Drosophila FMN family protein Cappuccino (Capu) to form an actin 
meshwork in fly oocytes (335, 336). Spir and FMN proteins interact directly by the Spir KIND domain 
and the evolutionary conserved formin/Spir interaction (FSI) sequence at the very C-terminus of FMN 
proteins which is stabilised by electrostatic interactions of a negatively charged acidic groove within 
the KIND domain and a positively charged basic cluster of the FMN-FSI sequence (324, 337, 338). 
Very recently, an intramolecular interaction between the N-terminal KIND and the C-terminal FYVE 
domains was unravelled which prevents membrane association of Spir proteins. The KIND/FSI and 
KIND/FYVE interactions are competitive as FMN proteins can only interact with membrane bound 
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Spir proteins thereby releasing the KIND/FYVE interaction. Together with findings that Spir proteins 
are monomeric in the cytoplasm, a mechanism has been proposed in which Spir adopts an inactive, 
back-folded cytoplasmic state, next to an active, open and membrane bound state (Figure 14) (327). 
 
 
Figure 14 | Model for the Spir/FMN actin nucleator complex at vesicle membranes. Spir proteins are supposed to be back-
folded in the cytoplasm via the recently discovered KIND/FYVE interaction. In this state, FMN family formins cannot bind to 
Spir proteins. Spir proteins transiently interact in a non-specific fashion with negatively charged intracellular membranes. At 
this state, FMN associates with Spir via the Spir-KIND/FMN-FSI interaction leading to the formation of a heterotetrameric 
Spir/FMN complex. The current model suggests that Spir nucleates actin monomers via its WH2 domains and passes over to 
FMN proteins which elongate the Spir nucleated filaments. FMN dissociates from Spir and processively moves with the 
growing barbed (+) end of actin filaments continuously inserting new actin monomers by its FH2 domains. KIND, kinase 
non-catalytic C-lobe domain; WH2, Wiskott-Aldrich syndrome protein homology 2; GTBM, globular tail domain binding 
motif; SB, Spir-box; FYVE, Fab1, YOTB/ZK632.12, VAC1, EEA1; FSI, formin/Spir interaction sequence; FH, formin homology. 
Only the C-terminal half of FMN proteins, including FH1, FH2 and FSI, is shown for better orientation. 
 
Very recently, an alternatively spliced exon has been discovered in a more C-terminal part of the 
linker region of vertebrate Spir-1 proteins, which was termed exon C (Figure 13) (339). This exon is 58 
amino acids in length and highly conserved across vertebrates, although not present in zebrafish. 
Exon C mediates the association of Spire1C, as the protein was termed accordingly, to mitochondrial 
membranes. It has been observed that the mitochondrial Spire1C cooperates with the endoplasmatic 
reticulum (ER) localised inverted formin 2 (INF2) to polymerise actin filaments used to induce 
mitochondrial fission (Figure 15). Furthermore, the short alternatively spliced exon B has been 
identified close to the WH2 domains. So far, no specific functions could be related to that exon. 
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1.7.3 Cooperation of myosin motors and actin assembly factors in membrane trafficking  
Within the last years growing evidence arose about the functional interconnection between 
intracellular cargo and their related receptors, motor proteins and actin assembly machineries to 
drive intracellular transport mechanisms (222, 334, 340–344). 
A body of evidence exists, dealing with the interplay of actin nucleation and myosin motor activity in 
order to generate forces to drive membrane invagination during endocytic events (340–343). The 
mammalian class I myosin member myosin 1E (Myo1E) has been revealed to be recruited to sites of 
clathrin-mediated endocytosis in mammalian cells along with the Arp2/3 complex actin nucleator 
and its activators WIP/WIRE and N-WASP (340). This co-recruitment facilitates first, the 
internalisation of cargo as an actin dependent process and second, the subsequent transport of the 
internalised membrane vesicles to endosomal compartments. The whole process demands a very 
tightly regulated protein and co-factor recruitment in space and time, to efficiently drive membrane 
invagination, vesicle scission and trafficking towards target compartments. Similar mechanisms have 
been demonstrated before in single cell organisms including fission yeast (341), budding yeast (342) 
and Dictyostelium (343) in which class I myosins cooperate with the Arp2/3 complex in actin 
polymerisation to subsequently induce endocytic events. In fission yeast, the classical Arp2/3 
complex activators Wsp1p and Vrp1p work together with Myo1p to activate Arp2/3 in order to 
generate branched actin filaments at sites of actin patch assembly as a prerequisite for endocytosis 
Figure 15 | Cooperation of Spire1C 
and INF2 in mitochondrial fission. 
Spire1C is located at the outer 
mitochondrial membrane, mediated 
by the alternatively spliced exon C, 
and physically interacts with the 
endoplasmatic reticulum associated 
inverted formin 2 (INF2) (339). The 
endoplasmatic reticulum wraps 
around the mitochondria and the 
Spire1C/INF2 mediated actin 
nucleation and polymerisation is 
suggested to generate pressure on 
the mitochondrial membranes in 
order to drive an initial membrane 
invagination (indicated by arrows). 
Subsequent recruitment of 
additional proteins is required to 
finally complete mitochondrial 
fission (339). 
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(341). In budding yeast, the sequential recruitment of Las17p, Vrp1p, syndapin Bzz1p and class I 
myosin Myo5p to endocytic sites induces actin polymerisation, and motor activity of Myo5p is 
essential for the following endocytic internalisation (342). A study on Dictyostelium actin assembly 
mechanisms has shown the formation of a multimeric protein complex by the p116 protein which 
links the Arp2/3 complex to the class I myosins myosin IB (myoB) and myosin IC (myoC) (343). In the 
proposed model myosin I moves the Arp2/3 complex nucleator machinery along F-actin to reach 
specific locales. 
Work in mouse metaphase oocytes provided insight into the cooperativity of actin nucleators, 
myosin motors and Rab GTPases (222, 334). As already described above, myosin Vb and Rab11 
cooperate to transport membrane vesicles towards the oocyte cortex in a completely actin 
dependent fashion (222). More intriguingly, the actin filaments serving as transport tracks are 
generated directly at the vesicle surface forming a complex actin mesh throughout the oocyte by 
Spir/FMN-2 mediated actin nucleation. Myosin Vb moves along these newly generated actin 
filaments to deliver Rab11-positive vesicles to the oocyte cortex. The Spir/FMN generated actin 
meshwork and the Rab11-positive vesicles are essential for proper spindle positioning during meiosis 
(256) and for the centred positioning of the oocyte nucleus (344). Here, a model has been proposed 
in which myosin Vb drives the so called active diffusion of the oocytic actin-coated vesicles to 
generate forces sufficient to move the nucleus. 
In collaboration with Edward Ziff and Seonil Kim (NYU Medical Center, New York, USA) the 
localisation of fluorescently labelled Spir-1 proteins in primary mouse hippocampal neurons has been 
unravelled to be mainly at the spine base (Edward Ziff and Seonil Kim, personal communication). As 
already mentioned, Wang and co-workers have shown that the recycling endosome, containing the 
GluA1 subunits of AMPA receptors is also located at the spine base. By Ca2+ regulated mechanisms, 
MyoVb and Rab11 cooperate to pull these endosomal membranes into the spine head to facilitate 
AMPA receptor insertion into the postsynaptic densities (251), potentially by the motor moving along 
actin tracks. Combining the Spir-1 localisation pattern and the endosome pulling mechanism, it is 
intriguing to speculate that the MyoVb/Rab11 dependent AMPA receptor subunit transport, leading 
to LTP induction and synaptic plasticity, might be coupled to Spir (and putatively FMN family 
members) regulated actin assembly. 
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1.7.4 Overlapping functions of Rab11 GTPases and Spir actin nucleators in exocytosis and recycling 
The functional correlation of Spir actin nucleators and Rab11 small GTPases has been described 
already a decade ago (325). Spir proteins colocalise with Rab11 on membrane surfaces of the trans-
Golgi network, post-Golgi vesicles and the recycling endosome, the major locales of Rab11 in 
eukaryotic cells (212–214). Furthermore, by experiments employing dominant-negative Spir protein 
fragments, the role of Spir proteins in exocytic and recycling transport of the vesicular stomatitis 
virus (VSV) G membrane protein in conjunction with Rab11 has been revealed (325). Besides the 
insights on Spir and Rab11 colocalisation and functional cooperation, a direct physical interaction of 
both proteins in vitro and in vivo has never been identified (Eugen Kerkhoff, personal 
communication). 
 
 
1.8 Aim of the thesis 
This thesis was aimed to obtain a deeper insight into the principles of intracellular vesicle transport 
processes and the underlying molecular mechanisms controlling regulated vesicle trafficking. The 
combined recruitment of myosin actin motor proteins and actin assembly factors to sites of active 
membrane transport seems to be a general mechanism conserved from single cell to higher order 
organisms. Based on published data on myosin V, Rab11, FMN and Spir cooperation in vesicle 
transport, a functional as well as physical interaction of the Spir actin nucleators and myosin V actin 
motors was investigated that might add to these observations and further support the principle of 
actin assembly protein/actin motor protein complex formation and its involvement in intracellular 
traffic. 
Spir and Rab11 proteins are functionally correlated in exocytic and recycling vesicle transport 
processes (325). However, a direct interaction of both proteins has not been identified and, thus, it is 
still unknown how Spir proteins specifically target Rab11-positive vesicles in order to contribute to 
distinct Rab11 driven transport processes. A recent study investigating the membrane targeting of 
the Spir/FMN actin nucleator complex revealed that the FYVE-type zinc-finger of the Spir-2 protein 
targets negatively charged intracellular membranes in a rather non-specific fashion without 
dependence on PIP3 (327). These findings exclude a solely Spir driven specific membrane targeting 
based on its membrane interaction capacities. It is intriguing to speculate that additional factors, 
such as other membrane associated proteins, might contribute to Spir targeting to Rab11 vesicles. 
Therefore, the role of myosin V actin motors as a linker between Spir and Rab11 in vitro and in living 
cells at vesicle surfaces was analysed. 
Accordingly, the thesis was intended to first unravel if Spir actin nucleators and myosin V actin motor 
proteins interact physically with each other in vitro and in eukaryotic cells at vesicle surfaces by 
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means of co-immunoprecipitation studies, GST-pulldowns and fluorescence microscopy studies in 
HeLa cells. The Spir/MyoV interaction at vesicle surfaces was analysed at the molecular level by FLIM-
FRET (fluorescence lifetime, Förster resonance energy transfer) microscopy. This part of the thesis 
was performed in collaboration with Dr. Thomas Weidemann (Max Planck Institute of Biochemistry, 
Martinsried, Germany). Subsequently, the interaction sites of both proteins were further 
characterised by means of mapping essential amino acids and by determining the crystal structure of 
the Spir:MyoVa complex. The crystallisation studies were performed in collaboration with Prof. Dr. 
Anne Houdusse and Dr. Olena Pylypenko (Institut Curie, Paris, France). 
The membrane targeting of Spir and myosin V was determined with respect to a potential mutual 
targeting of both proteins towards vesicle surfaces and putative regulatory mechanisms in 
membrane targeting, given the back-folded character of both Spir and myosin V full-length proteins 
at the inactive, cytoplasmic state. As it has been shown that the Rab27a effector protein 
melanophilin is able to open up and activate myosin Va in vitro by binding to its globular tail domain, 
a similar mechanism could apply for Spir proteins. 
For the final part of this thesis, the eventual formation of a tripartite Spir:MyoV:Rab11 complex at 
vesicle surfaces was investigated, deciding on vesicle identity and the generation of a distinct vesicle 
subpopulation. This complex would first allow for the functional Spir/Rab11 interaction in distinct 
intracellular transport processes in which the myosin V protein might act as a linker between Rab11 
and Spir. Second, the formation of a complex containing vesicle membrane receptors, actin assembly 
machineries and actin dependent motors could point towards a general mechanism used for 
trafficking of vesicles which require de novo generation of actin filaments. 
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2 Materials and methods 
 
2.1 Multiple sequence alignments of Spir protein sequences 
Multiple sequence alignments for GTBM and linker region of chosen Spir-1 and Spir-2 amino acid 
sequences were performed using the Clustal Omega Multiple Sequence Alignment tool (EMBL-EBI, 
Hinxton, UK) with manual confinements for the GTBM alignments. Calculations of protein sequence 
identities and similarities of Spir-linker and Spir-GTBM were done using the UniProt Align tool 
(UniProt Consortium). Respective cDNA sequences were obtained from the NCBI Gene database with 
the following accession numbers: Hs-Spir-1: NM_001128626.1, Hs-Spir-2: AJ422077, Mm-Spir-1: 
working sequence of the Kerkhoff Lab, Mm-Spir-2: AJ459115, Gg-Spir-1: XM_419119.4, Gg-Spir-2: 
XM_004944321.1, Xt-Spir-1: XM_012965027.1, Xt-Spir-2: XM_004913632.2, Br-Spir-1: 
NM_001044847.2, Br-Spir-2: NM_001007342.2. WebLogos (345) were generated from respective 
parts of the alignment of 223 Spir sequences and 44 MLPH sequences after reducing redundancy 
with CDhit (346), applying a 90% sequence similarity cut-off (in collaboration with Dr. Martin Kollmar, 
Max Planck Institute for Biophysical Chemistry, Göttingen, Germany). 
 
2.2 Agarose gel electrophoresis 
In order to separate PCR amplified DNA fragments and digested vectors and DNA inserts, PCR or 
restriction digest samples were mixed with 6x DNA loading dye and separated by agarose gel 
electrophoresis. Ultrapure agarose (ThermoFisher, Waltham, MA, USA) was solved in 0.5x TBE buffer 
by heating and shaking. Depending on the expected fragment size, agarose gels were used with 
suitable concentrations (in the range between 1% and 2.5%). Gel electrophoresis was usually 
performed at 120 V for 30 min in 0.5x TBE buffer. 
 
2.3 Agarose gel clean-up  
PCR amplified DNA fragments and digested vectors and DNA inserts were extracted from agarose 
gels for further processing. The DNA extraction was performed using the NucleoSpin Gel and PCR 
Clean-up kit (Macherey-Nagel, Düren, Germany). Respective bands in the gel were cut out and the 
gel slices were transferred into an Eppendorf tube. The slice was weighted and the double amount 
(mg to µl) of Binding Buffer (NTI) was added and subsequently incubated at 54°C to dissolve the gel 
completely. The solution was applied to a spin column containing a DNA binding membrane and 
centrifuged at 11,000 x g, 1 min, RT. The column was washed with 600 µl Wash Buffer (NT3) at 
11,000 x g, 1 min, RT. The membrane was dried by centrifugation at 11,000 x g, 2 min, RT. Bound 
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DNA was eluted in 30 µl Elution Buffer (EB) by incubating for 1 min and subsequent centrifugation at 
11,000 x g, 1 min, RT. 
 
2.4 Measurement of DNA and RNA concentrations 
The concentration of plasmid DNA, PCR amplified DNA fragments, isolated RNA as well as reverse 
transcribed cDNA was measured by spectrophotometric analysis using the GeneQuant photometer 
(GE Healthcare Life Sciences, Freiburg, Germany). The DNA was diluted 1:200 in autoclaved H2O (1:40 
for RNA preparations) and transferred into an opaque cuvette. The absorption of ultraviolet light (λ = 
260 nm) by the DNA is measured and the concentration is calculated accordingly. The contamination 
of the DNA sample was estimated by concurrent measurement of sample absorption at 280 nm, 
since proteins absorb light at 280 nm. The ratio of absorbance at 260 nm and 280 nm (A260/280) is 
calculated. An A260/280 ratio around 1.8 is considered as indicating 100% DNA (2.0 for RNA). 
 
2.5 PCR techniques 
2.5.1 Amplification of cDNA fragments for cloning 
DNA fragment amplification for cloning was performed using AccuPrime Pfx DNA Polymerase 
(ThermoFisher) employing 50 ng template DNA (plasmid DNA) (Table 2). The elongation time for DNA 
synthesis (tE) was adjusted to the length of the amplified fragment (60 sec per 1000 bp). The primer 
annealing temperature (TA) was usually set 5°C lower than the primers melting temperature. DMSO 
(5% to 10%) was added when using primers with high melting temperatures. Primers were designed 
manually, including restriction site overhangs, and ordered at Sigma-Aldrich (Taufkirchen, Germany) 
as lyophylised oligonucleotides. Very long primers or primers with high tendency to form secondary 
structures were purified by HPLC. An overview of all primers used in this thesis is provided in the 
supplements. 
Reagents Volume  Temperature Time 
Template DNA 50 ng  95°C 5 min 
Primer 5’ (10 µM) 3 µl  95°C 1 min 
Primer 3’ (10 µM) 3 µl  TA 30 sec 
10x Pfx buffer 5 µl  68°C tE 
Pfx DNA Polymerase 1 µl  68°C 5 min 
DMSO (optional) 5% - 10%  4°C hold 
H20 fill up to 50 µl    
Total volume 50 µl    
Table 2 | Protocol and cycling parameters for DNA fragment amplification by Pfx DNA Polymerase. 
TA = 5°C less than primers melting temperature  tE = 60 sec for 1000 bp 
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2.5.2 Colony PCR from bacterial colonies 
Colony PCR was performed to quickly check for positive bacterial colonies following transformation 
with newly generated plasmid DNA by using Taq DNA Polymerase with Standard Taq Buffer (New 
England Biolabs (NEB), Frankfurt am Main, Germany) (Table 3). Single colonies were picked and 
resuspended in 50 µl autoclaved H2O. The mixture was heated to 95°C for 10 min and centrifuged at 
16,000 x g for 5 min. 5 µl of the supernatant was used as template DNA. The respective cloning 
primers were used in order to obtain DNA bands with a specific length in agarose gel electrophoresis. 
 
Reagent Volume  Temperature Time 
Bacterial supernatant 5 µl  94°C 3 min 
dNTP mix (25 mM each) 0.2 µl  94°C  40 sec 
Primer 5’ (10 µM) 0.4 µl  TA 40 sec 
Primer 3’ (10 µM) 0.4 µl  72°C tE 
10x Taq buffer 2 µl  72°C  5 min 
Taq DNA Polymerase 0.2 µl  4°C  hold 
H2O 11.8 µl    
Total volume 20 µl    
Table 3 | Protocol and cycling parameters for Colony PCR using Taq DNA Polymerase. 
TA = 5°C less than primers melting temperature  tE = 60 sec for 1000 bp 
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2.5.3 QuikChange PCR for site-directed mutagenesis 
To introduce mutations (changes in the nucleotide sequence) into existing plasmid DNAs, 
QuikChange PCR was performed using the QuikChange Site-Directed Mutagenesis Kit (Agilent 
Technologies (former Stratagene), Santa Clara, CA, USA) and Pfu DNA polymerase (Promega, 
Mannheim, Germany) (Table 4). Primers were designed manually, including the desired mutations in 
the middle of the primers, and ordered at Sigma-Aldrich (Taufkirchen, Germany) as lyophylised 
oligonucleotides. Usually, these primers were purified by HPLC. An overview of primers used in this 
thesis is provided in the supplements. For each reaction 50 ng of template plasmid DNA was applied. 
 
Reagent Volume   Cycles Temperature Time 
Plasmid DNA 50 ng  1 1 95°C 30 sec 
dNTP mix (25 mM each) 1 µl  2 20 95°C 30 sec 
Primer 5’ (10 µM) 125 ng    55°C 1 min 
Primer 3’ (10 µM) 125 ng    68°C tE 
10x Pfu buffer 5 µl  
Pfu DNA Polymerase 1.5 µl  
DMSO (optional) 5% - 10%  
H2O fill up to 50 µl  
Total volume 50 µl  
Table 4 | Protocol and cycling parameters for QuikChange PCR with Pfu DNA Polymerase. 
TA = 55°C    tE = 120 sec for 1000 bp 
 
To destroy the residual template plasmid DNA, 1 µl DpnI endonuclease (NEB) was applied to each 
PCR reaction and incubated for 1 h at 37°C. DpnI specifically cleaves methylated and hemi-
methylated DNA (target sequence: 5’-Gm6ATC-3’), therefore only targeting the parental, methylated, 
DNA and not the newly synthesised, non-methylated DNA. Finally, NEB10-beta Competent E. coli 
cells were transformed according to the standard transformation protocol (see below). 
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2.5.4 One-Step RT-PCR from RNA preparations 
One-Step RT-PCR was performed using the QIAGEN One-Step RT-PCR Kit to amplify a corresponding 
cDNA fragment for cloning from template mRNA in a one-step reaction (Table 5). 200 ng RNA from 
mouse cerebellum preparations were used as template. Primers were designed manually, including 
restriction site overhangs, and ordered at Sigma-Aldrich as lyophylised oligonucleotides. An overview 
of primers used in this thesis is provided in the supplements. 
 
Reagent Volume  Temperature Time 
Template RNA 0.2 µg  50°C 30 min 
5x RT-PCR buffer 10 µl  95°C 15 min 
dNTP mix (10 mM each) 2 µl  94°C 30 sec 
Primer 5’ (10 µM) 3 µl  TA 1 min 
Primer 3’ (10 µM) 3 µl  72°C tE 
RT-PCR Enzyme Mix 2 µl  72°C 10 min 
RNase-free H2O fill up to 50 µl  4°C hold 
Total volume 50 µl    
Table 5 | Protocol and cycling parameters for One-Step RT-PCR from RNA. 
TA = 5°C less than primers melting temperature  tE = 60 sec for 1000 bp 
 
 
2.6 Cloning 
2.6.1 Restriction digest 
For restriction digests, 2 µg plasmid DNA were incubated with restriction endonucleases (NEB) in the 
appropriate buffer for 2-5 h at 37°C (Table 6, 7). 1 µl CIP (Alkaline Phosphatase, Calf Intestinal; NEB) 
was added both, 1 h and 30 min before the desired ending. CIP removes phosphate groups at the 5’ 
ends of the DNA and thus prevents re-ligation of the vector. Controls were used to check for proper 
digestion: undigested vector and the vector digested with only one of the two enzymes. For the 
digest of PCR amplified DNA fragments used as inserts, usually 7 µl of the gel extracted DNA was 
used. Following restriction digest, vector and inserts were separated by agarose gel electrophoresis 
and subsequently purified from gel for further processing. 
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Reagent Volume 
 Undigested Enzyme 1 Enzyme 2 Double digest 
Plasmid DNA 0.5 µg 0.5 µg 0.5 µg 2 µg 
Enzyme 1 - Enzyme dependent Enzyme dependent Enzyme dependent 
Enzyme 2 - Enzyme dependent Enzyme dependent Enzyme dependent 
10x NEBuffer 3 µl 3 µl 3 µl 3 µl 
H2O up to 30 µl up to 30 µl up to 30 µl up to 30 µl 
Total volume 30 µl 30 µl 30 µl 30 µl 
Table 6 | Protocol for vector digest. Enzyme: 2 µl for 5,000 U/ml, 1 µl for 10,000 U/ml, 0.5 µl for 20,000 U/ml. 
 
Reagent Volume 
Linear DNA insert 7 µl 
Enzyme 1 Enzyme dependent 
Enzyme 2 Enzyme dependent 
10x NEBuffer 3 µl 
H2O fill up to 30 µl 
Total volume 30 µl 
Table 7 | Protocol for insert digest. Enzyme: 2 µl for 5,000 U/ml, 1 µl for 10,000 U/ml, 0.5 µl for 20,000 U/ml. 
 
 
2.6.2 Ligation 
In order to combine digested vectors and DNA fragment inserts, a ligation was performed using T4 
DNA Ligase (NEB) at 16°C oN (alternatively for 1h, RT) (Table 8). 
 
Reagent Volume 
Digested vector 1-2 µl 
Digested insert 3-7 µl 
10x T4-Ligase buffer 2 µl 
T4 DNA Ligase 1 µl 
H2O fill up to 20 µl 
Total volume 20 µl 
Table 8 | Protocol for ligation of digested vectors and inserts. 
 
Following ligation, NEB10-beta Competent E. coli cells were transformed according to the standard 
transformation protocol (see below). 
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2.6.3 Transformation of Escherichia coli bacterial cells 
The following chemo-competent E.coli strains were used for transformations: E.coli 
Rosetta(DE3)pLysS (F– ompT hsdSB(rB– mB–) gal dcm (DE3) pLysSRARE2 (CamR)) and E.coli Rosetta (F– 
ompT hsdSB(rB– mB–) gal dcm pRARE2 (CamR)) were used for bacterial expression vectors, and NEB10-
beta Competent E. coli (Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 galK16 galE15 e14-
  ϕ80dlacZΔM15  recA1 relA1 endA1 nupG  rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-mcrBC); NEB) for 
cloning and plasmid DNA production and subsequent purification. Bacterial cells were thawed on ice. 
The complete ligation mixture (or 1 µl of existing plasmid DNA for re-transformations) was added to 
the cell suspension (100 µl) and incubated on ice for 1 h. A heat shock (42°C, 55 sec) followed to 
induce plasmid uptake. After a 2-min incubation on ice, 900 µl LB0 medium was added to the bacteria 
and incubated for at least 1 h at 37°C while shaking. Bacteria were pelleted for 10 min at 4,600 x g, 
RT and 800 µl of the supernatant was removed. Bacterial cells were resuspended in the remaining 
supernatant and bacteria were plated and cultured on respective agar selection plates oN at 37°C. 
 
2.6.4 Plasmid DNA extraction and purification from bacterial cells 
Following successful vector generation and transformation of E. coli cells, single colonies were picked 
and incubated in LB medium, containing respective antibiotics, and incubated at 37°C, oN, while 
shaking in order to produce sufficient amounts of plasmid DNA. On the next day, plasmid DNA was 
extracted and purified from the bacterial cells for further processing, including control of vector 
correctness, sequencing and long-term storage. Plasmid DNA extraction from bacterial cells was 
performed either as Plasmid-Mini-Purification (MiniPrep) for control digests, Plasmid-Mini-
Purification (MiniPrep) for sequencing, or Plasmid-Maxi-Purification (MaxiPrep). The QiaPrep Spin 
Miniprep Kit (Qiagen, Hilden, Germany) was used for MiniPrep and the Qiagen Plasmid Maxi Kit 
(Qiagen) was used for MaxiPrep. 
 
2.6.5 Plasmid-Mini-Purification (MiniPrep) for control digests 
Bacterial colonies were inoculated in 1.5 ml LB with respective antibiotics and incubated at 37°C, oN, 
while shaking. Cells were pelleted at 16,000 x g, 1 min and resuspended in 250 µl Resuspension 
Buffer P1 (QiaPrep Spin Miniprep Kit). 250 µl Lysis Buffer P2 was added and mixed gently. LyseBlue 
was added to the Resuspension Buffer so that now the cell solution turns blue which marks the right 
lysis conditions. Lysis was done for 5 min at RT. Afterwards, 250 µl Neutralisation Buffer P3 was 
added and mixed gently to turn the solution white. The solution was centrifuged at 16,000 x g, 5 min, 
RT to get rid of cell debris. 500 µl of the supernatant was added to 1 ml EtOH (100%) and incubated 
for 5 min at RT to precipitate the DNA. The solution was centrifuged at 16,000 x g, 10 min, RT. The 
DNA pellet was washed with 500 µl EtOH (70%) and centrifuged at 16,000 x g, 10 min, RT. Finally, the 
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supernatant was removed carefully, the DNA pellet was dried at 52°C and resuspended in 100 µl 
autoclaved H2O for further processing, including control digest to check for successful DNA fragment 
insertion. 
 
2.6.6 Plasmid-Mini-Purification (MiniPrep) for sequencing  
Bacterial colonies were inoculated in 10 ml LB with respective antibiotics and incubated at 37°C, oN, 
while shaking. Cells were pelleted at 4,600 x g, 10 min, RT and resuspended in 250 µl Resuspension 
Buffer P1 (QiaPrep Spin Miniprep Kit). 250 µl Lysis Buffer P2 was added and mixed gently. LyseBlue 
was added to the Resuspension Buffer so that now the cell solution turns blue which marks the right 
lysis conditions. Lysis was done for 5 min at RT. Afterwards, 350 µl Neutralisation Buffer N3 was 
added and mixed gently to turn the solution white. The solution was centrifuged at 16,000 x g, 10 
min, RT to get rid of cell debris. The supernatant was applied to a QIAprep spin column and 
centrifuged at 16,000 x g, 1 min, RT. The column was washed with 500 µl Binding Buffer PB and 
centrifuged at 16,000 x g, 1 min, RT. The column was again washed with 750 µl Wash Buffer PE and 
centrifuged at 16,000 x g, 1 min, RT. The membrane was dried by centrifugation at 16,000 x g, 2 min, 
RT. Bound DNA was eluted with 50 µl Elution Buffer EB by a 1-min incubation and centrifugation at 
16,000 x g, 1 min, RT. The purified plasmid DNA is now ready for further processing, including 
sequencing and subsequent cloning steps.  
2.6.7 Plasmid-Maxi-Purification  
Bacterial colonies were inoculated in 100 ml LB with respective antibiotics and incubated at 37°C, oN, 
while shaking. Cells were pelleted at 4,600 x g, 15 min, 4°C and resuspended in 10 ml Resuspension 
Buffer P1 (Qiagen Plasmid Maxi Kit). 10 ml Lysis Buffer P2 was added and mixed gently. LyseBlue was 
added to the Resuspension Buffer so that now the cell solution turns blue which marks the right lysis 
conditions. Lysis was done for 5 min at RT. Afterwards, 10 ml Neutralisation Buffer P3 was added, 
mixed gently to turn the solution white and incubated on ice for 10 min. The solution was 
centrifuged at 4,600 x g, 10 min, 4°C. Meanwhile, a Qiagen column was equilibrated with 10 ml 
Buffer QBT by gravity flow. The centrifugal supernatant was poured into the column using a filter 
paper to pick up cell debris and allowed to enter the column by gravity flow. The column was washed 
two times, 30 ml each, with Wash Buffer QC. Bound DNA was eluted in 15 ml Elution Buffer QF into a 
clean 50 ml Falcon tube. DNA was precipitated using 10.5 ml isopropanol (100%) and centrifuged at 
4,600 x g, 30 min, 4°C. The DNA pellet was washed with 5 ml ethanol (70%) and centrifuged at 4,600 
x g, 10 min, 4°C. The supernatant was carefully removed and the DNA pellet was dried at 50°C. The 
pellet was finally resuspended in 300 µl Tris-EDTA, pH 8.0 for long-term storage and was now ready 
for further processing, including transfections of eukaryotic cells. 
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2.6.8 Control digests 
Control digests were performed to check newly generated and isolated plasmid DNA for successful 
DNA fragment insertion. First, plasmid DNA was extracted and purified from bacterial colonies, and 
subsequently incubated with respective restriction endonucleases to obtain specific DNA bands on 
agarose gels. A master mix containing buffer, restriction endonucleases and H2O was prepared (Table 
9). 10 µl of plasmid DNA was incubated with 10 µl of the master mix for 2 h at 37°C. The presence of 
specific DNA bands was subsequently checked by agarose gel electrophoresis.  
Reagent Volume 
Plasmid DNA 10 µl 
10x NEBuffer 2 µl 
Enzyme 1 Enzyme dependent 
Enzyme 2 Enzyme dependent 
H2O fill up to 20 µl 
Total volume 20 µl 
Table 9 | Protocol for control digests. Enzyme: 2 µl for 5,000 U/ml, 1 µl for 10,000 U/ml, 0.5 µl for 20,000 U/ml. 
 
2.6.9 DNA Sequencing 
In order to verify DNA sequence correctness of newly generated plasmid DNA, the sequence was 
checked by a commercially available sequencing service (LGC Genomics, Berlin, Germany). Plasmid 
DNA was diluted to a concentration of 100 ng/µl with autoclaved H2O. Primers used for sequencing 
were either provided by the company, or own cloning primers or specifically synthesised sequencing 
primers were employed. Sequence correctness was verified by nucleotide sequence alignments 
(Nucleotide BLAST; NCBI) with the respective target cDNA sequence, and the correct reading frame 
throughout the desired sequence was analysed using Serial Cloner. 
 
2.7 Cell culture techniques 
HEK293 (human embryonic kidney) cells (ATCC, Manassas, Virginia, USA) and HeLa (human cervix 
carcinoma) cells (ATCC) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; 
ThermoFisher) supplemented with 10% fetal calf serum (FCSIII; GE Healthcare Life Sciences, 
HyClone), 2 mM L-Glutamine (ThermoFisher), penicillin (100 units/ml; ThermoFisher) and 
streptomycin (100 µg/ml; ThermoFisher) (from now on referred to as Full Medium) at 37°C, 5% CO2, 
95% humidity and were passaged regularly at 80% confluency. For passaging, old medium was 
removed and cells were washed once with 1x PBS to get rid of residual serum. Cells were detached 
using Trypsin-EDTA solution (0.05%; ThermoFisher) for 2-5 min (until detachment) at RT. Trypsin-
 45 2 Materials and methods 
EDTA was inactivated by adding Full Medium. A fraction of the cell suspension was then transferred 
into a new culture dish containing fresh medium, generally at a ratio of 1:5 for HeLa cells and 1:10 for 
HEK293 cells. 
 
2.7.1 Thawing cells 
Eukaryotic cells are kept in liquid nitrogen for long-term storage. A frozen stock was thawed rapidly 
at 37°C in a water bath and the cells were transferred into a 50 ml Falcon tube containing 15 ml Full 
Medium. The cell suspension was centrifuged at 800 x g, 6 min, RT. The supernatant was removed 
and cells were resuspended in 1 ml pre-warmed Full Medium. The cell suspension was finally 
transferred into a 10 cm dish (Greiner Bio-One, Frickenhausen, Germany) containing 9 ml pre-
warmed Full Medium. Cells were cultured at 37°C, 5% CO2. 
 
2.7.2 Freezing cells 
For long-term storage, cells were kept in liquid nitrogen. A specific Freezing Medium was prepared 
consisting of DMEM supplemented with 20% FCSIII, 2 mM L-Glutamine, penicillin (100 units/ml), 
streptomycin (100 µg/ml) and 10% DMSO. DMSO and FSCIII act as cyroprotective agents preventing 
the formation of ice crystals inside the cell. Eight 10 cm dishes with cells at approximately 80% 
confluency were normally used for one freezing procedure. The old medium was removed, cells were 
washed with 1x PBS and detached with Trypsin-EDTA as described above. Full medium was added to 
inactivate Trypsin-EDTA and the cell suspension was transferred into 5 ml Freezing Medium. After 
centrifugation at 800 x g, 6 min, RT the supernatant was removed and the cells were resuspended in 
18 ml Freezing Medium. 1 ml aliquots were transferred into cryovials (ThermoFisher, Nunc). Vials 
were stored in a cryo-box filled with isopropanol at -80°C, oN, to allow slow freezing (-1°C per 
minute). The slow freezing induces cell shrinkage due to loss of water and prevents formation of ice 
crystals inside the cell which would cause damage. On the next day, cryovials containing the cells 
were transferred into liquid nitrogen for long-term storage. 
 
2.7.3 Poly-L-Lysine coating of 6-well plates 
Prior to seeding HEK293 cells for transfections in 6-well plastic plates, the wells need to be coated 
with Poly-L-Lysine to prevent cell loss during multiple washing steps because of the weak HEK293 cell 
adhesion capacity. Poly-L-Lysine (Sigma-Aldrich) was diluted 1:10 in sterile H2O (Sigma-Aldrich). 1 ml 
of this dilution was added per well and shortly incubated. Wells were washed once with 1x PBS to get 
rid of residual solution and allowed to dry with a slightly open lid. Subsequently, cell seeding was 
perfomed as described. 
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2.7.4 Seeding cells  
Cells were seeded on 6-well plates, WillCo dishes or microscope cover glasses in the respective 
densities prior to transfections. To seed cells, old medium was removed, cells were washed with 1x 
PBS and detached with Trypsin-EDTA as described above. Full Medium was added to inactivate 
Trypsin-EDTA, cells were transferred into a Falcon tube and centrifuged at 800 x g, 6 min, RT. The 
supernatant was removed and cells were resuspended in an appropriate volume of Full Medium, 
according to the expected cell number. 10 µl of the cell suspension was mixed with 10 µl Trypan Blue 
solution (0.4%; Sigma-Aldrich) to distinguish between viable and dead cells. Only the white, living 
cells were counted in a Neubauer counting chamber, considering all four major squares and 
calculating the mean (𝑋�). One major square, consisting of 4 × 4 minor squares, is 1 𝑚𝑚 in length 
and 1 𝑚𝑚 in width. The distance between cover glass and counting chamber is 0.1 𝑚𝑚. Considering 
this, the counted cell number is in a volume of  1 × 1 × 0.1 𝑚𝑚 = 0.1 𝑚𝑚3 = 0.1  µ𝑙. To equal the 
dilution by Trypan Blue, the cell concentration is multiplied with 2. To normalise the concentration to 
ml volumes, the concentration is multiplied with 104 to get the number of cells per ml. 
 
𝑋� × 2 × 104 = 𝑠𝑠𝑙𝑙 𝑠𝑐𝑛𝑠𝑠𝑛𝑐𝑐𝑐𝑐𝑐𝑐𝑛 [𝑐𝑐𝑐𝑐𝑐
𝑚𝑐
] 
 
The volume of the cell suspension required to get the desired cell number was calculated as follows: 
 
𝑑𝑐𝑐𝑑𝑑𝑐𝑑 𝑛𝑛𝑚𝑛𝑐𝑑 𝑜𝑜 𝑐𝑐𝑐𝑐𝑐 [𝑐𝑐𝑐𝑐𝑐]
𝑐𝑐𝑐𝑐 𝑐𝑜𝑛𝑐𝑐𝑛𝑐𝑑𝑐𝑐𝑑𝑜𝑛 [𝑐𝑐𝑐𝑐𝑐
𝑚𝑐
]  = 𝑌 𝑚𝑙 𝑐𝑜 𝑠𝑠𝑙𝑙 𝑠𝑠𝑠𝑠𝑠𝑛𝑠𝑐𝑐𝑛 
 
The appropriate volume of the cell suspension was transferred into the respective culture plate or 
dish which was already filled with Full Medium. Seeded cells were allowed to attach over night at 
37°C, 5% CO2. 
 
2.7.5 Transfection of eukaryotic cells using Lipofectamine Reagent 
One day prior to transfection HEK293 and HeLa cells were seeded on 6-well plates, WillCo dishes or 
microscope cover glasses at densities as described individually for each experiment. Plasmid DNA 
was diluted in DMEM without supplements (DMEM w/s) to obtain a concentration of 0.1 µg/µl (e.g. 5 
µg in 50 µl). 6 µL of Lipofectamine Reagent (ThermoFisher) was mixed with 100 µL DMEM w/s (per 
sample) and incubated for 5 min at RT. Per sample, 100 µl of the Lipofectamine dilution and 0.5 to 
1.5 µg plasmid DNA (depending on the expected expression levels of the protein and on the number 
of transfected plamids per sample) were mixed and filled up with DMEM (w/s) to 200 µl. The mixture 
was incubated for 25-30 min at RT. Meanwhile, seeded cells were washed two times with DMEM w/s 
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to get rid of any residual serum that would disturb transfections. After the incubation time, 800 µl 
DMEM w/s was added to the transfection mixture and the whole solution (1 ml) was transferred to 
the cells. Transfections incubated for 4-5 hours at 37°C, 5% CO2. Finally, the transfection solution was 
removed and fresh Full Medium was added. Cells were incubated at 37°C, 5% CO2 for at least 24 
hours to allow efficient protein production. 
 
2.8 Protein work 
2.8.1 SDS-PAGE 
Protein preparations were mixed with SDS protein sample buffer (Laemmli buffer) and denatured at 
95°C for 10 min. Proteins were separated on SDS gels with respective concentrations (depending on 
the molecular weight of the proteins to be separated, between 7.5% and 15%) at 50 mA per gel in 1x 
SDS-PAGE buffer. To obtain even separations for each lane, every lane was filled with the same 
amount of protein sample. The Precision Plus Protein Standard (Dual Color; Bio-Rad, Munich, 
Germany) was used as a molecular weight marker. 
 
2.8.2 Western blotting – Protein transfer 
Proteins were transferred from SDS gels to nitrocellulose membranes (Protran Nitrocellulose 
Transfer Membrane, 0.45 µm pore size; GE Healthcare Life Sciences) by use of the Mini Trans-Blot 
Cell system (Bio-Rad) in 1x Transfer Buffer (containing 20% methanol). Protein transfer was 
performed depending on the molecular weight of the respective proteins. Smaller proteins were 
typically transferred at 150 mA, RT for 2 h; larger proteins were typically transferred either at 150 
mA, RT for 3h, or at 40V, 4°C, oN. Directly following the protein transfer, proteins were visualised by 
Ponceau S staining to check for equal loading of all lanes. Unspecific antibody binding sites were 
blocked with 5% milk powder solution in 1x PBST at 4°C, oN or for 1h, RT. Following blocking, blots 
were incubated with primary and secondary antibodies, and protein bands were detected as 
described below. 
 
2.8.3 Western blotting - Ponceau S staining 
Ponceau S staining was performed to show equal loading of all lanes. Membranes were incubated for 
5 min in Ponceau S staining solution and subsequently washed with de-ionised H2O to get clear bands 
without background. For complete decolouration the membrane was washed in 1x PBST. 
 
2.8.4 Western blotting - Antibody treatment 
After blocking, the membrane was incubated with the primary antibody according to antibody 
protocols (Table 10). To remove residual antibody solution, blots were washed in 1x PBST. 
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Subsequently, the blot was incubated with the secondary antibody, coupled to HRP (horse-radish-
peroxidase), according to antibody protocols (Table 11). To remove residual antibody solution, blots 
were washed in 1x PBST. Protein bands were visualised by chemiluminescence signals (Luminata 
Forte Western HRP Substrate; Merck Millipore, Darmstadt, Germany). The signal was recorded with 
an ImageQuant LAS 4000 Lumineszent Image Analyser (GE Healthcare Life Sciences). Recorded 
images were processed in Adobe Photoshop and assembled in Adobe Illustrator. To prepare the blot 
for incubation with a second or third primary antibody, the blot was stripped and blocked again.  
 
2.8.5 Antibody protocols 
Primary antibody Concentration and 
blocking solution 
Incubation 
conditions 
Living Colors® A.v. Peptide Antibody 
(Anti-GFP, rabbit  polyclonal; TakaraBio/Clontech,  
Saint-Germain-en-Laye, France) 
1:100; 5% milk =�  1 µg/ml 2 h, RT 
Anti-Spir-1 (SA2133), rabbit polyclonal (322) 1:1000; 1x PBST =�  0.5 µg/mL 3 h, RT 
Living Colors® DsRed, rabbit polyclonal antibody 
(TakaraBio/Clontech) 
1:1000; 5% milk =�  0.5 µg/ml; 2 h, RT 
Anti-c-Myc (9E10), mouse monoclonal antibody  
(Santa Cruz Biotechnology) 
1:500; 5% milk =�  0.4 µg/ml 2 h, RT 
Anti-myosin Va, rabbit polyclonal  
(Cell Signaling Technology, Leiden, Netherlands) 
1:750; 5% milk 3 h, RT 
Anti-Rab11a (D4F5 XP), rabbit monoclonal  
(Cell Signaling Technology) 
1:1000; 5% milk 3 h, RT 
Table 10 | Overview on primary antibody protocols for Western blotting.   
Secondary antibody Concentration and  
blocking solution 
Incubation 
conditions 
Donkey anti-rabbit, HRP-linked  
(GE Healthcare Life Sciences) 
1:5000; 1.6 % milk 1 h, RT 
Sheep anti-mouse, HRP-linked 
(GE Healthcare Life Sciences) 
1:5000; 1.6 % milk 1 h, RT 
Table 11 | Overview on secondary antibody protocols for Western blotting. 
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2.8.6 Western blotting – Blot stripping 
In order to remove primary and secondary antibodies from the membrane and to prepare it for 
following antibody treatments, blots were stripped in Stripping Buffer. 50 ml Stripping Buffer per 
membrane were supplemented with 345 µl β-Mercaptoethanol solution (12.8 M stock) and warmed 
to 50°C. Blots were incubated in warm Stripping Buffer for 3 × 20 𝑚𝑐𝑛 at 50°C. To remove residual 
Stripping Buffer, blots were washed extensivly for 4 × 15 𝑚𝑐𝑛 in 1x PBST. Finally, blots were blocked 
in 5% milk powder solution in 1x PBST as described and incubated with new antibody solutions. 
 
2.9 Production and purification of recombinant proteins in E.coli bacteria 
Escherichia coli strains were transformed with expression vectors generated for recombinant protein 
expression. GST-MyoVa/b-GTD proteins were expressed in E.coli Rosetta(DE3)pLysS (F– ompT 
hsdSB(rB– mB–) gal dcm (DE3) pLysSRARE2 (CamR); Merck Millipore, Novagen). His6-mCherry-Spir-2-
linker(LALA), GST-Rab11a-Q70L and GST-Spir-2-GTBM-SB-FYVE proteins were expressed in E.coli 
Rosetta (F– ompT hsdSB(rB– mB–) gal dcm pRARE2 (CamR); Merck Millipore, Novagen). 
  
The whole protein purification procedure was performed in two sequential purification steps. At first, 
a batch purification using specific beads for affinity based purification was done with Glutathione 
Sepharose 4B beads (GE Healthcare Life Sciences) for GST-tags, and Ni-NTA Agarose beads (Qiagen) 
for His6-tags, respectively. Second, a size exclusion chromatography (SEC) was performed using an 
ÄKTApurifier system (GE Healthcare Life Sciences) and High Load 16/60 Superdex 200 SEC column 
(GE Healthcare Life Sciences). For SEC, the column was first calibrated with Gelfiltration buffer (1.5 
CV, flow rate: 1 ml/min). The protein solution was then loaded on the column and separated in 
Gelfiltration buffer using a pre-designed method (Sdex1660completerun; 1.2 CV, flow rate: 1 
ml/min). 2-ml fractions were collected automatically. Single fractions were analysed by SDS gel 
electrophoresis and Coomassie staining for presence of respective protein bands with the desired 
size, and the right fractions were pooled using Amicon Ultra centrifugal filters (Merck Millipore) with 
respective molecular weight cut offs in order to increase the protein concentration. All purification 
steps were performed at 4°C. Protein concentrations were measured by Bradford assay as described 
below. Small aliquots were prepared (30-100 µl, depending on the protein concentration), quickly 
frozen in liquid nitrogen, and stored at -80°C. 
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2.9.1 Purification of GST-MyoVa/b-GTD 
The bacterial expression vectors pGEX-4T1-NTEV-mm-MyoVa-GTD or pGEX-4T1-NTEV-hs-MyoVb-GTD 
were expressed in E.coli Rosetta(DE3)pLysS. A 37°C oN culture was used to inoculate 1 l LB medium 
(1:50), supplemented with 100 mg/l ampicillin, 30 mg/l chloramphenicol. Bacteria were grown at 
37°C until an OD600 ~0.8. Protein expression was induced by adding 0.1 mM Isopropyl-β-D-
thiogalactopyranoside (IPTG; Sigma-Aldrich), and continued at 20°C, 18 h. Bacteria were harvested by 
pelleting at 5,500 x g, 30 min, 4°C and the bacterial pellet was washed in 1x PBST. Bacteria were 
pelleted again at 4,600 x g, 30 min, 4°C, resuspended in 5 times the pellet mass (v/w) Lysis buffer and 
subsequently lysed by ultra-sonication (6 x 30 sec, 6 cycles, 60% amplitude) on ice. The lysates were 
centrifuged at 75,000 x g, 2 x 30 min, 4°C, and the cleared supernatant was incubated with 1 ml 
Glutathion Sepharose 4B beads (1:1 suspension) for 2 h at 4°C on a rotating wheel. The beads were 
pelleted (500 x g, 5 min, 4°C) and washed 5 times in 5 ml Wash buffer. Bound proteins were eluted 
from the beads by Elution buffer for 5 x 30 min in 1 ml buffer for each elution step. The eluted 
fractions were concentrated via Amicon 50K centrifugal filters at 4,000 x g, 4°C in 10-min steps until ~1 ml protein solution is left. The concentrated protein solution was loaded on the ÄKTApurifier (2 
ml loop) by a syringe and the proteins were separated by size exclusion chromatography. All buffers 
for the respective purification steps are listed in Table 12. 
 
Wash buffer  
for GST-MyoVa/b-GTD 
 
 
 
      Lysis buffer 
- 1x PBS, pH 8.0 
- 2 mM β-Mercaptoethanol  
- 5% (v/v) Glycerol  
- 2 mM MgCl2 
- 0.05% Tween20 
- add freshly: 1 mM PMSF, complete Mini 
Protease Inhibitor Cocktail  
  
Elution buffer  
for GST-MyoVa/b-GTD 
 
- 20 mM Tris-HCl, pH 8.0 
- 150 mM NaCl 
- 2 mM β-Mercaptoethanol  
- 2 mM MgCl2 
- 5% Glycerol 
- 20 mM Glutathion  
  
Gelfiltration buffer  
for GST-MyoVa/b-GTD 
 
- 20 mM Tris-HCl, pH 8.0 
- 150 mM NaCl 
- 2 mM DTE 
- 2 mM MgCl2 
- 5% Glycerol 
- filter sterile, de-gas, store at 4°C 
Table 12 | Buffers for purification of GST-MyoVa/b-GTD proteins. 
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2.9.2 Purification of His6-mCherry-Spir-2-linker(LALA) 
The bacterial expression vector pProEx-HTb-mCherry-hs-Spir-2-linker(LALA) was expressed in E. coli 
Rosetta. A 37°C oN culture was used to inoculate 1 l LB medium (1:50), supplemented with 100 mg/l 
ampicillin, 30 mg/l chloramphenicol. Bacteria were grown at 37°C until an OD600 ~0.8. Protein 
expression was induced by 0.1 mM IPTG, and continued at 20°C, 18 h. Bacteria were harvested by 
pelleting at 5,500 x g, 30 min, 4°C and the bacterial pellet was washed in cold 1x PBST. Bacteria were 
pelleted again at 4,600 x g, 30 min, 4°C, resuspended in 5 times the pellet mass (v/w) Lysis buffer, 
and subsequently lysed by ultra-sonication (6 x 30 sec, 6 cycles, 60% amplitude) on ice. The lysates 
were centrifuged at 75,000 x g, 2 x 30 min, 4°C, and the cleared supernatant was incubated with 1 ml 
Ni-NTA Agarose beads (1:1 suspension) for 2 h at 4°C on a rotating wheel. The beads were pelleted 
(500 x g, 5 min, 4°C) and washed 5 times in 5 ml Wash buffer. Bound proteins were eluted from the 
beads by Elution buffer for 5 x 30 min in 1 ml buffer for each elution step. The eluted fractions were 
concentrated via Amicon 30K centrifugal filters at 4,000 x g, 4°C in 10-min steps until ~1 ml protein 
solution is left. The concentrated protein solution was loaded on the ÄKTApurifier (2 ml loop) by a 
syringe and the proteins were separated by size exclusion chromatography. All buffers for the 
respective purification steps are listed in Table 13. 
 
Wash buffer  
for His6-mCherry-Spir-2-linker (LALA) 
 
 
      Lysis buffer 
 
- 20 mM Tris-HCl, pH 8.0 
- 300 mM NaCl  
- 20 mM Imidazol  
- 5 mM β-Mercaptoethanol 
- add freshly: 1 mM PMSF, complete Mini Protease 
Inhibitor Cocktail  
  
Elution buffer  
for His6-mCherry-Spir-2-linker (LALA) 
 
- 20 mM Tris-HCl, pH 8.0 
- 300 mM NaCl 
- 300 mM Imidazol 
- 5 mM β-Mercaptoethanol   
  
Gelfiltration buffer  
for His6-mCherry-Spir-2-linker (LALA) 
- 2x PBS, pH 7.2 
- 10% Glycerol 
- filter sterile, de-gas, store at 4°C 
Table 13 | Buffers for purification of His6-mCherry-Spir-2-linker(LALA) proteins. 
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2.9.3 Purification of GST-Rab11a-Q70L 
The bacterial expression vector pGEX-4T1-NTEV-cl-Rab11a-Q70L was expressed in E. coli Rosetta. A 
37°C oN culture was used to inoculate 1 l LB medium (1:50), supplemented with 100 mg/l ampicillin, 
30 mg/l chloramphenicol. Bacteria were grown at 37°C until an OD600 ~0.8. Protein expression was 
induced with 0.1 mM IPTG, and continued at 20°C, 18 h. Bacteria were harvested by pelleting at 
5,500 x g, 30 min, 4°C and the bacterial pellet was washed in 1x PBST. Bacteria were pelleted again at 
4,600 x g, 30 min, 4°C, resuspended in 5 times the pellet mass (v/w) Lysis buffer, and subsequently 
lysed by ultra-sonication (6 x 1 min, 6 cycles, 60% amplitude) on ice. The lysates were centrifuged at 
75,000 x g, 2 x 30 min, 4°C and the cleared supernatant was incubated with 1 ml Glutathion 
Sepharose 4B beads (1:1 suspension) for 3 h at 4°C on a rotating wheel. The beads were pelleted 
(500 x g, 5 min, 4°C) and washed 5 times in 5 ml Wash buffer. Bound proteins were eluted from the 
beads by Elution buffer for 5 x 30 min in 1 ml buffer for each elution step. The eluted fractions were 
concentrated via Amicon 50K centrifugal filters at 4,000 x g, 4°C in 10-min steps until ~1 ml protein 
solution is left. The concentrated protein solution was loaded on the ÄKTApurifier (2 ml loop) by a 
syringe and the proteins were separated by size exclusion chromatography. All buffers for the 
respective purification steps are listed in Table 14. 
 
Wash buffer  
for GST-Rab11a-Q70L 
 
 
 
      Lysis buffer 
- 1x PBS, pH 7.8 
- 2 mM β-Mercaptoethanol 
- 5% Glycerol (v/v) 
- 2 mM MgCl2 
- 0.05% Tween20 
- add freshly: 1 mM PMSF, complete Mini 
Protease Inhibitor Cocktail  
  
Elution buffer  
for GST-Rab11a-Q70L  
- 20 mM Tris-HCl, pH 7.8 
- 150 mM NaCl 
- 2 mM β-Mercaptoethanol 
- 2 mM MgCl2 
- 5% Glycerol (v/v) 
- 20 mM Glutathion  
  
Gelfiltration buffer  
for GST-Rab11a-Q70L 
- 20 mM Tris-HCl, pH 7.8 
- 150 mM NaCl 
- 2 mM DTE 
- 2 mM MgCl2 
- 5% Glycerol 
- filter sterile, de-gas, store at 4°C 
Table 14 | Buffers for purification of GST-Rab11a-Q70L proteins. 
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2.9.4 Purification of GST-Spir-2-GTBM-SB-FYVE 
The bacterial expression vector pGEX-4T3-hs-Spir-2-GTBM-SB-FYVE was expressed in E. coli Rosetta. 
A 37°C oN culture was used to inoculate 1 l LB medium (1:50), supplemented with 100 mg/l 
ampicillin, 30 mg/l chloramphenicol. Bacteria were grown at 37°C until an OD600 ~0.8. Protein 
expression was induced with 0.15 mM IPTG, and continued at 18°C, 20 h. Bacteria were harvested by 
pelleting at 5,500 x g, 30 min, 4°C, and the bacterial pellet was washed in 1x PBST. Bacteria were 
pelleted again at 4,600 x g, 30 min, 4°C, resuspended in 40 ml Lysis buffer (supplemented with 0.1% 
Triton-X100, 2 protease inhibitor cocktail tablets (complete Mini, EDTA-free; Roche, Penzberg, 
Germany), 1 mM Phenylmethylsulfonylfluoride (PMSF; Sigma-Aldrich)) and subsequently lysed by 
ultra-sonication (6 x 1 min, 6 cycles, 60% amplitude) on ice. The lysates were centrifuged at 27,000 x 
g, 2 x 30 min, 4°C, and the cleared supernatant was incubated with 1 ml Glutathion Sepharose 4B 
beads (1:1 suspension) for 2.5 h at 4°C on a rotating wheel. The beads were pelleted (500 x g, 5 min, 
4°C) and washed 5 times in 5 ml Wash buffer. Bound proteins were eluted from the beads by Elution 
buffer for 4 x 30 min in 1 ml buffer for each elution step. 2 ml of the collected elution fractions were 
directly loaded on the ÄKTApurifier (2 ml loop) by a syringe and the proteins were separated by size 
exclusion chromatography. The residual 2 ml elution was loaded afterwards and the SEC was 
repeated with the same conditions to both, increase protein yield and avoide excess protein 
concentrations that could lead to protein precipitation. All buffers for the respective purification 
steps are listed in Table 15. 
 
Wash buffer  
for GST-Spir-2-GTBM-SB-FYVE 
      Lysis buffer 
 
- 2x PBS, pH 7.2 
- 10% Glycerol (v/v) 
- add freshly: 1 mM PMSF, complete Mini Protease 
Inhibitor Cocktail, 0.1% Triton-X100 
  
Elution buffer  
for GST-Spir-2-GTBM-SB-FYVE 
 
- 2x PBS, pH 7.2 
- 10% Glycerol (v/v) 
- 20 mM Glutathion 
  
Gelfiltration buffer  
for GST-Spir-2-GTBM-SB-FYVE 
 
- 2x PBS, pH 7.2 
- 10% Glycerol (v/v) 
- filter sterile, de-gas, store at 4°C 
Table 15 | Buffers for purification of GST-Spir-2-GTBM-SB-FYVE proteins. 
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2.9.5 Bradford assay to determine protein concentrations 
Bradford assay was used to determine concentrations of recombinant, bacterially expressed, purified 
proteins. The lab uses a self-prepared Bradford solution which needs an initial calibration to use for 
subsequent measurements. The Bradford stock solution (Coomassie Plus Protein Assay Reagent; 
ThermoFisher) was mixed 2:1 with de-ionised H2O. A calibration line was determined with H2O only, 
Bradford solution only and Bradford solution supplemented with BSA protein standard rising from 1 
µg to 15 µg in 1 µg steps. The absorption at 595 nm of the solution was measured and a calibration 
line was calculated with: 
𝑦 =  𝑐 × 𝑥 +  𝑏 
 
For subsequent measurements of protein concentrations, 1 ml calibrated Bradford solution was 
adjusted to RT in a transparent cuvette. 1 µl protein solution was added and incubated for 10 min at 
RT. The absorption of the solution at 595 nm was determined and the concentration of the protein 
solution as calculated with: 
𝑥 =  (𝐴595 –  𝑏) / 𝑐 
 
2.10 Co-immunoprecipitation 
HEK293 cells were seeded on Poly-L-Lysine coated 6-well plates (6 × 105 cells per well) as described 
above, one day prior to transfection. HEK293 cells were transfected with expression vectors encoding 
Myc-epitope-tagged Spir proteins and AcGFP-tagged myosin V fragments as described above in 
triplicates (the cells of three wells are pooled and handled as one sample). 48 hours post 
transfection, cells were washed two times with 1x PBS to remove residual medium and serum. Cells 
were scraped off the wells in 333 µl Lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 
10% (v/v) glycerol, 0.1% (v/v) Nonidet P-40, 1 mM PMSF, protease inhibitor cocktail) per well. The 
cells of three wells were pooled per sample and the cells were lysed for 40 min, 4°C on a rotating 
wheel. Cell lysates were centrifuged at 20,000 x g, 20 min, 4°C, to remove insoluble debris. 
Meanwhile, respective amounts of Protein G-Agarose beads (Roche) were washed three times in 
Pulldown Buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 0.1% (v/v) 
Nonidet P-40) and a 1:1 suspension of beads and Pulldown Buffer was prepared for subsequent use. 
The cleared supernatant was pre-incubated with 20 µl Protein G-Agarose beads (1:1 suspension) for 
1 h, 4°C on a rotating wheel to get rid of proteins unspecifically binding to the beads. 40 µl of the 
cleared supernatant were mixed with 5x Laemmli buffer and used as cleared lysates in Western blots 
to check for protein expression levels. Beads from the pre-incubation step were pelleted at 500 x g, 3 
min, 4°C and the supernatant was transferred into a new tube. The supernatant was subsequently 
incubated with 4 µg anti-c-Myc antibody (9E10, mouse monoclonal; Santa Cruz Biotechnology, Dallas, 
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TX, USA) for 1 h on ice. Subsequently, 40 µl Protein G-Agarose beads (1:1 suspension) were added 
and incubated for 2 h, 4°C on a rotating wheel. Beads were washed in Pulldown Buffer four times, 
500 µl each, and every time beads were pelleted at 500 x g, 2 min, 4°C. Beads were pelleted finally 
and any residual fluid was removed carefully but completely. Bound proteins were eluted by 40 µl 1x 
Laemmli buffer and denatured for 10 min at 95°C. Potential protein interactions in co-IPs and the 
protein expression levels in the cleared lysates were analysed by immunoblotting using respective 
antibodies. 
 
2.11 GST-pulldown from HEK293 lysates 
HEK293 cells were seeded on Poly-L-Lysine coated 6-well plates (6 × 105 cells per well) as described 
above, one day prior to transfection. HEK293 cells were co-transfected with expression vectors 
encoding Myc-Spir-2-FL, mStrawberry-FMN-2-FH2-FSI, eGFP-MyoVa-D-FL and eGFP-MyoVa-D-
Q1753R, respectively, as described above, in triplicates (the cells of three wells are pooled and 
handled as one sample). 24 hours post transfection, cells were washed two times with 1x PBS to 
remove residual medium and serum. Cells were scraped off the wells in 333 µl Lysis buffer (25 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 0.1% (v/v) Nonidet P-40, 1 mM PMSF, 
protease inhibitor cocktail) per well. The cells of three wells were pooled per sample and cells were 
lysed for 40 min at 4°C on a rotating wheel. Cell lysates were centrifuged at 20,000 x g, 20 min, 4°C, 
to remove insoluble debris. Meanwhile, respective amounts of GSH-Sepharose 4B beads were 
washed three times in Pulldown Buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 10% 
(v/v) glycerol, 0.1% (v/v) Nonidet P-40) and a 1:1 suspension of beads and Pulldown Buffer was 
prepared for subsequent use. The cleared supernatant was pre-incubated with 20 µl GSH-Sepharose 
4B beads (1:1 suspension) for 1 h, 4°C on a rotating wheel to get rid of proteins unspecifically binding 
to the beads. 40 µl of the cleared supernatant were mixed with 5x Laemmli buffer and used as 
cleared lysates in Western blots to check for protein expression levels. For GST-pulldown assays, 65 
µg GST-Rab11a-Q70L protein and 25 µg GST protein as a control, respectively, was coupled to 40 µl 
GSH-Sepharose 4B beads (1:1 suspension) in 500 µl Pulldown Buffer for 1:20 h, 4°C on a rotating 
wheel. Beads were pelleted at 500 x g, 2 min, 4°C and washed two times with Pulldown Buffer, 500 µl 
each, by pelleting beads each time at 500 x g, 2 min, 4°C. Beads were pelleted again and any residual 
fluid was removed completely. Beads from the pre-incubation step were pelleted at 500 x g, 3 min, 
4°C, and the supernatant (cell lysates) were transferred to the GST-protein coupled GSH-Sepharose 
4B beads and incubated for 2:15 h, 4°C on a rotating wheel. Beads were pelleted at 500 x g, 2 min, 
4°C and washed four times with Pulldown buffer, 500 µl each. Beads were pelleted finally and any 
residual fluid was removed carefully but completely. Bound proteins were eluted by 40 µl 1x Laemmli 
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buffer and denatured for 10 min at 95°C. Potential protein interactions in Pulldowns and the protein 
expression in cleared lysates were analysed by immunoblotting using respective antibodies. 
 
2.12 GST-pulldown from mouse brain 
Wild-type C57BL/6N mice were killed by cervical dislocation. One brain was used for one experiment. 
The brain was isolated immediately, washed three times in ice-cold 1x PBS and lysed in 1 ml Lysis 
Buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 0.1% (v/v) Nonidet P-
40, 0.1 M NaF, 1 mM Na3VO4, 1 mM PMSF, protease inhibitor cocktail) using a TissueRuptor (Qiagen). 
Cell lysis was completed for 45 min on ice by inverting regularly. Lysates were centrifuged at 20,000 x 
g, 4°C until the supernatant was clear (usually 3-4 times, 30 min each). 40 µl of the cleared 
supernatant were mixed with 5x Laemmli buffer and used as cleared brain lysates in Western blots to 
check for protein expression levels. 50 µg GST-fusion proteins were coupled to 40 µl washed (see 
above) GSH-Sepharose 4B beads (1:1 suspension) in 500 µl Pulldown Buffer for 1 h, 4°C on a rotating 
wheel. Beads were pelleted at 500 x g, 2 min, 4°C and washed two times with Pulldown Buffer, 500 µl 
each, by pelleting beads each time at 500 x g, 2 min, 4°C. Beads were pelleted again and any residual 
fluid was removed completely. Cleared brain lysates were incubated with GST-protein coupled beads 
for 2.5 h at 4°C on a rotating wheel. Beads were pelleted at 500 x g, 2 min, 4°C and washed five times 
with Pulldown Buffer, 500 µl each. Beads were pelleted finally and any residual fluid was removed 
carefully but completely. Bound proteins were eluted by 20 µl 1x Laemmli buffer and denatured for 
10 min at 95°C. Potential protein interactions in Pulldowns and the protein expression levels in 
cleared brain lysates were analysed by immunoblotting using respective antibodies. 
 
2.13 GST-pulldown experiments with purified proteins 
Respective amounts of GSH-Sepharose 4B beads were washed three times in Pulldown Buffer (25 
mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 0.1% (v/v) Nonidet P-40) and a 
1:1 suspension of beads and Pulldown Buffer was prepared for subsequent use. 50 µg GST-fusion 
proteins were coupled to 40 µl GSH-Sepharose 4B beads (1:1 suspension) in 500 µl Pulldown Buffer 
for 1 h, 4°C on a rotating wheel. Beads were pelleted at 500 x g, 2 min, 4°C and washed two times 
with Pulldown Buffer, 500 µl each, by pelleting beads each time at 500 x g, 2 min, 4°C. Beads were 
pelleted again and any residual fluid was removed completely. GST-protein coupled beads were 
incubated with 20 µg His6-mCherry-fusion peptides in 1 ml Pulldown Buffer for 2 h at 4°C on a 
rotating wheel. In order to identify the tripartite Rab11a/MyoVa/Spir-2 complex, 65 µg GST-Spir-2-
GTBM-SB-FYVE was coupled to beads. Subsequently, beads were incubated with 40 µg MyoVa and 35 
µg Rab11a proteins simultaneously for 2 h. Beads were pelleted at 500 x g, 2 min, 4°C and washed 
four times with Pulldown Buffer, 500 µl each. Beads were pelleted finally and any residual fluid was 
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removed carefully but completely. Bound proteins were eluted by 20 µl 1x Laemmli buffer and 
denatured for 10 min at 95°C. Potential protein interactions in Pulldowns were analysed by 
immunoblotting using respective antibodies.  
 
2.14 Quantitative GST-pulldown assays 
Respective amounts of GSH-Sepharose 4B beads were washed three times in Pulldown Buffer (25 
mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 10% (v/v) glycerol, 0.1% (v/v) Nonidet P-40) and a 
1:1 suspension of beads and Pulldown Buffer was prepared for subsequent use. Increasing amounts 
of GST-MyoVa/b-GTD fusion proteins were coupled to 20 µl GSH-Sepharose 4B beads (1:1 
suspension) in 500 µl Pulldown Buffer for 1 h, 4°C on a rotating wheel. Beads were pelleted at 500 x 
g, 2 min, 4°C and washed two times with Pulldown Buffer, 500 µl each, by pelleting beads each time 
at 500 x g, 2 min, 4°C. Beads were pelleted again and any residual fluid was removed completely. 
GST-protein coupled beads were incubated with 100 nM His6-mCherry-Spir-2-linker peptide in SPECS 
buffer (1x PBS pH 7.2, 50 mM NaCl) for 2 h at 4°C on a rotating wheel. Beads were pelleted at 500 x 
g, 2 min, 4°C and the supernatant was transferred into new tube. The supernatant was centrifuged 
for 10 min at 20,000 x g at 4°C to remove potential debris that could disturb fluorescence 
measurements. 
Each protein sample was allowed to adapt to 20°C for 15 min in a water bath. The concentration 
dependent binding of GST-MyoVa/b-GTD to the His6-mCherry-Spir-2-linker was determined by 
fluorospectrometric analysis using the FluoroMax-4 Spectrofluorometer (Horiba Jobin Yvon, 
Bensheim, Germany). The mCherry red fluorescent protein was excited at 548 nm and the emission 
at 610 nm was recorded (emission maximum of mCherry). The data were calculated as “fraction 
bound” compared to the fluorescence signals of His6-mCherry-Spir-2-linker alone, without any GST-
MyoV-GTD protein: 
𝑦 = 1 − 𝑦0 − 𝑦𝑐
𝑦0
 
 
With 𝑦0 is the fluorescence signal of His6-mCherry-Spir-2-linker alone, without GST-MyoV-GTD and 𝑦𝑐  
is the signal at the respective GST-MyoV-GTD concentration. 
 
The data were further processed in SigmaPlot 12.3 software (Systat Software, Erkrath, Germany) and 
the equilibrium binding data were fitted according to the equation: 
 y = 𝐵𝑚𝑐𝑚 ⋅ 𝑥
𝐾𝑑 + 𝑥  
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assuming a single binding site, and with 𝐵𝑚𝑐𝑚  representing the maximal amplitude, 𝐾𝑑 representing 
the equilibrium constant, and 𝑥 representing the concentration of GST-MyoV-GTD. The binding 
curves saturated at 40% since the His6-mCherry-Spir-2-linker protein preparation contained C-
terminal incomplete protein products, which are still fluorescent but cannot interact with MyoV-GTD. 
The Spir-2-linker region is predicted to be highly unstructured, which may be the reason for the 
relative instability of the recombinant His6-mCherry-Spir-2-linker fusion protein. 
 
2.15 Immunostaining 
HeLa cells were seeded on microscope cover glasses in a 6-well plate (3 × 105  cells per well) and 
transfected with in each experiment indicated expression vectors encoding Myc-epitope-tagged and 
fluorescently tagged proteins, as described above, on the next day. One day post transfection, cells 
were washed three times with 1x PBS to remove any residual medium and serum. Cells were fixed 
with paraformaldehyde (3.7% in 1x PBS) for 20 min at 4°C. Cells were again washed three times with 
1x PBS and subsequently permeabilised using 0.2% Triton X-100 (in 1x PBS) for 3.5 min, RT. After 
washing three times with 1x PBS, cells were incubated with 50 µl of an anti-c-Myc antibody solution 
(9E10, mouse monoclonal, 2 µg/ml; Santa Cruz Biotechnology) for 1:30 h, RT, in the dark. Cells were 
washed three times in 1x PBS and subsequently incubated with 50 µl of a conjugated anti-mouse 
secondary antibody solution (Cy5, from donkey, 3.25 µg/ml, Dianova; and TRITC, from donkey, 3.125 
µg/ml, Dianova, Hamburg, Germany) for 1:30 h, RT, in the dark. Primary and secondary antibody 
solutions were always prepared in 1x PBS, supplemented with 1% FCSIII. Cells were washed again 
three times in 1x PBS and once in de-ionised H2O to get rid of residual salts. Finally, cells were 
mounted on microscope slides with Mowiol solution, dried at RT in the dark and stored at 4°C. 
Immunostainings were subsequently analysed with a Leica AF6000LX fluorescence microscope, 
equipped with a Leica HCX PL APO 63x/1.3 GLYC objective and a Leica DFC350 FX digital camera 
(1392 x 1040 pixels, 6.45 µm x 6.45 µm pixel size) (all from Leica, Wetzlar, Germany). 3D stacks were 
recorded and processed with the Leica 3D-deconvolution software module. 
In case of the MyoVa autoregulation/activation experiments, the eGFP-MyoVa-FL expression levels 
were quantified. High expression levels of GFP-MyoVa-FL induced a vesicular localisation, whereas an 
even cytoplasmic distribution was only observed at low expression levels. In order to distinguish 
clearly between vesicular and cytoplasmic MyoVa localisation, cells were imaged at either state, and 
the sum of pixel grey values per cell was determined as a measure for the eGFP-MyoVa-FL expression 
levels. Based on that, only those cells were used for autoregulation analysis that have a sum of pixel 
grey values less than 20 × 106 for the expression of GFP-MyoVa-FL. 
Images were recorded using the Leica LASX software, further processed with Adobe Photoshop and 
subsequently assembled in Adobe Illustrator. 
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2.16 Colocalisation analysis 
The extent of colocalisation of Rab11a, Spir-2 and MyoVa was analysed using the ImageJ (V2.0.0) 
plug-in Coloc2. Here, the colocalisation rate for signals of individual fluorescence channels within one 
image is indicated by the Pearson’s Correlation Coefficient (PCC) as a standard statistical measure to 
unravel a linear correlation between the intensity of different fluorescent signals. A PCC value of 1 
indicates a perfect colocalisation, 0 indicates a random colocalisation and a PCC value of -1 indicates 
a mutually exclusive localisation of the analysed signals. To take the noise of each image into account 
and to gain an objective evaluation of PCC significance, a Costes significance test was performed. To 
do so, the pixels in one image were scrambled randomly and the correlation with the other 
(unscrambled) image was measured. PCC significance was observed when at least 95% of the 
randomised images show a PCC less than that of the original image, meaning that the probability for 
the measured correlation of two colours is significantly greater than the correlation of random 
overlap (347, 348). Statistical data analysis was done using the Student's t-test to compare two mean 
values for co-expression conditions with a confidence interval of 95%, and was performed using SPSS 
22 (IBM, Armonk, NY).  
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In order to characterise the functional correlation of Spir and MyoV proteins, a set of eukaryotic 
expression vectors encoding fluorescent protein and Myc-epitope tagged MyoVa, MyoVb, Spir-2, 
FMN-2 and Rab11a full-length proteins, deletion mutants and point mutants were employed, as well 
as prokaryotic expression vectors encoding Glutathione-S-transferase (GST) or His6-mCherry tagged 
and untagged MyoVa, MyoVb, Spir-2, FMN-2 and Rab11a full-length proteins, deletion mutants and 
point mutants. For better orientation throughout the results section, all proteins, protein fragments 
and mutants are depicted in Figure 16 (Spir-1/-2, FMN-2) and Figure 17 (MyoVa, MyoVb, Rab11a). A 
detailed list on all expression vectors, including information about vector backbone, amino acid 
boundaries, respective species, restriction sites used for cloning, method of protein purification and 
the purpose of each plasmid is presented in the supplements (Tables 16, 17). All expression vectors 
which were kindly provided by other research groups and laboratories are indicated and described. 
 
Figure 16 | Overview on Spir-1/-2 and FMN-2 protein fragments used in this thesis. (*) These vectors already existed in 
the lab of Eugen Kerkhoff. Spir-1/-2 proteins are all the human (Hs) isoforms. Numbers indicate amino acids. GTBM, 
globular tail domain binding motif; SB, Spir-box; FH, formin homology; FL, full-length; Mm, Mus musculus; aa, amino acid. 
 61 3 Results 
 
Figure 17 | Overview on myosin Va, myosin Vb and Rab11a protein fragments used in this thesis. (1), these expression 
vectors were generated and kindly provided by the lab of Bruno Goud, Institut Curie, Paris, France; (2), this expression 
vector was generated and kindly provided by the lab of Alistair Hume, University of Nottingham, Nottingham, UK. (3), these 
expression vectors were generated and kindly provided by the lab of Anne Houdusse, Institut Curie, Paris, France. (*) This 
expression vector already existed in the lab of Eugen Kerkhoff. Numbers indicate amino acids. D, isoform D; F, isoform F; CC, 
coiled-coil; GTD, globular tail domain; FL, full-length; Hs, Homo sapiens; Mm, Mus musculus; Cl, Canis lupus familiaris; aa, 
amino acid. 
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3.1 Spir and MyoV proteins co-exist in a protein complex 
Spir actin nucleators and MyoV actin motor proteins colocalise with the Rab11 small GTPase at 
vesicular structures and cooperate in exocytic vesicle transport processes (7, 222, 256, 325, 334). 
Despite extensive efforts, a direct interaction of Spir and Rab11 proteins could not be demonstrated, 
and it remained unclear how Spir proteins are targeted towards Rab11 vesicles. Furthermore, recent 
work of our lab could show that Spir proteins rather non-specifically bind to negatively charged lipid 
membranes by their FYVE-type zinc-finger (327), which precludes the possibility of lipid-specific 
vesicle targeting of Spir proteins. Altogether, this led to the assumption that other factors, such as 
membrane associated proteins, might function to induce the formation of a distinct vesicle 
subpopulation, i.e. vesicles harbouring both, Spir and Rab11 proteins. Due to the cooperative 
mechanisms of MyoV and Rab11 proteins in a diversity of cellular processes (222, 251, 253, 256, 334, 
349), the intriguing idea came up that the myosin V actin motor proteins possibly acts as a linker 
between Spir and Rab11 at vesicle membranes, therefore deciding on the vesicle identity. To follow 
this suggestion, an initial GST-pulldown from mouse brain lysates could show that a GST-tagged 
MyoVb globular tail domain protein (GST-MyoVb-GTD) is able to pull the Spir-1 protein from brain 
lysates (Figure 18). This finding manifests the co-existence of MyoV and Spir proteins in a protein 
complex. A GST-tagged C-terminal Formin-2 fragment (GST-FMN2-eFSI) also pulls the Spir-1 protein 
from brain lysates as expected, considering the well-established KIND-FSI interaction of Spir and FMN 
proteins (324, 338, 350). In the same experiment, MyoVa was pulled as well, further supporting the 
co-existence of Spir-1 and myosin V proteins in a protein complex. No interactions were observed for 
both, GST and buffer controls. 
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Figure 18 | Myosin V and Spir-1 proteins co-exist in a protein complex. GST-pulldown assays from mouse brain lysates 
with the GST-tagged MyoVb globular tail domain (GST-MyoVb-GTD) shows that GST-MyoVb-GTD strongly pulls Spir-1 as 
detected by immunoblotting (anti-Spir-1). A GST-tagged C-terminal FMN-2 fragment (GST-FMN2-eFSI) also strongly pulls 
Spir-1 from brain lysates. Interestingly, in the same experiment, MyoVa is also pulled, showing that Spir-1 and MyoVa co-
exist in a protein complex. No interactions are observed for the GST control and for buffer controls. Ponceau S staining 
shows equal loading of GST and GST-fusion proteins. An overview of the employed protein fragments is presented and the 
domains and sequence parts used for pulldowns are highlighted. N = 3 experimental repeats. eFSI, extended formin/Spir 
interaction sequence; GTD, globular tail domain; WB, Western blot. 
 
 
3.2 Identification of a highly conserved sequence motif within the central Spir linker region  
After revealing that Spir and MyoV proteins co-exist in a protein complex, initial co-
immunoprecipitation (co-IP) studies revealed that a potential Spir/MyoV interaction is neither 
mediated by the very N-terminal part of the Spir protein (KIND and WH2), nor by the very C-terminal 
part (Spir-box and FYVE) (not shown). Therefore, the putative MyoV interaction site is likely to be 
located within the central Spir linker region, between the WH2 domains and the Spir-box, a region 
that was formerly not known to contain distinct conserved domains or sequence motifs, and that 
was not shown before to serve distinct functions. A multiple sequence alignment of chosen 
vertebrate Spir-1 and Spir-2 amino acid sequences was performed for the central Spir region, starting 
from the last of the four WH2 domains (WH2-D), spanning the linker region until the FYVE-type zinc-
finger (Figure 19). The multiple sequence alignment reveals the high sequence conservation within 
WH2-D, the Spir-box and the FYVE-type zinc-finger, as was expected. Considering the central linker 
region, the sequence similarity between Spir-1 and Spir-2 protein sequences is rather low (3.74% 
identity, 8.41% similarity). Taking only the Spir-1 or the Spir-2 proteins into account, some sequence 
homology can be found within the linker, but not between Spir-1 and Spir-2 proteins, for most of the 
linker region.  
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Figure 19 | The central Spir linker region contains a highly conserved sequence motif. A multiple sequence alignment of 
linker regions from chosen vertebrate Spir-1 and Spir-2 amino acid sequences is presented starting from the last WH2 
domain (WH2-D) and ending with the FYVE-type zinc-finger. High sequence homology between all sequences was only 
observed for WH2-D, Spir-box, FYVE-type zinc-finger and GTBM, but not for other parts of the linker region. Species 
abbreviations are: Homo sapiens (Hs), Mus musculus (Mm), Gallus gallus (Gg), Xenopus tropicalis (Xt), Brachydanio rerio 
(Br). 100% sequence identity is indicated with an asterisk (*). Numbers indicate amino acids. 
 
 
Besides this, in the approximate middle of the linker region, a previously unrecognised short 
sequence motif of 27 amino acids is located which shows high sequence conservation also between 
Spir-1 and Spir-2 proteins (Figure 20). A subsequent multiple sequence alignment of this short 
sequence motif of vertebrate Spir-1 and Spir-2 amino acid sequences further strengthens the high 
rate of homology across those sequences (25.93% identity, 33.33% similarity). Throughout this thesis, 
the newly identified sequence motif is from now on referred to as globular tail domain binding motif 
(GTBM). By definition, this conserved sequence must be rather considered as a sequence motif than 
as a protein domain, because it does not show a defined higher order structural organisation by 
itself. The GTBM is composed of a positively charged basic amino acid cluster at the beginning and 
two negatively charged acidic clusters in the middle and at the end of the motif. A WebLogo of the 
respective sequence parts from 223 Spir sequences shows the abundance of individual amino acids 
for each sequence position (in collaboration with Dr. Martin Kollmar, Max-Planck-Institute for 
Biophysical Chemistry, Göttingen, Germany). Of significance, there are two highly conserved leucine 
residues (L408, L409 for human Spir-2), which are identical in almost all Spir sequences analysed. 
Considering the assumed role for the Spir linker region in MyoV interaction and the newly discovered 
highly conserved sequence motif within the linker region, it is intriguing to speculate that this short 
sequence motif is critical for mediating a Spir/MyoV interaction. 
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Figure 20 | The Spir GTBM contains highly conserved amino acid clusters with distinct chemical properties. A multiple 
sequence alignment of the 27 amino acid spanning conserved sequence motif within the central Spir linker region from 
chosen vertebrate Spir-1 and Spir-2 amino acid sequences is presented. The motif is composed of a positively charged basic 
amino acid cluster at the beginning and two negatively charged acidic clusters in the middle and at the end. Note the two 
highly conserved leucine residues within the basic cluster (L408, L409 for human Spir-2). The WebLogo of the respective 
sequence parts from 223 Spir sequences shows the abundance of individual amino acids at each sequence position. Species 
abbreviations: Homo sapiens (Hs), Mus musculus (Mm), Gallus gallus (Gg), Xenopus tropicalis (Xt), Brachydanio rerio (Br). 
100% sequence identity is indicated with an asterisk (*). Numbers indicate amino acids. 
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3.3 Spir/MyoV complex formation depends on the highly conserved sequence motif 
In order to analyse if the newly identified Spir GTBM is indeed required for the Spir/MyoV 
interaction, co-IP studies were performed employing several GFP-tagged MyoVb and Myc-epitope-
tagged Spir-1 and Spir-2 full-length proteins and deletion mutants (Figure 21). A C-terminal MyoVb 
protein (AcGFP-MyoVb-CC-GTD) co-precipitates with both full-length Spir proteins (Myc-Spir-1-FL and 
Myc-Spir-2-FL), which again proves the co-existence of Spir and MyoV in a protein complex. 
Importantly, also the globular tail domain of MyoVb (AcGFP-MyoVb-GTD) alone co-precipitates with 
Spir-2 showing that the MyoVb GTD is required and sufficient for Spir interaction. In order to reveal if 
the newly identified short sequence motif within the Spir linker region (GTBM) is indeed essential for 
MyoV interaction, Myc-tagged Spir-2 deletion mutants were generated which either express (Myc-
Spir2-GTBM-SB-FYVE) or not express (Myc-Spir2-SB-FYVE) the conserved motif and were analysed if 
they co-precipitate with AcGFP-MyoVb-GTD. Interestingly, Myc-Spir2-GTBM-SB-FYVE indeed co-
precipitates with the MyoVb GTD, whereas Myc-Spir2-SB-FYVE does not. This strongly points towards 
the necessity of the Spir GTBM for MyoV interaction.  
 
 
 
Figure 21 | Complex formation of Spir and MyoVb depends on the MyoVb GTD and the Spir GTBM. Co-
immunoprecipitation (co-IP) assays of HEK293 cells expressing AcGFP-tagged MyoVb deletion mutants and Myc-epitope 
tagged Spir-1 and Spir-2 proteins. Cell lysates were immunoprecipitated with anti-c-Myc antibodies. Cell lysates (input) and 
immunoprecipitates were analysed by immunoblotting (anti-GFP, anti-c-Myc). The Spir-2 GTBM and the MyoVb GTD were 
identified to be essential for the Spir/MyoV interaction. Only faint background bands are observed when using AcGFP as a 
negative control. An overview of the employed protein fragments is presented and the domains used for interaction studies 
are highlighted. N = 4 experimental repeats. CC, coiled-coil; GTD, globular tail domain; FL, full-length; WB, Western blot. 
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Important to note, also the MyoVa GTD binds to Spir-2 as was shown by co-IP experiments (Figure 
22). Again, the Spir-2 GTBM was crucial for the Spir/MyoVa interaction in the same way as it was 
shown for MyoVb. These results are in accordance with overlapping cellular functions of MyoVa and 
MyoVb proteins, common interaction partners and mechanisms for Rab11 vesicle transport. 
 
 
 
 
Figure 22 | Complex formation of Spir-2 and MyoVa-GTD depends on the Spir-2 GTBM. Co-immunoprecipitation (co-IP) 
assays of HEK293 cells expressing AcGFP-tagged MyoVa-GTD and Myc-epitope tagged Spir-2 deletion mutants. Cell lysates 
were immunoprecipitated with anti-Myc antibodies. The cell lysates (input) and immunoprecipitates were analysed by 
immunoblotting (anti-GFP, anti-Myc). The Spir-2 GTBM is crucial for MyoVa-GTD interaction. An overview of the employed 
protein fragments is presented and the domains used for interaction studies are highlighted. N = 2 experimental repeats. 
GTD, globular tail domain; SB, Spir-box; FL, full-length; WB, Western blot. 
 
 
The Spir GTBM consists of distinct amino acid clusters with distinct chemical properties (compare 
Figure 20), i.e. positive and negative charge distributions and hydrophobic residues. In order to 
identify essential residues involved in the Spir/MyoV interaction, the minimal interaction sequence of 
the Spir-2 GTBM was mapped (Figure 23). Co-IP studies employing a set of Myc-epitope-tagged N-
terminal and C-terminal Spir-2 deletion mutants starting or ending with distinct amino acid clusters 
(Figure 23B) and AcGFP-tagged MyoVb-GTD proteins shows that the C-terminal Myc-Spir2-398-714 
(complete GTBM) and the N-terminal Myc-Spir2-2-423 (ending after the first acidic cluster) co-
precipitate with AcGFP-MyoVb-GTD, whereas the C-terminal Myc-Spir2-411-714 (starting after the 
basic cluster) and the N-terminal Myc-Spir2-2-410 (ending after the basic cluster) do not (Figure 23A). 
Taken together, only the basic cluster at the beginning and the first acidic cluster in the middle of the 
conserved Spir GTBM are indispensable for Spir/MyoV interaction (Figure 23C). This means that the 
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second acidic cluster at the end is not necessarily required for MyoV interaction, although an indirect 
involvement in terms of strength, stability and specificity of the interaction might not be excluded. 
 
 
 
 
Figure 23 | Mapping of the Spir-2 myosin V interaction sequence. (A) Co-immunoprecipitation (co-IP) experiments 
employing AcGFP-tagged MyoVb-GTD (GFP-MyoVb-GTD) as well as N-terminal and C-terminal Spir-2 deletion mutants show 
MyoVb-GTD co-precipitation with the C-terminal Myc-Spir2-398-714 and the N-terminal Myc-Spir2-2-423 fragments. 
MyoVb-GTD does not co-precipitate with C-terminal Myc-Spir2-411-714 and N-terminal Myc-Spir2-2-410 fragments. 
Numbers indicate amino acids. N = 2-4 experimental repeats. (B) Overview of the Spir-2 deletion mutants used in (A) 
compared to full-length Spir-2 (amino acids 1-714) and their capacity to interact (+) or not interact (-) with MyoVb-GTD. (C) 
The minimal mapped Spir/MyoV interaction sequence of human Spir-2 contains amino acids 398 to 423 and involves the 
basic cluster at the beginning and the first acidic cluster in the middle of the Spir-2 GTBM. GTD, globular tail domain; SB, 
Spir-box; WB, Western blot. 
 
 
3.4 Spir-2 and MyoV proteins interact directly in vitro 
The data obtained so far showed that Spir proteins co-exist in a protein complex with MyoVa and 
MyoVb, respectively, which is mediated by the MyoV GTD and the Spir GTBM. Nevertheless, the 
formation of a protein complex including Spir and MyoV proteins could also be mediated or 
supported by additional proteins and complex members and does per se not argue for a direct 
interaction of both proteins. Thus, to examine a direct physical interaction of Spir and MyoV proteins, 
GST-pulldown studies were performed using bacterially expressed and purified recombinant Spir-2-
linker peptides and MyoVa/MyoVb-GTD proteins (Figure 24A). Here, both, GST-MyoVa-GTD and GST-
MyoVb-GTD, are able to pull a His6-mCherry-tagged Spir-2-linker protein (mCherry-Spir2-linker), 
strongly suggesting a direct protein interaction of Spir and MyoV. As mentioned above, the Spir 
GTBM contains two highly conserved leucine residues (L408, 409 for human Spir-2), which might 
contribute to the protein interactions. The binding of a mutant Spir-2-linker peptide in which these 
two leucines are substituted by alanines (L408A, L409A; His6-mCherry-Spir-2-linker-LALA, mCherry-
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Spir2-linker-LALA) is strongly reduced compared to the wild-type GTBM, emphasising the relevance 
of the two leucine residues for the Spir/MyoV interaction. GST and His6-mCherry proteins were used 
as controls and did not show any binding. 
In order to gain deeper insights about binding strength and significance of the His6-mCherry-Spir-2-
linker:MyoV-GTD complexes, the equilibrium constants (or dissociation constants, Kd) for the His6-
mCherry-Spir-2-linker:MyoVa-GTD and His6-mCherry-Spir-2-linker:MyoVb-GTD complexes were 
determined by fluorescence-spectroscopic measurements of the His6-mCherry-tagged Spir-2-linker 
peptide with increasing concentrations of GST-MyoVa-GTD and GST-MyoVb-GTD, respectively (Figure 
24B). For both complexes, the Kd is in the higher nanomolar range (728 ± 113 nM for His6-mCherry-
Spir-2-linker:MyoVa-GTD, and 377 ± 84 nM for His6-mCherry-Spir-2-linker:MyoVb-GTD). The binding 
curves saturated at 40% since the His6-mCherry-Spir-2-linker protein preparation contained C-
terminal incomplete protein products, which are still fluorescent but cannot interact with MyoV-GTD. 
The Spir-2-linker region is predicted to be highly unstructured, which may be the reason for the 
relative instability of the recombinant His6-mCherry-Spir-2-linker fusion protein. 
 
 
 
 
Figure 24 | Spir-2 directly interacts with MyoVa and MyoVb GTDs. (A) GST-pulldown studies employing purified bacterially 
expressed recombinant proteins to analyse a direct interaction of Spir-2 with MyoVa and MyoVb are shown. Both, GST-
MyoVa-GTD and GST-MyoVb-GTD, pull the His6-mCherry-Spir-2-linker (mCherry-Spir2-linker) protein as detected by 
immunoblotting (anti-RFP), arguing for a direct protein interaction. The substitution of two highly conserved leucine 
residues within the Spir-2 GTBM to alanines (human Spir-2-L408A,L409A; mCherry-Spir2-linker-LALA; compare Figure 20) 
largely impairs binding of this mutant to GST-MyoVa/Vb-GTD. Only faint background bands are detected using the GST 
protein or the His6-mCherry protein as controls. Ponceau S staining shows equal loading of GST-fusion proteins. N = 4 
experimental repeats. (B) Fluorescence spectroscopy was used to determine the dissociation constants (Kd) for MyoVa 
(blue) and MyoVb GTD (red) binding to mCherry-Spir2-linker (aa 361-519 of human Spir-2). Error bars represent SEM (n = 4 
experimental repeats). (C) An overview of the employed protein fragments is presented and the domains used for 
interaction studies are highlighted. GTD, globular-tail-domain; LALA, L408,409A; WB, Western blot. 
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3.5 The Spir GTBM is necessary for colocalisation of Spir-2 and MyoV at vesicle membranes 
Spir and MyoV proteins were shown to directly interact with each other in vitro. It was assumed that 
the functional cooperation of Spir actin nucleators and Rab11 small GTPases in vesicle transport 
processes is mediated by MyoV actin motor proteins linking Spir and Rab11 at the same vesicle 
membranes thereby determining the vesicle identity. In line with that, further analysis was aimed to 
decipher if Spir and MyoV proteins also colocalise and interact in eukaryotic cells at vesicle 
membranes. Co-expression of GFP-tagged full-length MyoVa and MyoVb proteins (eGFP-MyoVa-FL, 
AcGFP-MyoVb-FL), respectively, and Myc-epitope-tagged full-length Spir-2 (Myc-Spir2-FL) in HeLa 
cells revealed that both, MyoVa and MyoVb, perfectly colocalise with Spir-2 at vesicle membranes 
(Figure 25).  
 
 
 
Figure 25 | Myosin V and Spir-2 colocalise at vesicle membranes. Both, GFP-tagged full-length MyoVa (eGFP-MyoVa-FL; 
green; A) and GFP-tagged full-length MyoVb (AcGFP-MyoVb-FL; green; B), colocalise with Myc-epitope-tagged full-length 
Spir-2 (Myc-Spir2-FL; red) at vesicle membranes when transiently co-expressed in HeLa cells, as indicated by overlapping 
punctae (merge; yellow; see also higher magnification in insets). 5 cells were recorded for each condition and one 
representative cell is presented here. Scale bars represent 10 µm. 
 
 
 As a proof of principle, the requirement of the Spir GTBM for Spir-2 colocalisation with MyoV at 
vesicle membranes was investigated by co-expression of GFP-tagged MyoVa and MyoVb GTD 
(AcGFP-MyoVa-GTD, AcGFP-MyoVb-GTD), respectively, and Myc-tagged Spir-2 deletion mutants 
carrying (Myc-Spir2-GTBM-SB-FYVE) or not carrying (Myc-Spir2-SB-FYVE) the conserved sequence 
motif necessary for MyoV binding in vitro (Figure 26). All proteins show a vesicular localisation by 
itself when expressed alone, as expected (Figure 26A). AcGFP-MyoVa-GTD perfectly colocalises with 
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Myc-Spir2-GTBM-SB-FYVE (Figure 26B, upper panel) just as the full-length proteins do (compare 
Figure 25). In contrast, Myc-Spir2-SB-FYVE does only in part colocalise with MyoVa-GTD and is also 
localised to vesicles on which MyoVa-GTD is not present (Figure 26B, lower panel). Here, MyoVa-GTD 
is also largely localised to the nucleus which was not observed when co-expressed with Myc-Spir2-
GTBM-SB-FYVE. Identical results were obtained employing the MyoVb GTD. AcGFP-MyoVb-GTD 
perfectly colocalises with Myc-Spir2-GTBM-SB-FYVE at vesicle membranes (Figure 26C, upper panel), 
whereas the localisation of MyoVb-GTD and Myc-Spir2-SB-FYVE does not largely overlap (Figure 26C, 
lower panel). In summary, these data indeed show that the highly conserved Spir GTBM is not only 
essential for the direct interaction of Spir and MyoV proteins in vitro, but for the colocalisation of 
both proteins in eukaryotic cells at vesicle membranes as well. 
 
 73 3 Results 
 
 
Figure 26 | MyoVa and MyoVb GTDs colocalise with Spir-2 at vesicle membranes depending on the Spir-2 GTBM. (A) 
AcGFP-MyoVa-GTD, AcGFP-MyoVb-GTD, Myc-Spir2-GTBM-SB-FYVE and Myc-Spir2-SB-FYVE show a typical vesicular 
localisation pattern when expressed alone. (B and C) AcGFP-tagged GTDs of MyoVa (B) and MyoVb (C), respectively, (green) 
were transiently co-expressed with Myc-tagged Spir-2 deletion mutants (red) in HeLa cells. (B) MyoVa-GTD perfectly 
colocalises with Spir-2 in a vesicular pattern only in presence of the Spir-2 GTBM (Myc-Spir2-GTBM-SB-FYVE; upper panel) 
as indicated by overlapping punctae (merge; yellow; see also higher magnification in insets) but not in its absence (Myc-
Spir2-SB-FYVE; lower panel). (C) MyoVb-GTD also perfectly colocalises with Spir-2 only in presence of the Spir-2 GTBM 
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(Myc-Spir2-GTBM-SB-FYVE; upper panel) as indicated by overlapping punctae (merge; yellow; see also higher magnification 
in insets) but not in its absence (Myc-Spir2-SB-FYVE; lower panel). Fixed cells are shown in each case, using the auto-
fluorescence of the GFP-tag and immunostainings against the Myc-epitope tag (TRITC-conjugated secondary antibodies) for 
fluorescence microscopic image recording. 5 cells were recorded for each condition and one representative cell is 
presented here. Scale bars represent 10 µm. 
 
 
3.6 Spir-2 and MyoV proteins directly interact at vesicle membranes 
In order to exclude a random colocalisation of Spir-2 and MyoV proteins at vesicle membranes and, 
thus, to prove a direct MyoVa and Spir-2 interaction at vesicle surfaces, FLIM-FRET (fluorescence 
lifetime imaging, Förster resonance energy transfer) microscopy studies were performed to unravel 
the molecular interactions of Spir-2 and MyoVa in living cells at vesicle membranes, depending on 
the Spir-2 GTBM (Figure 27). These experiments were done in collaboration with Dr. Thomas 
Weidemann (Max Planck Institute of Biochemistry, Martinsried, Germany). The fluorescence lifetime 
of a donor fluorophore is measured in presence of an acceptor fluorophore. If donor and acceptor 
fluorophores are in close proximity (max. distance of 10 nm; (351)), the fluorescence energy is 
transferred from the excited donor to the acceptor, reducing the fluorescence lifetime of the donor. 
If donor and acceptor fluorophores are spatially separated, the energy transfer is not possible and 
the fluorescence lifetime is comparable to that of the donor alone. AcGFP-MyoVa-GTD was used here 
as the fluorescence donor. Several C-terminal Spir-2 fragments were used as the fluorescence 
acceptors: the MyoV binding incompetent mStrawberry-Spir2-SB-FYVE and mStrawberry-Spir2-
GTBM-SB-FYVE-LALA mutants, and the MyoV interacting mStrawberry-Spir2-GTBM-SB-FYVE 
fragment. The fluorescence lifetime of the AcGFP-MyoVa-GTD donor was measured at vesicle 
membranes when expressed alone or when co-expressed with either of the fluorescence acceptors. 
The fluorescence lifetime of AcGFP alone was measured to test for AcGFP-MyoVa-GTD homo-FRET 
signals. As a positive FLIM-FRET control, an AcGFP-linker-mStrawberry construct was used. The 
isolated GTDs of MyoV proteins have been observed to be monomeric in solution, showing that they 
do not interact with each other by themselves (revealed by gel filtration experiments) (211). 
Therefore, AcGFP-MyoVa-GTD was co-expressed with an mStrawberry-tagged version (mStrawberry-
MyoVa-GTD) to exclude FRET signals due to dense vesicle packaging (high protein concentrations at 
the vesicle surface). Based on the measured donor fluorescence lifetime, the FRET efficiency E was 
calculated for each condition with: 
𝐸 =  1 – τ𝐷𝐷
τ𝐷
 
 
with τ𝐷 is the fluorescence lifetime of the donor alone and τ𝐷𝐷  in presence of an acceptor (352). 
The positive FLIM-FRET control (AcGFP-linker-mStrawberry) reveals a FRET efficiency of 20.9% 
(median value; Figure 27C). Compared to that, the FRET efficiency of AcGFP-MyoVa-GTD alone is 
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completely abolished (0.0% FRET efficiency) and is even lower than that of the AcGFP fluorescent 
protein alone (1.4% FRET efficiency). Only a slight increase in FRET efficiency is observed when 
AcGFP-MyoVa-GTD is co-expressed with free floating mStrawberry proteins (2.2% FRET efficiency). A 
strong increase in FRET efficiency of the AcGFP-MyoVa-GTD donor is observed when co-expressed 
with a C-terminal Spir-2 fragment containing the GTBM for MyoV interaction, and the Spir-box and 
FYVE-type zinc-finger for vesicle membrane targeting (mStrawberry-Spir2-GTBM-SB-FYVE; 14.7% 
FRET efficiency). As the donor fluorescence lifetime reduction is only possible if MyoVa and Spir-2 
proteins are in close proximity (within 10 nm of distance between the fluorophores), these results 
strongly support a direct interaction of MyoVa and Spir-2 at vesicle membranes. In contrast, co-
expression of a C-terminal Spir-2 fragment only encoding Spir-box and the FYVE-type zinc-finger 
(mStrawberry-Spir2-SB-FYVE; 1.6% FRET efficiency) and the Spir-2 GTBM-LALA mutant protein 
(mStrawberry-Spir2-GTBM-SB-FYVE-LALA; 2.4% FRET efficiency), respectively, both of which do not 
interact with MyoVa-GTD, do not alter the fluorescence lifetime of the AcGFP-MyoVa-GTD donor. Co-
expression of mStrawberry-MyoVa-GTD (2.0% FRET efficiency) does also not increase the FRET 
efficiency compared to AcGFP-MyoVa-GTD alone. This shows that there is no false positive FRET 
signal due to dense protein packing on vesicle surfaces and further indicates that a direct interaction 
of MyoVa-GTD and the Spir-2-GTBM is required for the observed FLIM-FRET signal. 
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Figure 27 | FLIM-FRET analysis of transiently expressed AcGFP-tagged MyoVa-GTD (donor) and mStrawberry-tagged C-
terminal Spir proteins (acceptors) at vesicle membranes in HeLa cells. (A and B) Representative cells showing the lifetime 
shift due to FRET. Confocal fluorescence images (green channel, AcGFP; red channel, mStrawberry; and fluorescence 
lifetime images of the AcGFP-tagged donor) of AcGFP-MyoVa-GTD expressed alone (A), and in presence of the interacting 
acceptor mStrawberry-Spir-2-GTBM-SB-FYVE (B) are shown. Scale bar represents 10 µm. (C) The average FRET efficiencies 
per cell measured at vesicle membranes are presented for the indicated transiently expressed donor-acceptor 
combinations. A box-and-whisker plot is shown with every dot representing a single cell. The region of interest (ROI) was 
manually confined to the cytoplasm (average FRET efficiencies for AcGFP alone and the AcGFP-linker-mStrawberry positive 
control). For all other experiments, the ROI was further reduced by a threshold algorithm that identifies vesicles in the 
AcGFP channel. Box-and-whisker plots indicate 2nd and 3rd quartile (box), median (red horizontal line), and 1.5x interquartile 
range (whiskers). The median value is also indicated above each box. 10-15 cells have been analysed for each condition. 
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3.7 Crystal structure of the MyoVa-GTD:Spir-2-GTBM complex 
In collaboration with Prof. Dr. Anne Houdusse and Dr. Olena Pylypenko (Institut Curie, Paris, France), 
the direct interaction of Spir and MyoVa proteins was further characterized by solving the crystal 
structure of the MyoVa-GTD:Spir-2-GTBM complex (PDB ID 5JCY; Figure 28) to get a deeper insight 
into the contributing amino acids and the underlying molecular interactions within the complex at 
atomic detail. The MyoV globular tail domain is composed of two subdomains, the N-terminal 
subdomain 1 (SD-1) and the C-terminal SD-2 (210). The Spir-2-GTBM peptide binds to SD-1 of the 
MyoVa GTD in an extended conformation in the cleft between helices H3 and H5 of the GTD. At the 
end, the peptide forms a two-turn alpha helix. Importantly, the Spir-2-GTBM residues involved in 
MyoV-GTD interaction (see Figure 30 for more detail) are conserved among Spir proteins (compare 
Figure 20), which is also consistent with the data obtained from Spir-1 binding assays (compare 
Figure 21). The MyoVa GTD undergoes only minor conformational changes when bound to the Spir-2 
GTBM (211). The Spir-GTBM binding pocket is structurally conserved in MyoVa and MyoVb (211), 
which is also in line with the Spir capacity to physically interact with both, MyoVa and MyoVb GTDs 
(compare Figure 24). The Spir binding pockets of MyoVa and MyoVc differ in some way, although the 
overall structures of MyoVa and MyoVc proteins are similar (211). Direct protein interaction studies 
revealed binding of Spir-2-GTBM to MyoVc-GTD in a micromolar range (211). Nevertheless, MyoVc is 
considerably different from MyoVa and MyoVb regarding functionality, expression patterns and in 
terms of its inability to bind to Rab11 (207), and was therefore not further investigated here. 
 
 
 
Figure 28 | Crystal structure of the MyoVa-GTD:Spir-2-GTBM complex. The Spir-2 GTBM peptide (purple) binds in an 
extended conformation to subdomain 1 (SD-1) of MyoVa-GTD (orange), between helix 3 (H3) and helix 5 (H5). An overview 
of employed proteins is presented and the domains used for structural analysis are highlighted. GTD, globular tail domain; 
SD, subdomain; H, helix. 
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3.8 Similarities and differences between Spir and MLPH binding to MyoVa-GTD 
Of importance, the Spir GTBM was found to bind to the same site of MyoVa-GTD as was shown 
before to be involved in the direct interaction with the melanophilin (MLPH) protein (210, 353). 
MLPH is a critical component for the transport of melanosomes to the periphery of melanocytes, 
which ultimately drives skin and hair pigmentation (80, 83, 175). Here, MLPH forms a tripartite 
complex with the myosin Va actin motor protein and the melanosome associated Rab27a GTPase 
(83). Interestingly, MLPH and Spir proteins share a similar domain organisation with similar functions 
(Figure 29). In principle, both proteins consist of a vesicle membrane targeting unit, a MyoV/MyoVa 
interaction unit, and an actin nucleation (Spir: KIND and WH2) and F-actin binding (MLPH: ABD) unit, 
respectively. 
 
 
Figure 29 | Spir and MLPH proteins share a similar domain organisation. Comparison of the Spir-2 and MLPH protein 
domain organisation shows the presence of similar functional units. Both proteins share a MyoV protein interaction unit in 
their central regions (GTBM for Spir-2; GTBM and exon-F binding domain (EFBD) for MLPH). Both proteins encode a 
membrane targeting unit at their C-terminus (Spir-2) and N-terminus (MLPH), respectively, consisting of a FYVE-type zinc-
finger and a related potential small GTPase binding Spir-box (SB, in Spir-2) and synaptotagmin-like protein homology 
domains (H1 and H2, in MLPH). The MLPH-H1-FYVE-H2 cluster is essential for MLPH interaction with Rab27a (354). Both 
proteins share an actin interaction cluster as well, where Spir-2 encodes an actin nucleating KIND/WH2 cluster at its N-
terminus, and MLPH encodes an F-actin binding domain (ABD) at its C-terminus. Adapted and modified from Pylypenko, 
Welz et al., 2016 (211). Information on the MLPH domain organisation from Hume et al., 2006 (355). 
 
 
By its synaptotagmin homology domains (SHD1, SHD2), MLPH binds to activated Rab27a on 
melanosome membranes and recruits MyoVa (81, 83, 84, 354–357), probably supported by the FYVE-
type zinc-finger located between SHD1 and SHD2. Spir proteins non-specifically bind to negatively 
charged intracellular membranes by its FYVE-type zinc-finger (327). In contrast to Spir proteins, 
MLPH owns two MyoVa binding regions. First, the GTBD which interacts with the globular tail domain 
(originally, this binding site was termed GTBD (355); due to its characteristics of being rather a short 
sequence motif instead of a structured domain and for better comparison with the Spir GTBM it will 
here also be termed MLPH GTBM). Second, the exon-F binding domain (EFBD) interacts with exon F 
encoded myosin Va sequences (see also Introduction, Figure 9) (108, 355). 
Both, Spir-2-GTBM and MLPH-GTBM, bind to MyoVa-GTD within a similar range of micromolar 
affinities (210, 211). Spir-2-GTBM and MLPH-GTBM are similar regarding the N-terminal regions of 
the conserved sequence motifs (Figure 30B,C) and comparing the two complex structures 
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demonstrates that both GTBMs interact with MyoVa-GTD in an analogical way. A network of 
hydrogen bonds is formed with the H4’’-H5-loop of the GTD and two conserved leucine residues of 
the motifs (L408 and L409 in human Spir-2; L188 and L189 in mouse MLPH) are located in equivalent 
positions within cavities of the MyoVa-GTD surface (Figure 30B,C; lower panels). As mentioned 
before, the substitution of the two highly conserved Spir-2 leucine residues by alanines significantly 
impairs Spir-2 binding to MyoVa/b-GTD (Figure 24A). The C-terminal parts of the Spir-2 GTBM and 
the MLPH GTBM differ from each other and, thus, show distinct binding modes (Figure 30B,C; upper 
panels). The MLPH GTBM specifically binds to the GTD of MyoVa, in contrast to the Spir GTBM 
interacting with all three MyoV isoforms. The MLPH-GTBM:MyoVa-GTD complex formation requires 
a conformational flexibility of the MyoVa GTD to accommodate F191, a conserved hydrophobic 
residue (Phe, Ile or Val) in melanophilin (210, 353) (Figure 30C, upper panel). At the position 
corresponding to MLPH-F191, Spir-2-GTBM has the highly conserved A411 residue. This alanine 
residue allows binding without conformational changes of MyoV-GTD (Figure 30B, upper panel). 
Spir GTBM and MLPH GTBM present a similar charge distribution along the sequence motifs. 
Whereas each N-terminal sequence part is positively charged, their C-terminal parts carry negatively 
charged residues (Figure 30B,C). The charge complementarity described for binding of MLPH-GTBM 
to MyoVa-GTD (210) is therefore potentially also used by Spir-2-GTBM. 
In summary, three characteristics of the conserved sequence motif within Spir (and MLPH) proteins 
can be described which are demanded for the Spir-GTBM:MyoV-GTD interaction. First, clusters of 
positive and negative charges in the N-terminal and C-terminal regions, respectively, may facilitate 
the proper orientation of the peptide towards the GTD surface. Second, an extended N-terminal 
region of the motif may form hydrogen bonds with backbone atoms of the GTD. Third, hydrophobic 
residues (for instance L408, L409 in human Spir-2) may anchors in small surface pockets of the GTD. 
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Figure 30 | Direct binding of Spir and MLPH to MyoVa-GTD exhibits similarities and differences. (A) Spir-2-GTBM (purple) 
and MLPH-GTBM (white) bind to the same site of MyoVa-GTD (orange) with binding similarities at the N-termini of Spir and 
MLPH GTBMs but with differences at their C-termini. (B and C) Middle panels: The Spir GTBM sequence logo indicates 
sequence conservation in Spir-1 and Spir-2 proteins (compare Figure 20); The MLPH GTBM sequence logo indicates 
sequence conservation in MLPH proteins. The sequence motifs of Spir and MLPH involved in MyoV-GTD binding show a 
similar charge distribution with positively charged N-terminal regions and negatively charged C-terminal regions and display 
two highly conserved leucine residues within the N-terminal part of the motif (L408, L409 for human Spir-2; L188, L189 for 
mouse MLPH). Lower panels: N-terminal regions of the Spir-2 GTBM and the MLPH GTBM show some sequence similarities 
and form similar contacts with MyoVa-GTD. An identical network of hydrogen bonds (dashed lines) involves the side chain 
of MyoVa-E1595 and main chain atoms of D1592 and N1590 which interact with backbone atoms of the Spir/MLPH peptide. 
The R406 side chain and the two conserved leucine residues L408 and L409 of human Spir-2 are packed on the MyoVa-GTD 
surface in a similar way as the K186 side chain, and the conserved leucine residues L188 and L189 of MLPH. Upper panels: 
C-terminal regions of Spir-2-GTBM and MLPH-GTBM are less similar regarding their MyoVa-GTD binding mode. Thus, MLPH-
GTBM forms specific contacts with MyoVa-GTD. The Spir-2 hydrophobic residues A411, P412, L414 and M417 are packed in 
the hydrophobic cleft between the helices H3 and H5 of the MyoVa GTD. Within Spir-2, the conserved L414 side chain 
anchors the C-terminal Spir-2 fragment. Therefore, the interacting hydrophobic surface is extended in comparison to the 
binding of MLPH-GTBM. The F191 and F196 side chains of the MLPH GTBM form hydrophobic contacts with residues in the 
cleft between H3 and H5 of the MyoVa GTD. The side chain of MyoVa-R1528 stabilises the MLPH GTBM by forming 
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hydrogen bonds with MLPH-S190. The side chain conformation of MyoVa-Y1596 (marked in red) is different within the two 
complexes. That would allow a modulation of the binding surface in order to optimise the binding to the respective target 
peptide. (D) Hydrophobic residues anchoring Spir-2-GTBM (purple) on the MyoVa-GTD surface. Spir-2-A411 is packed on 
top of MyoVa-Y1596 (green) side chain. (E) Spir-2 (purple) and MLPH (grey) GTBMs projected on the surface of apo-MyoVa 
(PDB ID 4LX1). The apo-MyoVa hydrophobic cleft between the H5 and H3 is compatible with Spir-2 binding, but not with 
MLPH binding, in which the side chain of F191 clashes with MyoVa-Y1596 (green). In the Spir-2 GTBM, the conserved L414 
side chain anchors the C-terminal Spir-2 fragment extending the interacting hydrophobic surface compared to MLPH-GTBM 
binding. (F) Hydrophobic residues anchoring MLPH-GTBM (grey) in the MyoVa-GTD pocket (PDB ID 4LX2). MyoVa-Y1596 
(green) side chain is rotated to bury the side chain within the protein core (see also panel D) to accommodate MLPH-F191 in 
the binding pocket. GTD, globular tail domain; H, helix; MLPH:MyoVa-GTD complex (PDB ID 4LX2). 
 
 
3.9 Spir proteins induce MyoVa targeting to vesicle membranes  
Up to here, the direct interaction of Spir and MyoV proteins in vitro and at vesicle membranes in 
living cells was shown. The coordination and regulation of a mutual Spir and MyoV membrane 
targeting is so far unknown. At the inactive state, the myosin V dimer is structurally back-folded by 
an intramolecular interaction of its two GTDs with its motor domains (98–100) (Figure 5). At this 
state, the ATPase activity of the motor is inhibited (101, 102), and binding of cargo to the GTD or 
increased Ca2+ levels are able to release this inhibition, thereby activating the MyoV dimer (98, 104, 
252). The MLPH GTBM was described before to have the capacity to open up the back-folded MyoV 
conformation and to convert it into an extended conformation (109). In accordance, the ATPase 
activity of the MyoV dimer was observed to be activated by MLPH in vitro (108, 109, 124). Based on 
the structural similarity between Spir GTBM and MLPH GTBM, as described before, it is intriguing to 
speculate that the Spir GTBM could play an identical role in opening and activating the MyoV dimer, 
and finally in the mutual targeting of both proteins to vesicle membranes. Transiently over-expressed 
GFP-tagged full-length MyoVa proteins (eGFP-MyoVa-FL) show an even cytoplasmic distribution, and 
known activators, such as Ca2+ influx into cells, reorient MyoVa towards vesicular structures, as 
presented by a punctate pattern across the cell (103). Considering a function of Spir proteins in MyoV 
activation, the presence of Spir proteins should also reorient MyoVa from a cytoplasmic state 
towards a vesicular pattern, similar to what was observed before for known activators, in a way that 
Spir is able to bind to back-folded MyoV in the cytoplasm, probably release the back-folding, and 
subsequently targets it to vesicle membranes. 
In order to test this hypothesis, GFP-tagged full-length MyoVa (eGFP-MyoVa-FL) was transiently 
expressed in HeLa cells. Unfortunately, the previously described cytoplasmic localisation of MyoVa 
(103) was not as clear-cut as expected. It was rather the case that the localisation of MyoVa was 
strongly dependent on the protein expression levels, with high expression leading to vesicular 
localisation of the protein by itself, and only at low expression levels MyoVa showed the desired 
even cytoplasmic distribution (Figure 31B). Therefore, individual cells were recorded and the sum of 
pixel grey values, representing the expression levels of eGFP-MyoVa-FL, was measured for each cell. 
Subsequently, the protein localisation (cytoplasmic vs. vesicular) was correlated to the measured 
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protein expression levels for individual cells (Figure 31A). A box-and-whisker plot was generated that 
nicely demonstrates the dependence of cellular eGFP-MyoVa-FL  localisation on its expression levels. 
Based on these analyses, the sum of pixel grey values were measured for all cells in the following 
experimental setups, and only those cells were recorded and further investigated which showed a 
sum of pixel grey value below 20 × 106, to exclude vesicular MyoVa localisation by itself induced by 
over-expression artefacts. 
 
 
 
Figure 31 | Myosin Va protein localisation depends on protein expression levels. (A) The sum of pixel grey values was 
determined for individual cells expressing eGFP-MyoVa-FL, and each cell was classified into either vesicular or cytoplasmic 
localisation of the MyoVa protein. For both groups, a box-and-whisker plot was generated showing the sum of pixel grey 
value distribution for each localisation state. A clear correlation was found between protein expression levels and protein 
localisation with low expression levels leading to cytoplasmic localisation and vice versa. (B) Representative cells are shown 
for both, high protein expression leading to vesicular localisation of eGFP-MyoVa-FL (green and as heat map), and low 
protein expression leading to cytoplasmic MyoVa localisation. Heat maps represent grey values for MyoVa fluorescence 
intensities, rising from “0” (black) to “4096” (red), for better demonstration of expression levels and protein accumulation 
at vesicle membranes under high protein expression conditions. 
 
 
In subsequent fluorescence microscopy studies, eGFP-MyoVa-FL was co-expressed with N-terminal 
Spir-2 deletion mutants either carrying (Myc-Spir-2-KIND-WH2-GTBM, Myc-Spir2-KWM) or not 
carrying (Myc-Spir-2-KIND-WH2, Myc-Spir2-KW) the Spir GTBM required for MyoV interaction (Figure 
32). As those Spir-2 mutants miss the Spir-box and the FYVE-type zinc-finger, they are not targeted to 
vesicle membranes by themselves and show a cytoplasmic (and nuclear) localisation when expressed 
alone (Figure 32A). Single expression of eGFP-MyoVa-FL (Figure 32A) and co-expression with Myc-
Spir2-KW (Figure 32B, upper panel) shows and even cytoplasmic distribution of the MyoVa protein. In 
contrast, co-expression with Myc-Spir2-KWM, which interacts with MyoV proteins in vitro, 
significantly changes the localisation of the MyoVa protein and targets it to vesicular structures 
(Figure 32B, middle panel). Importantly, also the N-terminal Spir-2 mutant is now localised to vesicles 
 83 3 Results 
which is not observed when expressed alone (Figure 32A), and colocalises with MyoVa at vesicle 
surfaces. 
Furthermore, the melanocyte specific F isoform of MyoVa (carries exon F, but not exon D, preventing 
interaction with Rab8a and Rab10), which additionally carries the Q1753R point mutation, preventing 
Rab11 interaction (103) (eGFP-MyoVa-FL-QR), was used as a negative control for membrane 
targeting. Co-expression of the mutant eGFP-MyoVa-FL-QR and Myc-Spir2-KWM does not change the 
localisation of mutant MyoVa (Figure 32B, lower panel), in contrast to the wild-type MyoVa protein. 
These results strongly suggest a coordinated and mutual membrane targeting of Spir and MyoV 
proteins to Rab11 vesicles, most likely to subsequently form a multimeric membrane associated 
protein complex. 
 
 
 
Figure 32 | Spir-2 facilitates myosin Va recruitment to vesicle membranes. (A) N-terminal Myc-epitope-tagged Spir 
fragments (Myc-Spir2-KIND-WH2, Myc-Spir2-KW; Myc-Spir2-KIND-WH2-GTBM, Myc-Spir2-KWM; red) and GFP-tagged full-
length MyoVa proteins (eGFP-MyoVa-FL, eGFP-MyoVa-FL-QR; green) show an even cytoplasmic and nuclear localisation 
when transiently expressed in HeLa cells (single expression). (B) eGFP-MyoVa-FL (green and as heat map) shows an even 
cytoplasmic distribution that is not changed by co-expression of an N-terminal Spir-2 fragment (Myc-Spir2-KW; red), which 
is not able to bind to MyoV and lipid membranes (upper panel). In contrast, co-expression of a MyoV binding N-terminal 
Spir-2 fragment (Myc-Spir2-KWM; red) induces targeting of MyoVa to vesicle membranes and to overlapping Spir-2 and 
MyoVa localisation at vesicle surfaces (middle panel, see also higher magnification in insets). Heat maps represent grey 
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values for eGFP-MyoVa fluorescence intensities, rising from “0” (black) to “4096” (red), to document equal expression 
levels of MyoVa proteins in each depicted cell, and accumulation of fluorescent proteins at vesicle membranes induced by 
Myc-Spir2-KWM. To address the dependence of motor protein vesicle targeting on membrane associated small GTPases, 
the GFP-tagged melanocyte specific F isoform of MyoVa (carries exon F, but not exon D), which additionally carries the 
Q1753R mutation (eGFP-MyoVa-FL-QR) was expressed. The point mutation prevents MyoVa binding to Rab11. Expression 
of the eGFP-MyoVa-FL-QR mutant shows an even cytoplasmic distribution that was not changed upon co-expression of the 
MyoV binding N-terminal Spir-2 fragment (Myc-Spir2-KWM; red, lower panel), in contrast to what is observed for the wild-
type MyoVa protein. At least 5 cells were recorded for each condition and one representative cell is depicted here. For all 
cells recorded, the fluorescence intensities of the eGFP-tagged MyoVa protein were measured and only those cells were 
further processed which have below-threshold levels of MyoVa protein expression (compare Figure 31). Scale bars 
represent 10 µm. An overview of employed proteins is presented and the domains used for localisation studies are 
highlighted. K, KIND; W, WH2; M, GTBM; IQ, isoleucine/glutamine motifs for calmodulin light chain binding; CC, coiled-coil; 
GTD, globular tail domain; FL, full-length. 
 
 
3.10 A tripartite Spir:MyoV:Rab11 complex determines vesicle specificity 
Spir actin nucleators and Rab11 small GTPases have been demonstrated to colocalise on vesicular 
structures and cooperate in exocytic and recycling transport processes (325), although a direct 
interaction of both proteins has never been observed. Furthermore, Rab11 and myosin V actin motor 
proteins directly interact with each other on vesicle membranes and function together in a wide 
range of cellular processes (222, 251, 256–260). Finally, Spir proteins have been shown to directly 
interact with MyoV proteins in vitro and at vesicle membranes. Therefore, the intriguing idea came 
up that myosin V actin motor proteins might act as a linker between Rab11 and Spir to form a 
tripartite Spir:MyoV:Rab11 complex at vesicle membranes, which in turn specifies a distinct vesicle 
subpopulation of Rab11- and Spir-positive vesicles, which possibly require de novo generation of 
actin filaments for transport through the cell. 
The crystal structures of the MyoVa-GTD:Spir-2-GTBM complex (PDB ID 5JCY; see also Figure 28) and 
the MyoVa-GTD:Rab11a complex (PDB ID 5JCZ) (211) reveal that the MyoVa-GTD binding sites for 
Rab11a and Spir-2-GTBM are distinct and on opposite ends of the domain. So, in theory, Spir and 
Rab11 proteins might be able to bind to the MyoV GTD simultaneously, which would support a linker 
function of the MyoV GTD for Spir and Rab11 at vesicle surfaces. To test this hypothesis, a series of 
experiments was performed in order to analyse the putative formation of a tripartite Spir-
2:MyoVa:Rab11a complex which is suggested to contribute in determining vesicle identity. 
An initial pulldown assay showed that a bacterially expressed and purified recombinant constitutively 
active Rab11a protein (GST-Rab11a-Q70L) is able to pull transiently co-expressed eGFP-tagged full-
length MyoVa (GFP-MyoVa-FL), Myc-epitope-tagged full-length Spir-2 (Myc-Spir2) and mStrawberry-
tagged C-terminal FMN-2 (Straw-FMN2-FH2-FSI) from HEK293 cell lysates (Figure 33A). GST-Rab11a-
Q70L is not able to pull a mutated MyoVa protein (GFP-MyoVa-Q1753R), as expected due to its 
mutation induced Rab11 binding deficit (103), which subsequently reduces the amount of pulled 
Myc-Spir2 and Straw-FMN2-FH2-FSI proteins. These data allow arguing on the formation of a large 
protein complex containing Rab11a, MyoVa, Spir-2 and FMN-2. Considering the markedly reduced 
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co-precipitation of Spir-2 and FMN-2 proteins in the case of Rab11a not binding to MyoVa (MyoVa-
Q1753R mutant), the idea of a linker function of MyoVa for Spir and Rab11 proteins within this 
complex is further supported. 
Next, the colocalisation of Spir-2 and Rab11a depending on MyoVa was determined by fluorescence 
microscopic analysis (Figure 33B). Immunostainings of Myc-epitope-tagged C-terminal Spir-2 deletion 
mutants, co-expressed with fluorescent-protein labelled C-terminal MyoVa (eGFP-MyoVa-CC-GTD) 
and Rab11a (mStrawberry-Rab11a) were examined. The MyoV-binding Myc-Spir2-GTBM-SB-FYVE 
protein perfectly colocalised with eGFP-MyoVa-CC-GTD and mStrawberry-Rab11a in a vesicular 
pattern (upper panel). In opposite, Myc-Spir2-SB-FYVE, missing the MyoV binding site, is still localised 
to vesicle membranes driven by its FYVE-type zinc-finger (327), but is largely targeted to vesicles 
other than those carrying MyoVa and Rab11a, both of which still perfectly colocalise (lower panel). 
To further decipher these findings, the Pearson’s correlation coefficient (PCC) was determined to 
quantify the colocalisation of Spir-2 and Rab11a at vesicle surfaces in a MyoVa dependent manner 
(Figure 33C). The PCC for the colocalisation of Spir2-SB-FYVE was significantly reduced compared to 
the PCC for the colocalisation of Spir2-GTBM-SB-FYVE, demonstrating the dependence of the 
Rab11a/Spir-2 colocalisation on the Spir/MyoV binding site (Spir GTBM). Furthermore, the complete 
absence of MyoVa also significantly reduced the PCC for colocalisation of Spir2-GTBM-SB-FYVE with 
Rab11a compared to when MyoVa is present. The PCC for colocalisation of MyoVa and Rab11a is not 
altered in each of the experimental setups. Taken together, these data show that both, the capacity 
of Spir proteins to bind to MyoV (presence of the Spir GTBM), and the presence of MyoV itself, is 
critical to induce overlapping Spir-2/Rab11a localisation at vesicle membranes, and is in line with the 
concept of MyoV connecting Spir and Rab11 proteins into a tripartite Spir:MyoV:Rab11 complex at 
vesicle membranes. The same results were obtained for MyoVb (Figure 34). Fluorescence microscopy 
analysis revealed colocalisation of eGFP-tagged Rab11a, mStrawberry-tagged MyoVb-CC-GTD and 
Myc-epitope-tagged C-terminal Spir-2-GTBM-SB-FYVE at vesicle surfaces (Figure 34A). The PCC was 
determined to quantify the colocalisation of Spir-2 and Rab11a at vesicle surfaces in a MyoVb 
dependent manner (Figure 34B). The PCC for the colocalisation of Spir-2-GTBM-SB-FYVE and Rab11a 
was significantly reduced when MyoVb-CC-GTD is not present. MyoVb and Rab11a completely 
colocalise in each condition which does not depend on the presence of Spir-2. Thus, the PCC for 
colocalisation of MyoVb and Rab11a is not altered in each of the experimental setups. 
Finally, a GST-pulldown assay was performed to prove the formation of a tripartite Spir-
2:MyoVa:Rab11a complex in vitro without the support by additional factors (Figure 33D). Here, 
bacterially expressed and purified recombinant GST-Spir-2-GTBM-SB-FYVE, Rab11a-Q70L and MyoVa-
GTD proteins were employed. As expected, GST-Spir-2-GTBM-SB-FYVE was not able to pull Rab11a-
Q70L by itself, but strongly pulls MyoVa-GTD. Importantly, in presence of MyoVa-GTD, GST-Spir-2-
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GTBM-SB-FYVE is now also able to pull the Rab11a-Q70L protein. In summary, these data strongly 
support the role of the MyoVa GTD as a linker between Spir-2 and Rab11a as a prerequisite to form a 
tripartite complex at vesicle membranes allowing the specification of vesicle identity for a distinct 
Rab11- and Spir-positive vesicle subpopulation. 
 
 
 
Figure 33 | Myosin Va links Spir-2 and Rab11a into a tripartite complex. (A) GST-pulldown assay with bacterially 
expressed, purified GTP-locked GST-Rab11a-Q70L mutant from HEK293 cell lysates transiently expressing full-length Myc-
epitope-tagged Spir-2 (Myc-Spir2), mStrawberry-tagged C-terminal Formin-2 (Straw-FMN2-FH2-FSI), eGFP-tagged full-
length MyoVa (D isoform; GFP-MyoVa-FL) or eGFP-tagged full-length MyoVa, carrying the Q1753R point mutation (D 
isoform; GFP-MyoVa-Q1753R). GST-Rab11a-Q70L pulls GFP-MyoVa-FL from cell lysates, but not the GFP-MyoVa-Q1753R 
mutant. In presence of GFP-MyoVa-FL, GST-Rab11a-Q70L is also able to pull Myc-Spir2, as well as Straw-FMN2-FH2-FSI. 
Only faint Myc-Spir2 and Straw-FMN2-FH2-FSI bands were detected using the GFP-MyoVa-Q1753R mutant. Pulled proteins 
were detected by immunoblotting (anti-GFP, anti-Myc, anti-RFP). No bands were detected employing a GST control. 
Ponceau S staining reveals equal loading of GST-fusion proteins. N = 2 experimental repeats. (B) The localisation of 
transiently co-expressed tagged Rab11a (mStrawberry, mStraw-Rab11a; red), MyoVa-CC-GTD (eGFP, eGFP-MyoVa-CC-GTD; 
green) and the Myc-epitope-tagged (Myc; cyan) C-terminal Spir-2 proteins encoding (Myc-Spir2-GTBM-SB-FYVE) or lacking 
(Myc-Spir2-SB-FYVE) the MyoV binding motif was analysed by fluorescence microscopy. 3D-deconvoluted images indicate 
the localisation of the proteins on vesicular structures. 5 cells were recorded for each condition and one representative cell 
is presented here. Scale bars represent 5 µm. An overview of employed proteins is presented and the domains used for 
colocalisation studies are highlighted. (C) The colocalisation of tagged proteins as described in (C) was quantified for the 
indicated co-expressions by determining the Pearson’s correlation coefficient (PCC) as shown in a bar diagram. Each bar 
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represents the mean PCC value for at least 4 cells analysed. Error bars represent SEM. Statistical analysis was performed 
using Student's t-test to compare the mean PCC values of two co-expression conditions with a confidence interval of 95%. 
*, p < 0.05. (D) GST-pulldown assay employing bacterially expressed, purified GST-tagged Spir-2-GTBM-SB-FYVE protein 
(GST-Spir2-GTBM-SB-FYVE), MyoVa-GTD and the GTP-locked Rab11a-Q70L mutant. GST-Spir2-GTBM-SB-FYVE by itself does 
not pull Rab11a-Q70L. In contrast, the presence of the MyoVa GTD allows GST-Spir2-GTBM-SB-FYVE to pull Rab11a-Q70L, as 
indicated by immunoblotting (anti-MyoVa and anti-Rab11a). No bands were detected employing a GST control. Ponceau S 
staining reveals equal loading of GST-fusion proteins. N = 3 experimental repeats. 
 
 
 
Figure 34 | Myosin Vb links Spir-2 and Rab11a into a tripartite complex. (A) The localisation of transiently co-expressed 
tagged Rab11a (eGFP, GFP-Rab11a; green), MyoVb-CC-GTD (mStrawberry, Straw-MyoVb-CC-GTD; grey) and the Myc-
epitope-tagged C-terminal Spir-2 fragment encoding the MyoV binding motif (Spir-2-GTBM-SB-FYVE, Myc-Spir2-MSF; red) 
was analysed by fluorescence microscopy. 3D-deconvoluted images indicate the co-localisation of the proteins on vesicular 
structures. 5 cells were recorded and one representative cell is presented here. Scale bar represents 10 µm. (B) The 
colocalisation of tagged proteins as described in (A) was quantified for the indicated co-expressions by determining the 
Pearson’s correlation coefficient (PCC) as shown in a bar diagram. Each bar represents the mean PCC value for at least 4 
cells analysed. Error bars represent SEM. Statistical analysis was performed using Student's t-test to compare the mean PCC 
values of two co-expression conditions with a confidence interval of 95%. *, p < 0.05. An overview of employed proteins is 
presented and the domains used for colocalisation studies are highlighted. 
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Accordingly, in collaboration with Prof. Dr. Anne Houdusse and Dr. Olena Pylypenko (Institut Curie, 
Paris, France), a model for the tripartite Spir-2-GTBM:MyoVa-GTD:Rab11a complex was generated by 
superimposition of the MyoVa-GTD from the MyoVa-GTD:Spir-2-GTBM complex and the MyoVa-
GTD:Rab11a complex crystal structures which nicely shows the distinct Rab11 and Spir-GTBM binding 
sites on the MyoVa GTD and the connecting character of MyoVa-GTD between Spir-2 and Rab11a 
(Figure 35). 
 
 
Figure 35 | Model for the Spir-2-GTBM:MyoVa-GTD:Rab11a complex. This complex was generated by superimposition of 
the MyoVa GTD from the MyoVa-GTD:Rab11a complex (PDB ID 5JCZ; (211)) and the MyoVa-GTD:Spir-2-GTBM complex 
(PDB ID 5JCY; see also Figure 28) crystal structures. The Spir-2-GTBM peptide (purple) binds to subdomain 1 (SD-1) of the 
MyoVa GTD (orange) and Rab11a (green; Switch-1 in blue, Switch-2 in red) binds to its SD-2. An overview of the employed 
proteins is presented and the domains used for structural analysis are highlighted. 
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4 Discussion 
 
Accumulating evidence was generated for the cooperation of myosin actin motor proteins and actin 
assembly factors in intracellular membrane transport processes. In yeast, as well as in mammalian 
cells, the co-recruitment of the Arp2/3 complex and class I myosin motors has been described to 
facilitate endocytic events (340–343). Myosin Vb cooperates with Spir and FMN actin nucleators to 
peripherally transport Rab11-positive vesicles in metaphase mouse oocytes (222, 334), but the 
underlying mechanisms how the Spir/FMN actin nucleation activity and Rab11/MyoV motor activity 
are coordinated at the same vesicle surfaces remained unknown. 
The present thesis was aimed to gain deeper insights into the processes of actin dependent vesicle 
transport, and unravelled a direct physical interaction of Spir actin nucleators and myosin V actin 
motor proteins driving a mutual targeting towards intracellular vesicle membranes. The Spir/myosin 
V interaction is mediated by a newly identified highly conserved sequence motif within the central 
Spir linker region (globular tail domain binding motif, GTBM) and the myosin V globular tail domain 
(GTD). The Spir GTBM is highly conserved across species, from choanoflagellata to mammals, and 
decides on the targeting of the MyoV GTD to Spir-positive vesicles. 
Rab family small GTPases are well known to act as master regulators at different steps of intracellular 
transport. Rab11 is localised to intracellular membranes of the trans-Golgi-network (TGN), post-Golgi 
vesicles and the recycling endosome, and is thus involved in exocytic and recycling pathways (7). The 
Spir proteins have been identified to localise to Rab11-positive vesicles and cooperate in these 
intracellular trafficking pathways (325). So far, a direct interaction of Rab11 and Spir proteins has not 
been demonstrated. In line with that, this thesis revealed the formation of a tripartite 
Spir:MyoV:Rab11 complex both, in vitro and in living cells at vesicle membranes. The Spir-GTBM 
mediated interaction with MyoVa-GTD is critical for the tripartite complex formation and is required 
to target the complex to the same vesicle population. Superimposition of the Rab11a:MyoVa-GTD 
complex (PDB ID 5JCZ; (211)) and the Spir-2-GTBM:MyoVa-GTD complex (PDB ID 5JCY; see also Figure 
28) showed that the binding sites for Spir and Rab11 are distinct and on opposite ends of the MyoVa 
GTD. Together, these data unravel a role for the myosin V actin motors as a linker between Rab11 
and Spir proteins at vesicle membranes, which therefore determines the vesicle identity by 
mediating the formation of a specific Rab11- and Spir-positive vesicle subpopulation. This finally 
allows the coordination of Spir/FMN dependent actin nucleation and Rab11/MyoV mediated motor 
activity at the same vesicle population. 
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The melanophilin (MLPH) protein shows a similar domain organisation as the Spir proteins (see 
Figure 29), containing a membrane targeting unit, a myosin V binding unit, and an F-actin binding 
domain (compared to the actin nucleating KIND/WH2 unit in Spir proteins). MLPH mediates the 
interaction between the melanosome associated small GTPase Rab27a and myosin Va, in order to 
drive melanosome transport to the periphery of melanocytes, a process required for skin and hair 
pigmentation (80, 124, 169, 172–174). The polypeptide sequence of the Spir GTBM is similar to the 
MLPH GTBM binding to MyoVa-GTD, and also the Spir-2-GTBM:MyoVa-GTD (Figure 28) and MLPH-
GTBM:MyoVa-GTD (PDB ID 4LX2; (210)) complex structures share some similarities. Both GTBMs 
target the same site of the globular tail domain of MyoVa. These findings open the possibility that 
there might be a general mechanism for the association of Rab family GTPases, myosin actin motor 
proteins and actin monomer/F-actin binding proteins which contribute to specific vesicle transport 
processes. 
 
 
4.1 Mechanisms for Spir/MLPH induced unfolding of MyoV motors 
The inactive full-length myosin V dimer is back-folded by an intramolecular interaction of the motor 
domains and globular tail domains (GTDs) (98–100), and has been shown to be evenly distributed in 
the cytoplasm (103). MLPH has been observed to open up the back-folded myosin V dimer, to 
activate its ATPase activity and to facilitate its movement on actin filaments in vitro (107–109). 
However, the exact mechanism here has not yet been deciphered completely. Several studies have 
shown that the GTD binding sites for MLPH and for the MyoV motor domain are distinct and not 
overlapping (109, 358). Whereas the MLPH GTBM binds, as does the Spir-2 GTBM, to subdomain 1 
(SD-1) of the MyoVa GTD, the motor domain is suggested to bind to SD-2, and specific residues 
within the GTD are essentially involved in binding to MLPH and to the motor domain, respectively 
(98, 109, 210, 353, 358, 359). Consequently, an allosteric mechanism has been proposed in which 
MLPH-GTBM binding to MyoVa-GTD induces the release of the GTD-motor interaction, and in which 
the GTD-motor interaction competes with the GTD-MLPH interaction (109). It is suggested that 
binding of the MLPH GTBM does not induce a major conformational change within the GTD, but the 
GTD-motor interaction does so. MLPH is thought to prevent these conformational changes by binding 
to the GTD, thus inhibiting the GTD-motor interaction. The back-folded structure of the full-length 
MyoVa protein might therefore inhibit the binding of MLPH-GTBM to the GTD by allosteric effects as 
well, and thus strongly reduces its binding affinity. This is supported by studies demonstrating 
differences in the binding affinities of MLPH-GTBM binding to the isolated GTD (~0.5 µM) (210, 353, 
360) and to the GTD of full-length MyoVa (~20 µM) (109). 
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In a very recent study, the decreased binding capacity of the MLPH GTBM to the GTD of the back-
folded myosin Va dimer was attributed to a dimerising interaction between both GTDs of the heavy 
chain dimer, formed by the N-terminal linkers of the GTDs (Figure 36) (361). Both GTDs of the dimer 
are supposed to dimerise in a head-to-head orientation by which both SD-1 bind to each other, 
preventing MLPH binding to the GTD. Two conserved residues, R1490 and K1491, correspond to the 
respective R187 and K186 of the MLPH GTBM, and bind to the MLPH binding site of the opposing 
GTD-SD-1. Mutations of these two residues (R1490A and K1491A) increased the binding of MLPH to 
the GTDs of a full-length MyoVa dimer. Furthermore, it has been revealed that the GTD dimerisation 
by mutual binding to the opposing MLPH binding site is essential for the efficient binding of both 
GTDs to the motor domains of the dimer and to support the stabilisation of the typical triangular 
back-folded MyoVa structure (361). 
 
 
Figure 36 | Back-folding of the MyoV dimer is stabilised by the GTD N-terminal linkers. A model for the back-folded MyoV 
dimer is shown and the N-terminal linker of the GTD 1, as well as the Rab11 binding sites are indicated on left. The binding 
of the N-terminal linkers (orange and beige) to the opposing GTD, as well as the binding of the Spir (purple) and MLPH 
(white) GTBMs to the GTDs are presented in greater structural detail in the middle. The Spir GTBM, as does the MLPH 
GTBM, binds to the same site of the MyoVa GTD as the N-terminal linker from the opposing GTD does in the back-folded 
state, which also shows the distinct GTD binding sites for Spir/MLPH and the motor domains. Images provided by Olena 
Pylypenko (left and right) and adapted from Pylypenko, Welz et al., 2016 (211) (middle). 
 
 
Taking all these considerations into account, MLPH might be able to open and activate MyoVa in a 
dual-step manner with the auto-inhibited MyoVa dimer traversing two distinct states (361). First, a 
state in which MyoVa is strongly back-folded, supported by the GTD-GTD interaction mediated by 
their N-terminal linkers occupying the sites for MLPH and preventing MLPH-GTBM binding. Second, a 
pre-activated state in which the MLPH binding sites are exposed by the previous release of the N-
terminal linkers, allowing MLPH-GTBM to bind to the GTD which allosterically blocks the binding of 
the GTDs to the motor domains and consequently induces the unfolding of MyoVa. 
Besides the GTBM, melanophilin carries a second MyoVa binding site that interacts with the exon F 
encoded regions of MyoVa, the exon F binding domain (EFBD) (355). It has been shown that the 
presence of both MyoVa binding sites increases the affinity of MLPH to MyoVa compared to 
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presence of the GTBM alone, and accordingly, the binding of EFBD to MyoVa-exon F might be able to 
weaken the GTD-GTD interaction, thereby inducing the pre-activated state and paving the way for 
GTBM binding to the GTD (108). 
 
As Spir-2 was able to target the back-folded, cytoplasmic, GFP-tagged full-length myosin Va protein 
to vesicle membranes in a GTBM dependent fashion (see Figure 32), it is intriguing to speculate 
about a similar role for Spir proteins in the opening and activation of full-length myosin V motors. 
The overall protein organisation of Spir and MLPH proteins is very similar, as well as the amino acid 
sequence of both GTBMs (Figure 37), explaining a similar binding mode of the Spir GTBM and the 
MLPH GTBM to the MyoVa GTD, although there are differences, as well (see Figure 30). 
 
 
Figure 37 | Comparison of Spir and melanophilin proteins. (A) The Spir-GTBM sequence is highly conserved in Spir-1 and 
Spir-2 proteins as indicated by the sequence logo (left). The respective human Spir-2-GTBM sequence is shown below the 
WebLogo. The melanophilin (MLPH)-GTBM sequence is also highly conserved in MLPH proteins (right). The respective 
murine MLPH-GTBM sequence is shown below the WebLogo. The WebLogos (345) for both GTBMs were generated from 
the alignment of 223 Spir protein sequences and 44 MLPH sequences. Both, Spir and MLPH GTBMs, show a similar charge 
distribution with positive charges at the N-terminus and negative charges at the C-terminus, and have two highly conserved 
leucine residues within the positively charged cluster. (B) Comparison of the Spir-2 and MLPH protein domain organisation 
shows the presence of similar functional units. Both proteins share a MyoV protein interaction unit in their central regions 
(GTBM for Spir-2; GTBM and exon-F binding domain (EFBD) for MLPH). Both proteins encode a membrane targeting unit at 
their C-terminus (Spir-2) and N-terminus (MLPH), respectively, consisting of a FYVE-type zinc-finger and a related potential 
small GTPase binding Spir-box (SB in Spir-2) and synaptotagmin-like protein homology domains (H1 and H2 in MLPH). The 
MLPH-H1-FYVE-H2 cluster is essential for MLPH interaction with Rab27a (354). Both proteins share an actin interaction 
cluster as well, in which Spir-2 encodes an actin nucleating KIND/WH2 cluster at its N-terminus, and MLPH encodes an F-
actin binding domain (ABD) at its C-terminus. Adapted and modified from Pylypenko, Welz et al., 2016 (211). Information 
on the MLPH domain organisation from Hume et al., 2006 (355). 
 
 
 
 
 93 4 Discussion 
The similarity of GTD binding by MLPH and Spir GTBMs strongly suggests a mechanism for MyoV 
activation in accordance to the MLPH induced opening of MyoVa, in a way that the Spir GTBM is able 
to weaken the GTD-motor interaction in an allosteric manner in order to release the back-folded 
conformation and induce motor activity (Figure 38). 
 
 
 
However, a second MyoV binding site was not detected within the Spir-2 protein, a finding which 
would disagree with a two-step opening mechanism as proposed for MLPH. The binding patterns of 
the C-terminal regions of Spir-2 and MLPH GTBMs differ as Spir-2-GTBM forms a larger hydrophobic 
interaction surface compared to MLPH-GTBM. It could be the case that such minor differences in 
terms of molecular interactions are sufficient to induce the Spir dependent opening of MyoV 
proteins. However, no significant conformational changes in the MyoV GTD following Spir-2-GTBM 
binding have been observed (211). Therefore, it would be of great importance to further analyse the 
effects of Spir-GTBM binding to MyoV-GTD as well as the exact molecular mechanisms leading to 
MyoV activation in more detail. Mutational analysis of both the Spir GTBM and the MyoV GTD in 
combination with protein interaction studies, fluorescence microscopy, electron microscopy, 
fractional ultracentrifugation and ATPase activity assays would help to gain deeper insights on Spir 
induced myosin V opening, membrane targeting and activation. In accordance to studies on the 
MLPH GTBM, it would be very helpful to show if the isolated Spir GTBM is able to induce unfolding of 
the full-length MyoV protein and to induce the ATPase activity of the motor domain by itself, using 
purified proteins and peptides. Additionally, it would be meaningful to unravell if there are similar 
differences in the binding affinities of Spir-GTBM to the isolated GTDs and to full-length myosin V 
proteins, as was observed for the MLPH GTBM. 
 
 
Figure 38 | Schematic representation of MyoV 
activation. In the myosin V OFF state, MyoV is 
back-folded supported by the mutual binding of 
the GTDs N-terminal linkers (orange and beige). 
Spir/MLPH GTBM (purple) binding to MyoV 
globular tail domains induces unfolding into an 
extended structure, and activation of MyoV 
motors. Adapted from Pylypenko, Welz et al., 
2016 (211). 
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4.2 Rab11 by itself is not able to activate MyoV in vivo 
It has been recently revealed that the Drosophila Rab11 protein (dRab11) is able to activate the 
motor function of Drosophila myosin V (Dm-MyoV) in vitro (362). It was proposed that dRab11 either 
directly blocks the binding of Dm-MyoV GTDs to its motor domains by occupying identical binding 
sites, or by allosteric inhibition of Dm-MyoV-GTD-motor interactions. Recent data shows that the 
binding sites for the motor domain and for Rab11 on the MyoV GTD are both located at subdomain 2 
(SD-2), but on opposite surfaces (211, 362). The E1791 residue within the loop connecting helix 11 
and helix 12 of the MyoVa GTD-SD-2 (H11-H12 loop) is involved in binding to the motor domain and 
to Rab11 (109, 211). Therefore, it might be a competing interaction between GTD-motor and GTD-
Rab11 binding which leads to motor activation following vesicle targeting. However, when expressed 
in living cells, the back-folded full-length myosin Va protein is not targeted to vesicle surfaces by the 
active, membrane associated Rab11 GTPase alone (see Figure 32) (103), demonstrating the 
importance of additional mechanisms besides the presence of Rab11 at vesicle surfaces, which are 
demanded for myosin V opening and targeting to Rab11 vesicle membranes. A sterical hindrance 
might exist which inhibits the association of the membrane bound Rab11 and the large cytoplasmic 
MyoV dimer, preventing an active Rab11 driven MyoV opening mechanism. Co-expression of N-
terminal Spir-2 fragments induced a re-orientation of full-length myosin Va proteins to Rab11-
positive vesicle membranes (see Figure 32). One may speculate about a mechanism by which Spir 
proteins activate back-folded MyoV proteins in the cytoplasm, induce the release of the auto-
inhibitory GTD-motor interaction, and target the motor towards vesicle surfaces. Once they reach 
the vesicle membrane, active Rab11 binds to the MyoV GTD and stabilises the opened, active MyoV 
conformation in order to fulfil its role in vesicle transport. 
 
 
4.3 Coordinated recruitment of Spir and MyoV proteins to vesicle surfaces 
Based on the data obtained in this thesis the following model is proposed for the coordinated 
recruitment of Spir actin nucleators and myosin V actin motor proteins to Rab11 vesicle membranes 
(Figure 39). In this model, both, Spir and MyoV proteins exist in two distinct states. There is an 
inactive  cytoplasmic state in which the myosin V dimer is back-folded and auto-inhibited, a condition 
that is also suggested for Spir proteins (327). At this state, the ATPase activity of MyoV is inhibited 
and the motor only weakly interacts with actin filaments (101, 102). The potentially auto-inhibited, 
cytoplasmic Spir proteins do not interact with FMN proteins, preventing efficient actin nucleation in 
the cytoplasm. However, Spir proteins have been shown to transiently interact non-specifically with 
negatively charged intracellular membranes during which the back-folding is released and Spir is 
opened up (327). By so far unknown activating mechanisms, Spir and MyoV proteins are co-recruited 
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to Rab11-positive vesicles forming a vesicle associated tripartite Rab11:MyoV:Spir protein complex. 
The newly identified Spir-GTBM is essentially involved in the opening mechanism of MyoV proteins 
and the interaction of the MyoV GTD and Rab11 is thought to further stabilise the whole protein 
complex and supports its functionality at the vesicle membrane. Here, the MyoV actin motor acts as 
a linker between Rab11 and Spir at vesicle surfaces. Furthermore, Spir proteins are thought to 
dimerise once they are targeted to vesicle membranes (321, 333), and interact with FMN proteins to 
form a functional actin nucleator complex which generates actin filaments directly at the vesicle 
surface. These de novo generated actin filaments are supposed to associate with MyoV motors to 
finally exert forces on membrane vesicles. Therefore, the Spir/myosin V interaction provides the base 
to coordinate Spir/FMN actin nucleation activity and Rab11/MyoV motor activity at the same vesicle 
population. The existence of two distinct activity states, including auto-inhibited back-folded MyoV 
and Spir proteins, allows for induced, specific targeting of actin nucleation and motor activity to 
vesicle membranes. 
 
 
Figure 39 | Model for the formation of a Spir/FMN actin nucleator/MyoV actin motor complex at Rab11 vesicle 
membranes. Spir and MyoV proteins adopt an auto-inhibited, (potentially in case of Spir) back-folded and cytoplasmic 
conformation on the one hand, and an active, open conformation on the other hand in which the proteins are targeted to 
vesicle membranes as part of a multimeric protein complex. The recently discovered Spir-KIND/FYVE interaction is thought 
to induce a back-folded, cytoplasmic Spir protein conformation which does not interact with Formin family formin (FMN) 
proteins (327). Spir proteins have also been shown to transiently interact with vesicle membranes, mediated by the FYVE-
type zinc-finger, during which the protein opens up. MyoV at its inactive state is back-folded by the interaction of the 
globular tail domains (GTDs) with the motor domains of the dimer. By yet poorly understood activation mechanisms, Spir 
and MyoV proteins are targeted to Rab11-positve (Rab11-GTP) vesicle membranes. The newly identified Spir-GTBM is 
essentially involved in the opening mechanism of MyoV proteins. The interaction of MyoV-GTD and Rab11 is thought to 
further stabilise the whole protein complex and supports its functionality at the vesicle membrane. The membrane 
targeted, unfolded Spir protein is consequently free to interact with FMN proteins to form a functional actin nucleator 
complex to generate new actin filaments directly at vesicle surfaces. These de novo generated actin tracks might then be 
used by MyoV actin motors to either move the whole vesicle, or to pull out tubular membrane structures in order to reach 
microtubule tracks. 
 
 96 4 Discussion 
This model is supported by two studies showing the influence of the actin nucleotide state on myosin 
V run length (363, 364). It has been revealed that younger, ADP+Pi rich actin filaments increase the 
run length of myosin Va by 1.3- to 1.5-fold. Furthermore, younger actin filaments also induce a rise in 
landing rates (the rate at which myosin V attaches to F-actin and starts a processive run) of myosin 
Va on actin filaments (363). These findings perfectly fit to a cooperation of an actin nucleation 
machinery (Spir/FMN) and myosin V motor activity, generating new actin filaments at vesicle 
membranes which might be subsequently available for actin motor proteins. 
 
 
4.4 Nanotube formation as a potential mechanism for switching vesicle transport tracks 
The final role of a functional interaction of actin nucleation factors, F-actin binding proteins and actin 
motor proteins at vesicle surfaces needs to be further investigated. The Spir/FMN and Rab11/MyoVb 
dependent actin driven long-range vesicle transport has been revealed in metaphase oocytes in 
which the microtubules are trapped in the mitotic spindle and are thus not available for vesicle 
transport. In contrast, somatic cells harbour a very complex microtubule network which enables 
rapid transport towards the cell periphery and backwards. Therefore, a completely actin based long-
range transport, similar to metaphase oocytes, seems to be rather unlikely in somatic cells. 
Live cell imaging studies of Spir-2-positive vesicles in HeLa cells have revealed the existence of 
different vesicle states, including resting phases and fast movement on microtubule tracks (321). 
During the resting phases, a dynamic and continuous outgrowth of membrane nanotubes from the 
vesicle surface has been observed (321). Accordingly, a model is proposed in which the interaction of 
Spir, FMN and MyoV proteins at Rab11 vesicles induces the formation of such nanotubules by 
Spir/FMN dependent actin nucleation and polymerisation, and subsequent myosin V motility along 
de novo generated F-actin tracks (Figure 40). The indirect membrane association of myosin V (by 
interactions with Rab11, Ra11-FIP2 and Spir proteins) might therefore enable the motor to exert a 
pulling force on the vesicle membrane and to generate tubular structures. Those might then be used 
to reach the microtubule network in more centred regions of the cell, and allow vesicle switching to 
microtubule tracks for fast long-range transport. 
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Figure 40 | Model for the formation of nanotubes from somatic cell vesicles. Somatic cell vesicles have been shown to 
exist in different states, including resting phases and fast movement on microtubule (MT) tracks (321). During the resting 
phases, a dynamic and continuous outgrowth of nanotubes from the vesicle surface has been observed (321). Spir, Formin 
(FMN), Rab11 and MyoV proteins are supposed to form a functional complex at the vesicle surface. The Spir/FMN actin 
nucleator complex mediates de novo generation of actin filaments at the vesicle surface with the barbed end (+) potentially 
pointing away from the vesicle. These newly generated actin tracks are then supposed to be used by Rab11/MyoV motor 
complexes to move along and exert a pulling force on the vesicle membrane inducing nanotube formation. Anchoring of 
actin filaments might be provided by annexin actin binding proteins (365), or directly by MyoV motors by forming 
complexes with other membrane associated proteins (e.g. Rab11-FIP2). FMN, processively moving with the elongating actin 
barbed end, might account for the initial contact with the MT tracks (366), in order to induce vesicle switching to MT based 
fast transport. Additional proteins, such as MT dependent motors, might contribute to these processes. 
 
 
This theory gets support as the myosin motors myosin Vb, myosin VI and myosin Ib have been 
reported to be involved in membrane tabulation in vivo (196, 367–369). Myosin Ib (MyoIb) is a 
membrane associated single-headed motor, which directly binds to lipid membranes by its highly 
basic C-terminal tail homology 1 (TH1) domain (370, 371), and is essential for the formation of 
membrane tubules from the TGN and from sorting endosomes (368, 369). The process and 
mechanism of nanotube formation was described in detail for MyoIb recently (372). By means of a 
reconstituted system engaging purified proteins and giant unilamellar vesicles (GUVs), it has been 
shown that myosin Ib is able to form membrane tubules along F-actin bundles at physiologically 
relevant densities (372). A similar mechanism of membrane tabulation induced by motor proteins 
has been described before for microtubule associated motors (373, 374). In vitro studies have 
revealed the formation of tubular networks along microtubules emanating from the Golgi and 
endoplasmatic reticulum (375–377), and processive microtubule associated motors generated forces 
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on the membranes to which they are attached to, in order to form nanotubues along microtubules 
(378–380). 
Formin family formins have been shown to directly interact with microtubules via their FH2 domains 
and the C-terminal Formin/Spir interaction (FSI) sequence (366). When bound to microtubules, 
formins are not able to nucleate and elongate actin filaments anymore as the FH2 domain is 
occupied. Formin proteins processively move with the elongating barbed end of actin filaments and 
could therefore mediate the initial contact of the vesicle associated protein complex with the 
microtubule network. As soon as the formin reaches the microtubule, actin polymerisation would be 
stopped right in time. Additional vesicle membrane associated proteins that may join the protein 
complex, such as kinesin or dynein microtubule dependent motors, would be able to attach to the 
microtubules and mediate long-rang vesicle transport. 
Open questions remain regarding the orientation and attachment of actin filaments when newly 
generated at vesicle surfaces. Spir proteins are attached to the membrane via their C-terminal FYVE-
type zinc-finger. The KIND and WH2 domains are thus oriented away from the vesicle surface. Spir 
induced actin nucleation starts with actin monomer binding to WH2C and WH2D domains and is 
followed by G-actin binding to WH2B and WH2A (with A to D in N-to-C-terminal direction) (318). The 
actin nucleus formed at the WH2 domains has consequently an orientation with the barbed end 
pointing towards the KIND domain and the pointed end towards the vesicle. Formin binds to Spir-
KIND and consequently polymerises Spir-generated actin nuclei by moving processively with the 
growing actin filament barbed end. Taken together, it seems obvious that the actin filament pointed 
end is oriented towards the vesicle surface, and the barbed end towards the cytoplasm, away from 
the vesicle. Myosin V motors move towards the barbed end of actin filaments which would thus 
allow myosin V movement away from the vesicle surface and a potential nanotube formation. 
Nothing is currently known about the attachment of actin filaments at vesicle surfaces. Annexins as 
actin binding proteins might be potential candidates in capturing newly generated F-actin tracks at 
the vesicle membrane. Another possibility might be provided by the myosin V motors themselves 
which have also been reported to act as tethering factors (4, 35, 381–388). The high abundance of 
myosin V and Rab11 proteins in the cell would allow for the association of multiple Rab11/MyoV 
complexes at the surface of one vesicle, and a situation in which some complexes are used to capture 
the actin tracks and attach them to the surface, and some are used to mediate the actin based 
movement. Myosin V motors also directly bind to the Rab11-interacting protein Rab11-FIP2 (264). 
Rab11-FIP2 carries a C2 membrane binding domain (244, 247) which provides the possibility that 
myosin V forms at least two distinct protein complexes at Rab11-positive membranes; one complex 
with Rab11 and one complex with Rab11-FIP2, both of which could have distinct functions in 
tethering of actin filaments and movement along those, respectively. 
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Undoubtedly, further investigations are required to analyse in detail the molecular processes 
occuring on vesicle membranes. In vitro reconstitution of intracellular membranes and associated 
proteins by means of giant unilamellar vesicles (GUVs) and purified Spir, MyoV, Rab11 and FMN-2 
proteins as well as actin will help to shed light into the interplay of these interaction partners in 
terms of actin nucleation and elongation, myosin V motor movement and subsequent changes in 
membrane morphology. 
So far, one might not exclude the presence of additional proteins that might also be included in a 
much larger protein complex assembling at vesicle surfaces. The role of actin anchoring proteins, 
such as annexins, as well as other Spir interacting proteins, including Arf family GTPases should be in 
focus of future studies. The presence of MyoV/Rab11-FIP2 complexes could broaden the spectrum of 
protein interactions at vesicle surfaces, as well as the presence of microtubule associated motor 
proteins (kinesins and dynein). Consistently, a proteomics approach of Spir- and Rab11-positive 
vesicles would tremendously help to identify additional proteins that might join Spir, MyoV and 
Rab11 at vesicle membranes. 
Live cell imaging experiments of HeLa cells expressing fluorescently tagged Spir-2 and Rab11-FIP2 
proteins revealed a very dynamic exchange of both proteins at vesicle membranes (unpublished 
observations). Some vesicles only carry Spir-2, some carry only FIP2, and some vesicles carry both 
proteins. Time-lapse imaging also revealed the conversion of Spir-2-positive vesicles into FIP2-
positive ones and vice versa. Having this in mind, the formation of such multimeric protein 
complexes might be considered as a dynamic process of proteins joining and leaving the complex and 
not as a static clump of proteins sitting at one spot of the vesicle surface. 
 
The association of a large set of proteins into a protein complex requires the exact and well-
regulated timing and order of events for protein joining, including here the opening and activation of 
MyoV and Spir proteins. In order to form a multimeric protein complex, both, the total and relative 
protein concentrations decide on proper complex functioning. There is a roughly 20-fold excess of 
myosin V motor proteins over the Spir-1 and Spir-2 proteins in a single HeLa cell (~50,000 MyoV 
proteins, ~1830 Spir-1 and ~815 Spir-2 proteins) (389), arguing that only a small subset of MyoV 
proteins can actually associate with Spir proteins at vesicle surfaces. The low abundance of Spir 
proteins in total and especially in relation to the myosin V motors, leads the so far employed cell 
biological approaches by means of transient protein over-expression to the edge of obtaining 
meaningful results. Thus, it will be indispensable in the future, to study the protein dynamics at 
endogenous expression levels in order to precisely define the temporal and spatial steps involved in 
MyoV and Spir activation and recruitment towards Rab11-positve vesicles. The combination of state-
of-the-art gene editing tools, such as CRISPR/Cas9 and the MIN-tag technology (390), and the latest 
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advances in the development of novel fluorescent proteins, for instance mNeonGreen and mRuby3 
(391, 392), will be very useful to generate stable cell lines allowing the visualisation of low abundant 
proteins such as Spir. The use of modern fluorescence microscopy methods, including TIRF (total 
internal reflection) microscopy and FCS / FCCS (fluorescence correlation spectroscopy / fluorescence 
cross-correlation spectroscopy) (393–395), would enable protein quantification as well as 
determining  the dynamics of Spir, FMN, MyoV, Rab11 and additional associated proteins at vesicle 
surfaces, and their correlation with vesicular motility and morphological changes. 
 
 
4.5. Diverse Rab/MyoV interactions suggest similar mechanisms for other transport processes 
Myosin V actin motor proteins interact, next to Rab11a, with a large set of Rab family GTPases and 
are thus involved in diverse cellular functions (Figure 42). Several studies have revealed the direct or 
indirect interactions of myosin Va with Rab3A (194), Rab3b, Rab3c, Rab3d, Rab6a, Rab6a’, Rab6b 
(103), Rab8a, Rab10 (55), Rab11b, Rab14, Rab11c (or Rab25) (103), Rab27a (81, 83, 84) and Rab39b 
(103). Rab39b has been shown to be a neuronal specific Rab GTPase which is localised to the Golgi 
complex, a broad range of cytoplasmic vesicles and within neurites at which overlapping localisation 
with myosin Va has been revealed (103). Rab3A as well as Rab27b form complexes with myosin Va in 
order to enable exocytosis of synaptic vesicles for synaptic transmission (194, 195). 
Myosin Vb has been shown to interact with Rab8a (196, 197) and Rab10 (196) and myosin Vc has 
been revealed to interact with Rab10 (55), Rab38 and the closely related Rab32 (which do not 
interact with MyoVa or MyoVb) playing a role in melanosome biogenesis (207). Additionally, myosin 
Vc interacts with Rab7a and Rab8a within melanocytes which localise to immature (Rab7a) and 
mature (Rab8a) melanosomes (396, 397) and could provide a Rab32/38 independent pathway during 
melanosome biogenesis (207). 
Due to the large diversity of Rab/MyoV protein interactions and the herein newly identified 
Spir/MyoV interaction, it might be intriguing that a functional Spir:MyoV:Rab-GTPase complex might 
exist in different flavours depending on the participating MyoV motor and Rab GTPase. A differential 
complex composition would allow targeting actin nucleation and motor protein function to different 
vesicle subpopulations in order to drive distinct vesicle transport processes that require de novo 
generation of actin filaments directly at vesicle surfaces. In line with that, initial experiments 
employing Rab8a revealed a colocalisation with Spir-2 and MyoVa at vesicle surfaces, comparable to 
the Rab11a:MyoVa:Spir-2 tripartite complex (Figure 41). Accordingly, a similar tripartite complex 
formation is suggested which might also be involved in exocytic as well as endocytic transport 
processes described for Rab8 (126, 164). However, further investigations, including detailed 
colocalisation analyses, indirect and direct protein interaction studies and functional cell based 
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assays are required to describe the exact interplay between Rab8, Spir and myosin V proteins and its 
functional consequences. 
 
 
Figure 41 | Spir-2 forms a tripartite complex with Rab8a and MyoVa at vesicle surfaces. Preliminary data on HeLa cells 
transiently over-expressing Myc-epitope-tagged Spir-2-GTBM-SB-FYVE (Myc-Spir2-MSF; cyan), eGFP-tagged MyoVa-CC-GTD 
(GFP-MyoVa-CC-GTD; green) and mStrawberry-tagged Rab8a (mStraw-Rab8a; red) as analysed by fluorescence microscopy. 
All proteins show a vesicular localisation pattern when expressed alone (not shown) and colocalise at vesicle surfaces under 
co-expression conditions, indicated by overlapping punctae (merge; see also higher magnification insets). Scale bar 
represents 10 µm. An overview of employed MyoVa and Spir-2 proteins is presented and the domains used for 
colocalisation studies are highlighted. 
 
 
On top of the multitude of interactions between Rab GTPases and MyoV motor proteins, the concept 
of a Rab cascade, also named Rab conversion or Rab maturation, has been described, which would 
make the principle of Rab GTPase/MyoV motor interaction as the base of vesicle transport much 
more complex and complicated (398–400). In this network of Rab GTPases and motor proteins, 
different Rabs are sequentially targeted to the vesicle surface, which in turn recruit Rab-GEFs and 
Rab-GAPs to activate the “new” Rab GTPase and to inactivate the “old” one (162, 220, 223, 401). This 
sequence of events might be a decisive element in the determination of the compartment identity, 
and therefore for the compartment/vesicle maturation (162). The exchange of Rab proteins at the 
vesicle membrane could also influence the recruitment of specific MyoV motors in a temporal and 
spatial fashion. Rab cascades have been described for both, endocytic (223, 399, 402–404) and 
exocytic, secretory pathways (401, 405–408). A well-established Rab-MyoV network is the Rab11-
Rab8-MyoVb network as described during ciliogenesis and apical lumen formation, and in yeast 
secretory pathways (220, 223, 405, 409, 410). Here, Rab11 is located at an upstream membrane 
compartment and recruits a GEF for Rab8, for instance Rabin8, in order to activate Rab8 for 
subsequent membrane targeting (220). The active Rab8 protein now recruits Rab8 specific effector 
proteins to the membrane to drive further vesicle maturation. One of those effectors is a Rab11-GAP 
to inactivate Rab11 and to release it from the membrane surface (162, 223, 401). A similar 
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mechanism is proposed for an interplay between Rab11, Rab8 and MyoVb in the secretion of 
discoidal/fusiform-shaped vesicles (DFVs) in bladder umbrella cells (398).  
The complex formation of Rab11 (and potentially Rab8), MyoV and Spir proteins at vesicle 
membranes might open the possibility that Spir proteins could be somehow differentially regulated 
in the processes of Rab cascades or might even influence those by itself. 
 
 
Figure 42 | Overview on Rab GTPase contributions to intracellular transport processes and their potential interactions 
with MyoV motor proteins in these processes. This overview shortly summarises the function of Rab GTPases in distinct 
subcellular processes and the therein established interactions with the indicated MyoV motor proteins (dark blue). Known 
Rab/MyoV protein interactions, which might contribute to these processes but what has not been proven to date, are 
indicated in light blue. Endocytic events are drawn in yellow and exocytic events in green. In general, Rab GTPases are 
crucial for exocytosis from post-Golgi vesicles (e.g. Rab3A) and by recycling pathways (e.g. Rab11), but also for endocytic 
uptake (not shown here). Rab8 is involved in recycling processes via macropinocytosis, a tubular membrane network and 
exocytic vesicles, e.g. for recycling of the transferrin receptor. Rab10 is localised to the same tubular network and might 
thus function in a similar way. A number of Rab GTPases are critically involved in different steps of melanosome biogenesis, 
maturation and transport (Rab32/Rab38, Rab7a, Rab8a, Rab27a), arising from the early endosome (EE) and the recycling 
endosome (RE), and in the release of melanin for subsequent endocytic uptake by keratinocytes (Rab11b) (411). Rab 
GTPases are also involved in intra-organelle trafficking (e.g. Rab6). Not much is known about the role of Rab GTPases in 
mitochondria function, but a body of evidence exists for MyoV proteins mediating mitochondria dynamics, including fission 
and motility (412–414). Rab GTPases furthermore contribute to specific transport processes in specific cell types (e.g. 
Rab3A, Rab27b and Rab39b in neuronal cells; Rab8 and Rab11 in epithelial cells) which are not shown here. EE, early 
endosome; LE/MVB, late endosome/multi-vesicular body; RE, recycling endosome; ER, endoplasmatic reticulum; TGN, 
trans-Golgi network; GLUT4, glucose transporter type 4. 
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4.6 The Spir/MyoV interaction in context of cellular processes 
Myosin V motor proteins have been implicated in the trafficking and dynamics of mitochondria (412–
414). Mitochondria are generally transported bidirectional over longer distances along microtubule 
tracks by kinesin and dynein driven mechanisms (413). Two distinct roles for myosin V motors are 
proposed, especially within neuronal cells. First, myosin V is expected to act as a tethering factor, 
which removes mitochondria from transporting microtubule tracks and transfers them to actin 
networks to create a stationary pool of mitochondria (412). This has been shown as the depletion of 
myosin V induced an increase of mitochondrial transport, affecting both, velocity and duty cycle 
along microtubule tracks. Additionally, MyoV depletion induced an increase in mitochondrial length, 
supposing a role for MyoV in mitochondrial fission (412). Together, it might be the case that the 
myosin V driven pausing of mitochondria during their transport along microtubules is necessary for 
mitochondrial fission when attached to actin networks in a stationary phase. Both, mitochondria 
fission but also the storage at stationary pools itself might be essential processes to evenly distribute 
mitochondria along the length of the axons and within the axon terminals in order to provide 
sufficient energy for synaptic activity. Actin networks and the associated myosin V motors might also 
be involved in rather short range transport of mitochondria within the actin rich presynaptic 
terminals (414). 
The newly discovered and described splice isoform of Spir-1, containing the alternatively spliced exon 
C and accordingly named Spire1C, has been shown to localise to mitochondrial membranes and 
drives mitochondrial fission in collaboration with the endoplasmatic reticulum associated inverted 
formin 2 (INF2) (339). Exon C mediates the Spire1C mitochondrial targeting and is located 
downstream of the GTBM which would allow MyoV binding of Spire1C in the cytoplasm and, thus, a 
potential Spire1C induced targeting of MyoV proteins to mitochondrial membranes. The exact 
targeting mechanism of myosin V motors to mitochondria is still unknown which might open the 
possibility that a Spir-GTBM mediated Spire1C/MyoV interation induces MyoV localisation to 
mitochondria membranes. 
 
A study by Wang and co-workers showed a cooperation of Rab11 and MyoVb in the activity 
dependent transport of AMPA receptor subunits into the postsynaptic densities (PSD) of dendritic 
spines (251). Synaptic activity induced influx of Ca2+ ions into the spine drives the opening of the 
back-folded MyoVb protein leading to the subsequent association with Rab11 located at the AMPA 
receptor containing recycling endosome. The Rab11/MyoVb motor protein complex now provides 
the force to pull the endosomal membrane into the spine head to reach the PSD and to finally 
facilitate the AMPA receptor subunit insertion. So far, the origin of the actin filaments used for the 
MyoVb driven motility is not clear. In collaboration with Prof. Dr. Edward Ziff and Dr. Seonil Kim (NYU 
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Medical Centre, New York, USA) a localisation of the Spir-1 protein at the spine base of mouse 
primary hippocampal neurons was already revealed (unpublished observations). Therefore, and 
based on the data presented here, a functional cooperation of Spir proteins, Rab11 and MyoVb in 
actin filament nucleation and MyoV driven motor activity seems intriguing as an underlying process 
for this type of AMPA receptor transport and insertion into the PSD. 
Recent studies report that mutations and deletions of the FMN-2 protein lead to non-syndromic 
intellectual disability in humans (415–417). Together with the already described phenotypes for spir-
1gt/gt mutant mice (defects in emotional learning and memory) (418), as well as for Fmn-2-/- knockout 
mice (defects in age-related associative learning and memory) (419), a cooperative mechanism of 
Spir, FMN, Rab11 and MyoV proteins in processes underlying learning and memory might be 
intriguing. 
 
Spir-1 proteins have been shown to be recruited to invadosomes of Src-transformed cells in which 
they participate in a protein complex containing Src kinase, the formin mDia1 and actin (420). Spir-1 
is thereby involved in the proteolytic activity of these cells by the release of membrane-type matrix 
metalloproteinases (MT-MMPs). MMPs are required to drive ECM degradation and disruption of 
tissue and cellular barriers, and need to be specifically targeted to invadosomal sites before their 
release. Consistently, Spir-1 over-expression in such cells induced cell invasions that were faster and 
increased in number (420). In the same study, an interaction of the C-terminal part of Spir-1 
(including Spir-box and FYVE-type domain) and the Rab3A GTPase has been identified, and thus, a 
role for Spir-1 in the directed trafficking of MMPs to invadosomal sites and in conjunction with Rab3A 
has been proposed. Considering the reported direct interaction of Rab3A and myosin Va (194) and 
the functional cooperation of Rab3A and Spir-1 in invadosome activity, it might point towards the 
formation of a similar tripartite complex including a Rab family GTPase, an actin motor protein and 
an actin nucleating or elongating protein, which finally decides on cell invasion and cancer 
metastasis. Nevertheless, the exact role of the myosin V actin motor proteins in these processes 
need to be further investigated. This assumption is supported by a study on Rab27a, highly related to 
Rab3A, which has been described to be involved in cell invasion and the metastatic potential of 
breast cancer cells by regulating the transport of ECM degrading enzymes (421). 
 
Besides the transport of cell originating vesicles, desired vesicles which are readily transported, there 
are processes of hijacking the cellular transport machineries by extracellular cargo, such as by 
pathogens, including virus and bacteria. Rab GTPases, such as Rab7, Rab8b and Rab11, are generally 
involved in the endocytic and exocytic transport of different types of virus (422–427). Rab11 is 
important for the successful budding and processing of influenza A virus particles (422). Rab11 
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dependent transport also underlies the release of mumps virus from polarised epithelial cells (423). 
Rab7a is essentially involved in the late stages of the HIV-1 replication cycle (424). Both, Rab8 and 
Rab11 have been shown to significantly contribute to the secretion of the New World hantavirus 
(Andes virus) particles via the recycling endosome (425), and Rab8b has also been observed to be 
involved in the release of West Nile virus particles (426). Not much is known about the exact Rab 
GTPase mediated transport and release mechanisms of virus particles, especially about the 
involvement of myosin V motor proteins. However, there is a study demonstrating the necessity of 
MyoVc in complex with Rab8 for the release of dengue virus particles (427) which could point 
towards a general role of Rab GTPase/MyoV motor protein complexes in virus particle transport. Also 
here, Spir proteins could play a major role in collaboration with Rab GTPases and MyoV motor 
proteins. 
Furthermore, Spir-1 and Spir-2 proteins have been reported to contribute to the invasion process of 
Salmonella typhimurium, although both proteins influence different invasion steps (428), and Spir-2 
has been also implicated in the invasion process of Listeria monocytogenes (429). 
 
 
4.7 Conclusion 
In summary, this thesis revealed that the coordination of an actin nucleation machinery (Spir/FMN) 
and Rab11/MyoV based motor activity at the surface of intracellular vesicle membranes is mediated 
by a direct interaction of Spir and myosin V proteins. This interaction involves a herein newly 
identified short sequence motif within the Spir proteins that is highly conserved across species, and 
the globular tail domain of the myosin V actin motors. The Spir/MyoV interaction drives the 
formation of a tripartite Rab11:MyoV:Spir protein complex at vesicle membranes that is suggested to 
facilitate vesicle transport by combining de novo actin filament nucleation and myosin dependent 
force generation. Nevertheless, a lot of open questions still remain regarding the molecular dynamics 
of protein complex formation, the whole spectrum of proteins finally involved in the functional 
multimeric complex, and the factors inducing activation and membrane targeting of Spir and MyoV 
proteins. The diversity of interactions of Rab GTPases and MyoV motors, as well as initial findings on 
other Rab GTPase cooperations with Spir proteins, allows speculating on far reaching contributions of 
such protein complexes including Rab GTPases, MyoV motors, and actin nucleating, elongating and 
binding proteins in intracellular transport processes underlying a multitude of cellular processes. 
Deciphering these molecular and cellular aspects will be of fundamental importance for future 
studies and might be indispensable to understand intracellular transport processes as the base of 
proper cell function, development and survival, but also in terms of disease manifestation and 
potential treatment targets. 
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6.1 Sequence related data 
 
Spir-1, homo sapiens (756 amino acids) 
NM_001128626.1          NP_001122098.1 
 
MAQAAGPAGGGEPRTEAVGGEGPREPGAAGGAAGGSRDALSLEEILRLYNQPINEEQAWAVCYQCCGS
LRAAARRRQPRHRVRSAAQIRVWRDGAVTLAPAADDAGEPPPVAGKLGYSQCMETEVIESLGIIIYKA
LDYGLKENEERELSPPLEQLIDHMANTVEADGSNDEGYEAAEEGLGDEDEKRKISAIRSYRDVMKLCA
AHLPTESDAPNHYQAVCRALFAETMELHTFLTKIKSAKENLKKIQEMEKSDESSTDLEELKNADWARF
WVQVMRDLRNGVKLKKVQERQYNPLPIEYQLTPYEMLMDDIRCKRYTLRKVMVNGDIPPRLKKSAHEI
ILDFIRSRPPLNPVSARKLKPTPPRPRSLHERILEEIKAERKLRPVSPEEIRRSRLAMRPLSMSYSFD
LSDVTTPESTKNLVESSMVNGGLTSQTKENGLSTSQQVPAQRKKLLRAPTLAELDSSESEEETLHKST
SSSSVSPSFPEEPVLEAVSTRKKPPKFLPISSTPQPERRQPPQRRHSIEKETPTNVRQFLPPSRQSSR
SLEEFCYPVECLALTVEEVMHIRQVLVKAELEKYQQYKDIYTALKKGKLCFCCRTRRFSFFTWSYTCQ
FCKRPVCSQCCKKMRLPSKPYSTLPIFSLGPSALQRGESSMRSEKPSTAHHRPLRSIARFSSKSKSMD
KSDEELQFPKELMEDWSTMEVCVDCKKFISEIISSSRRSLVLANKRARLKRKTQSFYMSSPGPSEYCP
SERTISEI 
 
KIND    WH2    GTBM   Spir-box   FYVE-type 
 
Spir-2, homo sapiens (714 amino acids) 
AJ422077                CAD19439.1 
 
MARAGSCGGAAAGAGRPEPWELSLEEVLKAYEQPLNEEQALAVCFQGCRGLRGSPGRRLRDTGDLLLR
GDGSVGAREPEAAEPATMVVPLASSEAQTVQSLGFAIYRALDWGLDESEERELSPQLERLIDLMANND
SEDSGCGAADEGYGGPEEEEEAEGVPRSVRTFAQAMRLCAARLTDPRGAQAHYQAVCRALFVETLELR
AFLARVREAKEMLQKLREDEPHLETPRAELDSLGHTDWARLWVQLMRELRRGVKLKKVQEQEFNPLPT
EFQLTPFEMLMQDIRARNYKLRKVMVDGDIPPRVKKDAHELILDFIRSRPPLKQVSERRLRPLPPKQR
SLHEKILEEIKQERRLRPVRGEGWAARGFGSLPCILNACSGDAKSTSCINLSVTDAGGSAQRPRPRVL
LKAPTLAEMEEMNTSEEEESPCGEVTLKRDRSFSEHDLAQLRSEVASGLQSATHPPGGTEPPRPRAGS
AHVWRPGSRDQGTCPASVSDPSHPLLSNRGSSGDRPEASMTPDAKHLWLEFSHPVESLALTVEEVMDV
RRVLVKAEMEKFLQNKELFSSLKKGKICCCCRAKFPLFSWPPSCLFCKRAVCTSCSIKMKMPSKKFGH
IPVYTLGFESPQRVSAAKTAPIQRRDIFQSLQGPQWQSVEEAFPHIYSHGCVLKDVCSECTSFVADVV
RSSRKSVDVLNTTPRRSRQTQSLYIPNTRTLDFK 
 
KIND        WH2    GTBM   Spir-box   FYVE-type 
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Myosin Va, Mus musculus, Transcript variant X1 (1880 amino acids) 
XM_006510827.2          XP_006510890.1  
 
MAASELYTKFARVWIPDPEEVWKSAELLKDYKPGDKVLLLHLEEGKDLEYRLDPKTGELPHLRNPDIL
VGENDLTALSYLHEPAVLHNLRVRFIDSKLIYTYCGIVLVAINPYEQLPIYGEDIINAYSGQNMGDMD
PHIFAVAEEAYKQMARDERNQSIIVSGESGAGKTVSAKYAMRYFATVSGSASEANVEEKVLASNPIME
SIGNAKTTRNDNSSRFGKYIEIGFDKRYRIIGANMRTYLLEKSRVVFQAEEERNYHIFYQLCASAKLP
EFKMLRLGNADSFHYTKQGGSPMIEGVDDAKEMAHTRQACTLLGISESYQMGIFRILAGILHLGNVGF
ASRDSDSCTIPPKHEPLTIFCDLMGVDYEEMCHWLCHRKLATATETYIKPISKLQATNARDALAKHIY
AKLFNWIVDHVNQALHSAVKQHSFIGVLDIYGFETFEINSFEQFCINYANEKLQQQFNMHVFKLEQEE
YMKEQIPWTLIDFYDNQPCINLIESKLGILDLLDEECKMPKGTDDTWAQKLYNTHLNKCALFEKPRMS
NKAFIIKHFADKVEYQCEGFLEKNKDTVFEEQIKVLKSSKFKMLPELFQDDEKAISPTSATSSGRTPL
TRVPVKPTKGRPGQTAKEHKKTVGHQFRNSLHLLMETLNATTPHYVRCIKPNDFKFPFTFDEKRAVQQ
LRACGVLETIRISAAGFPSRWTYQEFFSRYRVLMKQKDVLGDRKQTCKNVLEKLILDKDKYQFGKTKI
FFRAGQVAYLEKLRADKLRAACIRIQKTIRGWLLRKRYLCMQRAAITVQRYVRGYQARCYAKFLRRTK
AATTIQKYWRMYVVRRRYKIRRAATIVIQSYLRGYLTRNRYRKILREYKAVIIQKRVRGWLARTHYKR
TMKAIVYLQCCFRRMMAKRELKKLKIEARSVERYKKLHIGMENKIMQLQRKVDEQNKDYKCLMEKLTN
LEGVYNSETEKLRNDVERLQLSEEEAKVATGRVLSLQEEIAKLRKDLEQTRSEKKSIEERADKYKQET
DQLVSNLKEENTLLKQEKETLNHRIVEQAKEMTETMERKLVEETKQLELDLNDERLRYQNLLNEFSRL
EERYDDLKEEMTLMLNVPKPGHKRTDSTHSSNESEYTFSSEFAETEDIAPRTEEPIEKKVPLDMSLFL
KLQKRVTELEQEKQLMQDELDRKEEQVFRSKAKEEERPQIRGAELEYESLKRQELESENKKLKNELNE
LRKALSEKSAPEVTAPGAPAYRVLMEQLTSVSEELDVRKEEVLILRSQLVSQKEAIQPKDDKNTMTDS
TILLEDVQKMKDKGEIAQAYIGLKETNRSSTMDYQELNEDGELWMVYEGLKQANRLLESQLQSQKRSH
ENEAEALRGEIQSLKEENNRQQQLLAQNLQLPPEARIEASLQHEITRLTNENLYFEELYADDPKKYQS
YRISLYKRMIDLMEQLEKQDKTVRKLKKQLKVFAKKIGELEVGQMENISPGQIIDEPIRPVNIPRKEK
DFQGMLEYKREDEQKLVKNLILELKPRGVAVNLIPGLPAYILFMCVRHADYLNDDQKVRSLLTSTINS
IKKVLKKRGDDFETVSFWLSNTCRFLHCLKQYSGEEGFMKHNTSRQNEHCLTNFDLAEYRQVLSDLAI
QIYQQLVRVLENILQPMIVSGMLEHETIQGVSGVKPTGLRKRTSSIADEGTYTLDSILRQLNSFHSVM
CQHGMDPELIKQVVKQMFYIVGAITLNNLLLRKDMCSWSKGMQIRYNVSQLEEWLRDKNLMNSGAKET
LEPLIQAAQLLQVKKKTDDDAEAICSMCNALTTAQIVKVLNLYTPVNEFEERVSVSFIRTIQMRLRDR
KDSPQLLMDAKHIFPVTFPFNPSSLALETIQIPASLGLGFIARV 
 
motor       IQ/IQ   coiled-coil     GTD 
 
Exon A  Exon B  Exon C  Exon D  Exon E  ExonF 
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Myosin Va, homo sapiens, Transcript variant_X2 (1879 amino acids) 
XM_011521607.1            XP_011519909.1 
 
MLTCLDETALKFARVWIPDPEEVWKSAELLKDYKPGDKVLLLHLEEGKDLEYHLDPKTKELPHLRNPD
ILVGENDLTALSYLHEPAVLHNLRVRFIDSKLIYTYCGIVLVAINPYEQLPIYGEDIINAYSGQNMGD
MDPHIFAVAEEAYKQMARDERNQSIIVSGESGAGKTVSAKYAMRYFATVSGSASEANVEEKVLASNPI
MESIGNAKTTRNDNSSRFGKYIEIGFDKRYRIIGANMRTYLLEKSRVVFQAEEERNYHIFYQLCASAK
LPEFKMLRLGNADNFNYTKQGGSPVIEGVDDAKEMAHTRQACTLLGISESHQMGIFRILAGILHLGNV
GFTSRDADSCTIPPKHEPLCIFCELMGVDYEEMCHWLCHRKLATATETYIKPISKLQATNARDALAKH
IYAKLFNWIVDNVNQALHSAVKQHSFIGVLDIYGFETFEINSFEQFCINYANEKLQQQFNMHVFKLEQ
EEYMKEQIPWTLIDFYDNQPCINLIESKLGILDLLDEECKMPKGTDDTWAQKLYNTHLNKCALFEKPR
LSNKAFIIQHFADKVEYQCEGFLEKNKDTVFEEQIKVLKSSKFKMLPELFQDDEKAISPTSATSSGRT
PLTRTPAKPTKGRPGQMAKEHKKTVGHQFRNSLHLLMETLNATTPHYVRCIKPNDFKFPFTFDEKRAV
QQLRACGVLETIRISAAGFPSRWTYQEFFSRYRVLMKQKDVLSDRKQTCKNVLEKLILDKDKYQFGKT
KIFFRAGQVAYLEKLRADKLRAACIRIQKTIRGWLLRKKYLRMRKAAITMQRYVRGYQARCYAKFLRR
TKAATIIQKYWRMYVVRRRYKIRRAATIVLQSYLRGFLARNRYRKILREHKAVIIQKRVRGWLARTHY
KRSMHAIIYLQCCFRRMMAKRELKKLKIEARSVERYKKLHIGMENKIMQLQRKVDEQNKDYKCLVEKL
TNLEGIYNSETEKLRSDLERLQLSEEEAKVATGRVLSLQEEIAKLRKDLEQTRSEKKCIEEHADRYKQ
ETEQLVSNLKEENTLLKQEKEALNHRIVQQAKEMTETMEKKLVEETKQLELDLNDERLRYQNLLNEFS
RLEERYDDLKEEMTLMVHVPKPGHKRTDSTHSSNESEYIFSSEIAEMEDIPSRTEEPSEKKVPLDMSL
FLKLQKRVTELEQEKQVMQDELDRKEEQVLRSKAKEEERPQIRGAELEYESLKRQELESENKKLKNEL
NELRKALSEKSAPEVTAPGAPAYRVLMEQLTSVSEELDVRKEEVLILRSQLVSQKEAIQPKNTMTDST
ILLEDVQKMKDKGEIAQAYIGLKETNRSSALDYHELNEDGELWLVYEGLKQANRLLESQLQSQKRSHE
NEAEALRGEIQSLKEENNRQQQLLAQNLQLPPEARIEASLQHEITRLTNENLYFEELYADDPKKYQSY
RISLYKRMIDLMEQLEKQDKTVRKLKKQLKVFAKKIGELEVGQMENISPGQIIDEPIRPVNIPRKEKD
FQGMLEYKKEDEQKLVKNLILELKPRGVAVNLIPGLPAYILFMCVRHADYLNDDQKVRSLLTSTINSI
KKVLKKRGDDFETVSFWLSNTCRFLHCLKQYSGEEGFMKHNTSRQNEHCLTNFDLAEYRQVLSDLAIQ
IYQQLVRVLENILQPMIVSGMLEHETIQGVSGVKPTGLRKRTSSIADEGTYTLDSILRQLNSFHSVMC
QHGMDPELIKQVVKQMFYIIGAITLNNLLLRKDMCSWSKGMQIRYNVSQLEEWLRDKNLMNSGAKETL
EPLIQAAQLLQVKKKTDDDAEAICSMCNALTTAQIVKVLNLYTPVNEFEERVSVSFIRTIQMRLRDRK
DSPQLLMDAKHIFPVTFPFNPSSLALETIQIPASLGLGFISRV 
 
motor       IQ/IQ   coiled-coil     GTD 
 
Exon A Exon C Exon D Exon E ExonF 
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Myosin Vb, homo sapiens (1848 amino acids) 
NM_001080467.2          NP_001073936.1 
 
MSVGELYSQCTRVWIPDPDEVWRSAELTKDYKEGDKSLQLRLEDETILEYPIDVQRNQLPFLRNPDIL
VGENDLTALSYLHEPAVLHNLKVRFLESNHIYTYCGIVLVAINPYEQLPIYGQDVIYTYSGQNMGDMD
PHIFAVAEEAYKQMARDEKNQSIIVSGESGAGKTVSAKYAMRYFATVGGSASETNIEEKVLASSPIME
AIGNAKTTRNDNSSRFGKYIQIGFDKRYHIIGANMRTYLLEKSRVVFQADDERNYHIFYQLCAAAGLP
EFKELALTSAEDFFYTSQGGDTSIEGVDDAEDFEKTRQAFTLLGVKESHQMSIFKIIASILHLGSVAI
QAERDGDSCSISPQDVYLSNFCRLLGVEHSQMEHWLCHRKLVTTSETYVKTMSLQQVINARNALAKHI
YAQLFGWIVEHINKALHTSLKQHSFIGVLDIYGFETFEVNSFEQFCINYANEKLQQQFNSHVFKLEQE
EYMKEQIPWTLIDFYDNQPCIDLIEAKLGILDLLDEECKVPKGTDQNWAQKLYDRHSSSQHFQKPRMS
NTAFIIVHFADKVEYLSDGFLEKNRDTVYEEQINILKASKFPLVADLFHDDKDPVPATTPGKGSSSKI
SVRSARPPMKVSNKEHKKTVGHQFRTSLHLLMETLNATTPHYVRCIKPNDEKLPFHFDPKRAVQQLRA
CGVLETIRISAAGYPSRWAYHDFFNRYRVLVKKRELANTDKKAICRSVLENLIKDPDKFQFGRTKIFF
RAGQVAYLEKLRADKFRTATIMIQKTVRGWLQKVKYHRLKGATLTLQRYCRGHLARRLAEHLRRIRAA
VVLQKHYRMQRARQAYQRVRRAAVVIQAFTRAMFVRRTYRQVLMEHKATTIQKHVRGWMARRHFQRLR
DAAIVIQCAFRMLKARRELKALRIEARSAEHLKRLNVGMENKVVQLQRKIDEQNKEFKTLSEQLSVTT
STYTMEVERLKKELVHYQQSPGEDTSLRLQEEVESLRTELQRAHSERKILEDAHSREKDELRKRVADL
EQENALLKDEKEQLNNQILCQSKDEFAQNSVKENLMKKELEEERSRYQNLVKEYSQLEQRYDNLRDEM
TIIKQTPGHRRNPSNQSSLESDSNYPSISTSEIGDTEDALQQVEEIGLEKAAMDMTVFLKLQKRVREL
EQERKKLQVQLEKREQQDSKKVQAEPPQTDIDLDPNADLAYNSLKRQELESENKKLKNDLNELRKAVA
DQATQNNSSHGSPDSYSLLLNQLKLAHEELEVRKEEVLILRTQIVSADQRRLAGRNAEPNINARSSWP
NSEKHVDQEDAIEAYHGVCQTNSKTEDWGYLNEDGELGLAYQGLKQVARLLEAQLQAQSLEHEEEVEH
LKAQLEALKEEMDKQQQTFCQTLLLSPEAQVEFGVQQEISRLTNENLDLKELVEKLEKNERKLKKQLK
IYMKKAQDLEAAQALAQSERKRHELNRQVTVQRKEKDFQGMLEYHKEDEALLIRNLVTDLKPQMLSGT
VPCLPAYILYMCIRHADYTNDDLKVHSLLTSTINGIKKVLKKHNDDFEMTSFWLSNTCRLLHCLKQYS
GDEGFMTQNTAKQNEHCLKNFDLTEYRQVLSDLSIQIYQQLIKIAEGVLQPMIVSAMLENESIQGLSG
VKPTGYRKRSSSMADGDNSYCLEAIIRQMNAFHTVMCDQGLDPEIILQVFKQLFYMINAVTLNNLLLR
KDVCSWSTGMQLRYNISQLEEWLRGRNLHQSGAVQTMEPLIQAAQLLQLKKKTQEDAEAICSLCTSLS
TQQIVKILNLYTPLNEFEERVTVAFIRTIQAQLQERNDPQQLLLDAKHMFPVLFPFNPSSLTMDSIHI
PACLNLEFLNEV 
 
motor    IQ/IQ      coiled-coil     GTD 
 
Exon A Exon C Exon D Exon E 
 127 6 Supplement 
6.2 Overview of cloning vectors 
6.2.1 pcDNA3 (Invitrogen, ThermoFisher) 
The eukaryotic expression vector pcDNA3 was used to generate Myc-epitope-tagged Spir and myosin 
V proteins for ectopic expression in HEK293 and HeLa cells. Gene expression is regulated by the 
strong CMV promoter. An ampicillin resistance gene is present for bacterial selection. 
 
Copyright by Invitrogen, ThermoFisher 
 
6.2.2 pAcGFP-C1 (TakaraBio/Clontech) 
The eukaryotic expression vector pAcGFP-C1 was used to generate N-terminal AcGFP-tagged Spir and 
myosin V proteins for ectopic expression in HEK293 and HeLa cells. Gene expression is regulated by 
the strong CMV promoter. A kanamycin resistance gene is present for bacterial selection. The AcGFP 
cassette was substituted by an mStrawberry cassette (released with AgeI / XhoI) to generate 
pmStrawberry-C1 expression vectors. 
 
Copyright by Invitrogen, ThermoFisher 
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6.2.3 peGFP-C2 (Takara/Clontech) 
The eukaryotic expression vector peGFP-C2 was used to generate N-terminal eGFP-tagged Spir and 
myosin V proteins for ectopic expression in HEK293 and HeLa cells. Gene expression is regulated by 
the strong CMV promoter. A kanamycin resistance gene is present for bacterial selection. The eGFP 
cassette was substituted by an mStrawberry cassette (released with AgeI / XhoI) to generate 
pmStrawberry-C2 expression vectors. 
Copyright by Invitrogen, ThermoFisher 
 
6.2.4 pGEX-4T-1-NTEV (based on pGEX-4T-1, GE Healthcare Lifesciences) 
The bacterial expression vector pGEX-4T-1-NTEV used here was modified by introducing a TEV 
(Tobacco Etch Virus) nuclear-inclusion-a endopeptidase site downstream of the GST coding sequence 
for cleavage of the GST tag following protein purification. This vector was used to generate N-
terminal GST-tagged Rab11a and myosin V proteins for expression of recombinant proteins in E.coli 
and subsequent protein purification. Gene expression is regulated by the tac promoter, a ubiquitous 
E.coli promoter. An ampicillin resistance gene is present for bacterial selection. 
 
Copyright by GSL Biotech LLC (SnapGene) 
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6.2.5 pGEX-4T-3 (GE Healthcare Lifesciences) 
The bacterial expression vector pGEX-4T-3 was used to generate an N-terminal GST-tagged Spir-2 
protein for expression of recombinant proteins in E.coli and subsequent protein purification. Gene 
expression is regulated by the tac promoter, a ubiquitous E.coli promoter. An ampicillin resistance 
gene is present for bacterial selection. 
 
6.2.6 pProEX-HTb 
The bacterial expression vector pProEX-HTb used here was modified by inserting the coding 
sequence of the mCherry red fluorescent protein at the beginning of the multiple cloning site (BamHI 
/ XhoI). This vector was used to generate N-terminal His6-mCherry-tagged Spir-2 peptides for 
expression of recombinant proteins in E.coli and subsequent protein purification. Gene expression is 
regulated by the trc promoter, a ubiquitous E.coli promoter. A TEV site is present downstream of the 
His6 amino acid sequence for cleavage of the His6 tag following protein purification. An ampicillin 
resistance gene allows for bacterial selection. 
 
Copyright by Invitrogen, ThermoFisher 
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6.3 Expression vectors used in this thesis 
6.3.1 Eukaryotic expression vectors 
Construct name Expression vector Boundaries 
(restriction sites) 
Purpose 
Myc-Spir1-FL pcDNA3-Myc-hs-Spir-1 aa 2 - 756 
(BamHI / SacI) 
Co-IP 
Myc-Spir2-FL pcDNA3-Myc-hs-Spir-2  aa 2 - 714 
(BamHI / HindIII) 
Co-IP, Immunostaining 
Myc-Spir2-KWM 
  
pcDNA3-Myc-hs-Spir-2-  
KIND-WH2-GTBM 
aa 2 - 437 
(BamHI / XhoI) 
Co-IP, Immunostaining 
Myc-Spir2-2-423 pcDNA3-Myc-hs-  
Spir-2-2-423 
aa 2 - 423 
(BamHI / XhoI) 
Co-IP  
 
Myc-Spir2-KW 
 
pcDNA3-Myc-hs-  
Spir-2-KIND-WH2 
aa 2 - 410 
(BamHI / XhoI) 
Co-IP, Immunostaining 
Myc-Spir2-MSF 
 
pcDNA3-Myc-hs-  
Spir-2-GTBM-SB-FYVE 
aa 361/398 - 714 
(BamHI / XhoI) 
Co-IP, Immunostaining 
Myc-Spir2-411-714 
 
pcDNA3-Myc-hs-  
Spir-2-411-714 
aa 411 - 714 
(BamHI / XhoI) 
Co-IP  
 
Myc-Spir2-SF 
 
pcDNA3-Myc-hs-  
Spir-2-SB-FYVE 
aa 438 - 714 
(BamHI / XhoI) 
Co-IP, Immunostaining 
Strawberry-  
Spir2-MSF 
pmStrawberry-C1-hs-  
Spir-2-GTBM-SB-FYVE 
aa 361 - 714 
(EcoRI / KpnI) 
Transient expression,  
FLIM-FRET 
Strawberry-  
Spir2-MSF-LALA 
pmStrawberry-C1-hs- 
Spir-2-GTBM-SB-FYVE-
L408A,L409A 
aa 361 - 714 
(EcoRI / KpnI) 
Transient expression,  
FLIM-FRET 
Strawberry-  
Spir2-SF 
pmStrawberry-C2-  
hs-Spir-2-SB-FYVE 
aa 438 - 714 
(XhoI / BamHI) 
Transient expression, 
FLIM-FRET  
GFP-MyoVa-D-FL (*) 
 
provided by  
Bruno Goud 
Lindsay et al., 2013 GST-Pulldown,  
Transient expression 
GFP-MyoVa-D-QR (*) provided by  
Bruno Goud 
Lindsay et al., 2013 GST-Pulldown,  
Transient expression 
GFP-MyoVa-F-QR (*) 
 
provided by  
Bruno Goud 
Lindsay et al., 2013 Transient expression 
GFP-MyoVa- 
CC-GTD (#) 
peGFP-C2-mm- 
MyoVa-CC-GTD 
aa 1260 - 1880 
(EcoRI / SalI) 
Transient expression 
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GFP-MyoVa-GTD 
 
pAcGFP-C1- 
mm-MyoVa-GTD 
aa 1467 - 1880 
(HindIII / SalI) 
Co-IP, Transient 
expression, FLIM-FRET 
Strawberry- 
MyoVa-GTD 
pmStrawberry-C1- 
mm-MyoVa-GTD 
aa 1467 - 1880 
(HindIII / SalI) 
Transient expression, 
FLIM-FRET 
GFP-MyoVb-  
CC-GTD 
pAcGFP-C1-  
hs-MyoVb-CC-GTD 
aa 904 - 1848 
(HindIII / SalI) 
Co-IP 
 
Strawberry- 
MyoVb-CC-GTD 
pmStrawberry-C2- 
hs-MyoVb-CC-GTD 
aa 909 – 1848 
(HindIII / XbaI) 
Transient expression 
GFP-MyoVb-GTD 
 
pAcGFP-C1-  
hs-MyoVb-GTD 
aa 1467 - 1848 
(HindIII / SalI) 
Co-IP, Transient 
expression 
GFP-Rab11a peGFP-C3-cl-Rab11a 1 – 216 
(XhoI / HindIII) 
Transient expression 
Strawberry-Rab11a pmStrawberry-C1-  
mm-Rab11a 
aa 2 - 216 
(EcoRI / BamHI) 
Transient expression  
 
Strawberry-FMN2-  
FH2-FSI 
pmStrawberry-C2-  
mm-FMN-2-FH2-FSI 
aa 1135 - 1578 
(BamHI / XhoI) 
GST-Pulldown 
 
GFP pAcGFP-C1  Co-IP, FLIM-FRET 
GFP-linker-  
Strawberry  
pAcGFP-C1-linker(A-S-  
G-A-G)-mStrawberry 
aa 1 - 236 
(BspEI / BglII) 
FLIM-FRET 
Table 16 | Overview on eukaryotic expression vectors. (*), these expression vectors were generated and kindly provided 
by the lab of Bruno Goud, Institut Curie, Paris, France; (#), this expression vector was generated and kindly provided by the 
lab of Alistair Hume, University of Nottingham, Nottingham, UK; aa, amino acid. 
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6.3.2 Bacterial expression vectors 
Construct name Expression vector Boundaries 
(restriction sites) 
Purification Purpose 
GST-Spir2-MSF pGEX-4T-3-hs-Spir-2-
GTBM-SB-FYVE 
aa 361 - 714 
(BamHI / XhoI) 
GSH Sepharose 4B,  
Superdex 200 
GST-Pulldown 
 
His6-mCherry-  
Spir2-linker  
pProEX-HTb-mCherry 
-hs-Spir-2-linker 
aa 361 - 519 
(XhoI / HindIII) 
Ni-NTA Agarose,  
Superdex 200 
GST-Pulldown,  
Binding studies 
His6-mCherry-  
Spir2-linker-
LALA 
pProEX-HTb-mCherry 
-hs-Spir-2-linker- 
L408A,L409A 
aa 361-519 
(mutagenesis) 
 
Ni-NTA Agarose,  
Superdex 200  
 
GST-Pulldown 
Spir2-linker 
peptide 
purchased from  
GenScript 
aa 401-427 
 
  Crystallisation, 
Fluorescence 
anisotropy 
GST-MyoVa-
GTD 
pGEX-4T-1-NTEV-
mm-MyoVa-GTD 
aa 1467 - 1880 
(HindIII / SalI) 
GSH Sepharose 4B,  
Superdex 200 
GST-Pulldown,  
Binding assays 
MyoVa-GTD (*) pProEX-HTb-hs-  
MyoVa-GTD 
aa 1461 - 1853 
(BamHI / XhoI) 
HisTrap, TEV,  
Superdex 200 
Crystallisation, 
GST-Pulldown 
GST-MyoVb-
GTD 
pGEX-4T-1-NTEV-  
hs-MyoVb-GTD 
aa 1467 - 1848 
(BamHI / XhoI) 
GSH Sepharose 4B,  
Superdex 200 
GST-Pulldown,  
Binding assays 
GST-Rab11a-
Q70L   
pGEX-4T-1-NTEV-cl-
Rab11a-Q70L 
aa 1 - 216 
(EcoRI / EcoRI) 
GSH Sepharose 4B,  
Superdex 200 
GST-Pulldown 
Rab11a-Q70L 
(*) 
pET28-rTEV-hs-
Rab11a-Q70L 
aa 1 - 173 
(NcoI / EcoRI) 
HisTrap, TEV,  
Superdex 200 
GST-Pulldown 
GST-FMN2-eFSI  pGEX-4T-1-NTEV-  
mm-FMN2-eFSI 
aa 1523 - 1578 
(BamHI / XhoI) 
GSH Sepharose FF,  
Superdex 200 
GST-Pulldown  
His6-mCherry  
 
pProEX-HTb-mCherry aa 1 - 236 
(BamHI / XhoI) 
Ni-NTA Agarose, 
Superdex 200 
GST-Pulldown  
 
GST   
 
pGEX-4T-1-NTEV  GSH Sepharose 4B,  
Superdex 200 
GST-Pulldown  
 
 Table 17 | Overview on bacterial expression vectors. (*), these expression vectors were generated and kindly provided by 
the lab of Anne Houdusse, Institut Curie, Paris, France; aa, amino acid. 
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6.4 Buffers, solutions and media 
Agar selection plates  
for bacterial culture 
 
- 25 g LB0 medium 
- 13 g select agar 
- fill up with H20 to 1 l 
- autoclave for 20 min at 121°C 
- cool to approx. 42°C 
- add antibiotics  
  
Agarose solution for  
gel electrophoresis 
- dissolve desired amount of agarose in 0.5x TBE by 
boiling and shaking (1% - 2.5%) 
  
Ampicillin solution (10%) - 1 g Ampicillin sodium salt in 10 ml H20 
- filter sterile and store aliquots at 4°C 
  
APS solution (10%) - dissolve 10% Ammoniumpersulfat (w/v) in H2O 
- store at 4°C  
  
β-Mercaptoethanol solution (12.8 M) - mix stock solution with H2O to obtain 12.8 M 
  
Coomassie staining solution - 10% acetic acid 
- 40% ethanol 
- 0.6% (w/v) Coomassie brilliant blue G250 
- 0.6% (w/v) Coomassie brilliant blue R250 
  
Chloramphenicol solution - dissolve 34 mg/ml in ethanol 
  
DNA ladder (1 kb; 100 bp) for  
agarose gel electrophoresis 
 
- 100 µl 6x DNA loading dye 
- 60 µl ladder (peqGOLD; 1 kb, 100 bp) 
- 440 µl H20 
 -  
DNA loading dye (6x) 
 
- 10 mM Tris-HCl, pH 7.6 
- 0.03% bromophenol blue 
- 60% glycerol 
- 60 mM EDTA 
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FCSIII for cell culture 
 
- inactivate at 56°C (waterbath) for 30 min 
- store 50 ml aliquots at -20°C 
  
Full Medium for cell culture - DMEM 
- 10% FCSIII 
- 2 mM L-Glutamine 
- 100 units/ml Penicillin 
- 100 µg/ml Streptomycin 
  
HEPES buffer solution for  
use in cell culture (1M) 
- dissolve in sterile H2O 
- adjust pH to 7.5 
- filter sterile, store 1 ml aliquots at -20°C 
  
IPTG stock solution (0.1 M) - dissolve in sterile H20 
- filter sterile, store 2 ml aliquots at -20°C 
  
Kanamycin stock solution              
(25 mg/ml) 
- dissolve Kanamycin monosulfate in H20 
- filter sterile and store 2 ml aliquots at -20°C 
  
LB medium (Luria/Miller) 
 
- dissolve 25 g/l in H20 
- autoclave for 20 min at 121°C 
  
Mouse Brain Pulldown buffer - 25 mM Tris-HCl, pH 7.4 
- 150 mM NaCl 
- 5 mM MgCl2 
- 10% (v/v) glycerol 
- 0.1% (v/v) Nonidet P-40 
- 0.1 M NaF 
- 1 mM Na3VO4 
- add freshly: 1 mM PMSF,  
complete Mini Protease Inhibitor Cocktail 
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Mowiol solution - dissolve 15 g Mowiol 4-88 in 70 ml H2O 
- add 30 ml glycerol 
- add 2.5% (w/v) n-propylgallat 
- centrifuge at 17,300 x g for 15 min 
- store 1 ml aliquots at -20°C 
  
Paraformaldehyde solution (3.7%) - dissolve 7.4 g paraformaldehyde in 100 ml 1x PBS 
- add 2 drops 10 M NaOH 
- incubate at 60°C for at least 30 min 
- add 100 ml 1x PBS, adjust to pH 7.4 
- store 10 ml aliquots at -20°C 
  
PBS (2x) for protein purification - 2300 mg/l = 16.2 mM Na2HPO4 
- 400 mg/l = 5.4 mM KCl 
- 400 mg/l = 2.94 mM KH2PO4 
- 16000 mg/l = 275 mM NaCl 
  
PBS (10x) - dissolve 95.5 g PBS powder in 1 l H20 
  
PBST (1x; 0.05% Tween20) - add 0.05% Tween20 to 1x PBS 
  
PMSF stock solution (0.1 M) - dissolve in ethanol 
- store 2 ml aliquots at -20°C 
  
Ponceau S staining solution - 5% acetic acid 
- 0.1% (w/v) Ponceau S 
  
Pulldown buffer 
 
- 25 mM Tris-HCl, pH 7.4 
- 150 mM NaCl 
- 5 mM MgCl2 
- 0.1% NP-40 
- 10% glycerol 
  
SDS-PAGE-buffer (10x) - 250 mM Tris 
- 1.9 M glycine 
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- 1% SDS (w/v) 
  
SDS protein sample buffer (5x) 
Laemmli buffer 
 
- 100 mM Tris-HCl, pH 6.8 
- 50% glycerol (v/v) 
- 15% SDS (w/v)  
- 25% β-Mercaptoethanol (v/v) 
- 0.025% bromophenol blue (w/v) 
- store 1 ml aliquots at -20°C 
  
SPECS buffer - 1x PBS 
- 50 mM NaCl 
  
Stripping buffer 
 
- 62.5 mM Tris-HCl, pH 6.7 
- 2% SDS 
  
TBE buffer (10x) 
 
- 890 mM Tris 
- 890 mM boric acid 
- 20 mM EDTA, pH 8.0 
  
Transfer buffer (10x) - 250 mM Tris 
- 1.92 M glycine 
  
Transfer Buffer (1x) - 25 mM Tris 
- 192 mM glycine 
- 20% methanol 
  
Tris-EDTA, pH 8.0 
for plasmid DNA storage 
- 20 mM Tris 
- 1 mM EDTA 
- adjust pH to 8.0 with HCl 
- autoclave 
  
Triton X-100 (0.2%) - 0.2% in 1x PBS 
  
Tween20 (10%) - dilute Tween20 in 1x PBS 
Table 18 | Overview on buffers, solutions and media. 
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6.5 SDS polyacrylamide gels 
Separating gel 
 7.5% 10% 12% 15% 
H2O 5.7 ml 4.8 ml 4.1 ml 3.45 ml 
3 M Tris pH 9.0 1.3 ml 1.3 ml 1.3 ml 1.3 ml 
Acrylamide30 2.6 ml 3.5 ml 4.2 ml 4.85 ml 
20% SDS 50 µl 50 µl 50 µl 50 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 
10% APS 50 µl 50 µl 50 µl 50 µl 
Table 19 | Preparation of SDS separation gels. 
 
Stacking gel 
H2O 2.6 ml 
1 M Tris pH 6.8 420 µl 
Acrylamide30 550 µl 
20% SDS 17 µl 
TEMED 5 µl 
10% APS 33 µl 
Table 20 | Preparation of SDS stacking gels. 
 
6.6 Primer 
Primer name Tm (°C) Primer sequence (5’ > 3’) 
Cloning primer   
part1-MyoVb-Beginn-5’ 90.7 CAGTGCACAAGGGTCTGGATCCCTGACCCTGATGAGGTAT
GGCGCTCAG 
HindIII-part2-MyoVb-Beginn-5’ 93.0 CCCAAGCTTTCGGTGGGCGAGCTCTACAGCCAGTGCACAA
GGGTCTGGATCCCT 
bis-MyoVb-tail-SacII-3’ 88.3 TCCCCGCGGTAATCCTGAGGGCCTTCAGCTCCCG 
MyoVb-tail-SacII-5’ 93.4 TCCCCGCGGGCGAGGCCCGCTCAGCAGAGCATC 
Hs-MyoVb-tail-Stop-BamHI-3’ 77.1 CGGGATCCCTAGACTTCATTGAGGAATTCCAGATT 
HindIII-Myc-hs-MyoVb-tail-5’ 65.3 CCCAAGCTTGCCGCCGCCATGGAGCAGAAGCTGATCTCCG
AGGAGGACCTGGAGGCCCGCTCAGCAGAGCATCTG 
hsMyoVb-HindIII-aa904-5’ 87.9 CCCAAGCTTCGGCCCTCAGGATTGAGGCCCGC 
hsMyoVb- HindIII -aa1143-5’ 81.0 CCCAAGCTTCGATGACGGTCTTCCTGAAGCTG 
hsMyoVb- HindIII -aa1336-5’ 85.5 CCCAAGCTTCGCTAAAGCAAGTTGCCAGGCTG 
 138 6 Supplement 
hsMyoVb- HindIII -aa1467-5’ 83.9 CCCAAGCTTCGCAGGGCATGCTGGAGTACCAC 
hsMyoVb-Stop-SalI-3’ 76.0 CGGTCGACCTAGACTTCATTGAGGAATTCCAG 
BamHI-MyoVb-tail-1467-5’ 82.5 CGGGATCCCAGGGCATGCTGGAGTACCAC 
MyoVb-tail-1467-Stop-XhoI-3’ 78.9 CCGCTCGAGTCAGACTTCATTGAGGAATTCCAG 
HindIII-mm-MyoVa-1467-5’ 74.8 CCCAAGCTTCGAAAGAAAAGGATTTCCAAGGAATG 
mm-MyoVa-Stop-SalI-3’ 82.9 GCGTCGACTCAGACCCGTGCGATGAAGCCCAG 
BamHI-MyoVa-tail-1467-5’ 73.4 CGGGATCCAAAGAAAAGGATTTCCAAGGAATG 
MyoVa-tail-1467-Stop-XhoI-3’ 84.2 CCGCTCGAGTCAGACCCGTGCGATGAAGCCCAG 
BamHI-Myc-hs-Spir2-1-5’ 68.9 CGGGATCCGCCGCCGCCATGGAGCAGAAGCTGATCTCCGA
GGAGGACCTGGACGCGGGTCGGCGCGCGGGAG 
Hs-Spir2-424-Stop-XhoI-3’ 91.5 CCGCTCGAGTCACTTGAGCAGCACGCGGGGCCG 
Hs-Spir2-437-Stop-XhoI-3’ 77.0 CCGCTCGAGTCAAGATGTATTCATCTCTTCCATTTC 
Hs-Spir2-442-Stop-XhoI-3’ 77.3 CCGCTCGAGTCAAGACTCTTCTTCCTCAGATGTATTC 
Hs-Spir2-451-Stop-XhoI-3’ 87.0 CCGCTCGAGTCACCGTTTCAGCGTCACCTCCCC 
BamHI-Myc-hs-Spir2-412-5’ 69.5 CGGGATCCGCCGCCGCCATGGAGCAGAAGCTGATCTCCGA
GGAGGACCTGGGCAGCGCCCAGCGCCCGCGG 
BamHI-Myc-hs-Spir2-425-5’ 99.3 CGGGATCCGCCGCCGCCATGGAGCAGAAGCTGATCTCCGA
GGAGGACCTGGCGCCTACCTTGGCTGAAATG 
BamHI-Myc-hs-Spir2-452-5’ 99.6 CGGGATCCGCCGCCGCCATGGAGCAGAAGCTGATCTCCGA
GGAGGACCTGGACCGCTCCTTCTCAGAGCATG 
Hs-Spir2-Stop-XhoI-3’ 80.5 CCGCTCGAGTCACTTGAAGTCAAGAGTCCTGGTG 
XhoI-hsSpir2-452-5’ 85.9 CCGCTCGAGCGACCGCTCCTTCTCAGAGCATG 
XhoI-Straw-Spir2-452-5’ 85.1 CCGCTCGAGCTGACCGCTCCTTCTCAGAGCATG 
hsSpir2-Stop-BamHI-3’ 75.7 CGGGATCCTCACTTGAAGTCAAGAGTCCTG 
Hs-Spir2-375-XhoI-5’ 93.1 CCGCTCGAGGGCGAGGGCTGGGCTGCCCGC 
HindIII-hs-Spir2-533-3’ 82.8 CCCAAGCTTCTAATCGGGGGTCATGGAGGCCTC 
QuikChange PCR primer    
QC-MyoVb-SacII-5’ 90.1 GAGCTGAAGGCCCTCAGGATTGAGGCCCGCTCAGCAGAG
CATC 
QC-MyoVb-SacII-3’ 90.1 GATGCTCTGCTGAGCGGGCCTCAATCCTGAGGGCCTTCAG
CTC 
QC-MyoVb-full-frame-5’ 88.2 CTCAGATCTCGAGCTCAAGCTTCGTCGGTGGGCGAGCTCT
ACAGC 
QC-MyoVb-full-frame-3’ 88.2 GCTGTAGAGCTCGCCCACCGACGAAGCTTGAGCTCGAGAT
CTGAG 
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HsMyoVb-Q1748R-5’ 84.9 CAAGCAGCCCAGCTCCTGCGCTTAAAGAAGAAAACCCAGG 
HsMyoVb-Q1748R-3’ 84.9 CCTGGGTTTTCTTCTTTAAGCGCAGGAGCTGGGCTGCTTG 
Hs-Spir2-Stop-533-5’ 88.1 GAGGCCTCCATGACCCCCTAGGCCTAACACCTGTGGCTGG
AGTTC 
Hs-Spir2-Stop-533-3’ 88.1 GAACTCCAGCCACAGGTGTTAGGCCTAGGGGGTCATGGA
GGCCTC 
Hs-Spir2-MyoLinkAAK-5’ 78.0 CGCCCGCGGCCCCGCGTGGCGGCCAAGGCGCCTACCTTGG
C 
Hs-Spir2-MyoLinkAAK-3’ 78.0 GCCAAGGTAGGCGCCTTGGCCGCCACGCGGGGCCGCGGG
CG 
Sequencing primer   
M5B-660bp-5’  GGCAAGTACATCCAGATTGGC 
M5B-1165bp-5’  GTCAAGACCATGTCCCTGCAG 
M5B-1678bp-5’  CTCTCTGATGGTTTTCTGGAG 
M5B-2182bp-5’  GTCCTGGAGAACCTCATCAAG 
M5B-2611bp-5’  CAGAAGCACGTGCGGGGCTGG 
Hs-MyoVbfl-3253-5’  CGGGATGAAATGACCATCATAAAG 
Hs-MyoVbfl-3912-5’  GAGGCCTATCACGGGGTCTGC 
Hs-MyoVbfl-4606-5’  CTGAAAAAGCACAATGATGAC 
Hs-MyoVbfl-5133-5’  CTCAGGTACAATATAAGTCAG 
Table 21 | Overview on primers used in this thesis. Tm, melting temperature. 
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6.7 Antibodies 
6.7.1 Primary antibodies 
Antibody Species/ 
clonality 
Purpose Company Order number 
Living Colors® A.v.  
Peptide Antibody  
rabbit 
polyclonal 
Western blot TakaraBio/ 
Clontech 
632376 
Living Colors® DsRed 
Polyclonal Antibody 
rabbit 
polyclonal 
Western blot TakaraBio/ 
Clontech 
632496 
anti-c-Myc (9E10) mouse 
monoclonal 
Western blot 
Immunostain 
Santa Cruz 
Biotechnology 
sc-40 
anti-Myosin Va rabbit 
polyclonal 
Western blot Cell Signaling 
Techology 
#3402 
anti-Rab11 (D4F5 XP) rabbit 
monoclonal 
Western blot Cell Signaling 
Technology 
#5589 
anti-Spir-1 (SA2133) rabbit 
polyclonal 
Western blot (Schumacher  
et al., 2004) 
- 
Table 22 | Overview on primary antibodies. 
 
 
6.7.2 Secondary antibodies 
Antibody Species Purpose Company Order Number 
Amersham ECL  
anti-mouse IgG,  
HRP-linked 
sheep Western blot GE Healthcare 
Life Sciences 
NA931-1ML 
Amersham ECL anti-rabbit 
 IgG, HRP-linked 
donkey Western blot GE Healthcare 
Life Sciences 
NA934-1ML 
anti-mouse-CY5 donkey Immunostain Dianova 715-175-151 
anti-mouse-TRITC donkey Immunostain Dianova 715-025-151 
Table 23 | Overview on secondary antibodies. 
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6.8 Chemicals and reagents 
6.8.1 Restriction endonucleases 
Restriction endonuclease Concentration Company Order number 
BamHI-HF 20,000 units/ml NEB R3136S 
BglII 10,000 units/ml NEB R0144L 
BspEI 10,000 units/ml NEB R0540S 
EcoRI-HF 20,000 units/ml NEB R3101L 
HindIII-HF 20,000 units/ml NEB R3104S 
KpnI-HF 20,000 units/ml NEB R3142L 
SacII 20,000 units/ml NEB R0157S 
SalI 20,000 units/ml NEB R0138S 
XhoI 20,000 units/ml NEB R0146L 
Table 24 | Overview on restriction endonucleases. 
 
 
6.8.2 DNA polymerases 
DNA polymerase Concentration/volume Company Order number 
AccuPrime™ Pfx DNA 
Polymerase 
2.5 units/µl ThermoFisher 12344-024 
Taq DNA Polymerase 5000 units/ml NEB M0273L 
Pfu DNA Polymerase 500 U Promega M7745 
Table 25 | Overview on DNA polymerases. 
 
 
6.8.3 Enzymes 
Enzyme Concentration/volume Company Order number 
Alkaline Phosphatase,  
   Calf Intestinal (CIP) 
10,000 units/ml NEB M0290L 
T4 DNA Ligase 400,000 units/ml NEB M0202L 
Table 26 | Overview on further enzymes. 
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6.8.4 Chemicals 
Article Quantity Company Order number 
1,4-Dithioerythritol (DTE) 5 g Sigma-Aldrich D8255-5G 
Acetic acid, Rotipuran, 100%, p.a. 1 l Carl Roth 3738.1 
Albumin standard (2.0 mg/ml) 10 x 1 ml ThermoFisher 23209 
Ammoniumpersulfat 100 g Sigma-Aldrich A3678 
Ampicillin sodium salt 25 g Sigma-Aldrich A9518-25G 
β-Mercaptoethanol 100 ml Carl Roth 4227.3 
Boric acid 1 kg Sigma-Aldrich B0252-1KG 
Brillant Blue G 250 10 g Carl Roth 9598.1 
Brillant Blue R 250 10 g Carl Roth 3862.1 
Bromophenol blue sodium salt 10 g Carl Roth A512.1 
Chloramphenicol 25 g Sigma-Aldrich C0378-25G 
Coomassie Plus Protein Assay  
Reagent for Bradford assays 
950 ml ThermoFisher 1856210 
cOmplete Mini, EDTA-free 25 tabs Roche 11836170001 
DL-Dithiothreitol (DTT) 5 g Sigma-Aldrich D0632-5G 
dNTP solution set 25 µM each NEB N0446S 
Ethanol >99.8 %, p.a. 2.5 l Carl Roth 9065.2 
Ethanol >99.8 % + 1 % MEK 2.5 l Carl Roth K928.1 
Ethidiumbromide solution, 0.5%  15 ml Carl Roth HP46.1 
Glycerine-solution for microscopy  Leica 11513872 
Glutathione Sepharose 4B 10 ml GE Healthcare  
Life Sciences 
17-0756-01 
Glycine, 99% 5 kg Carl Roth 3790.3 
Hydrochloric acid, Rotipuran, 25% 1 l Carl Roth 6331.1 
Immersion liquid, Type F  Leica 11513859 
Imidazole 500 g Sigma-Aldrich 56750-500G 
Isopropyl-β-D-1- 
thiogalactopyranoside (IPTG) 
5 g Sigma-Aldrich I6758-5G 
Isopropanol, >99.5% 2.5 l Carl Roth 9866.5 
Kanamycin B sulfate salt 250 mg Sigma-Aldrich B5264-250MG 
LB-Medium  
(Luria/Miller; 10 g/l NaCl) 
5 kg Carl Roth X968.4 
 
L-Glutathione reduced, >98% 25 g Sigma-Aldrich G4251-25G 
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LuminataTM Forte Western HRP 
Substrate 
100 ml Merck-Millipore WBLUF0100 
Magnesium chloride hexahydrate 100 g Sigma-Aldrich M2670-100G 
Methanol, LiChrosolv 2.5 l Merck-Millipore 1.06007.2500 
Milk powder 500 g Carl Roth T145.2 
MOWIOL 4-88 Reagent 100 g Calbiochem 475904 
N-propyl-gallate 100 g Sigma-Aldrich P3130 
Ni-NTA Agarose 25 ml Qiagen 1018244 
Nonidet P-40 BioChemica (NP-40) 500 ml AppliChem A1694,0500 
Paraformaldehyde 250 g Carl Roth 0335.1 
PBS-Buffer powder 10 l AppliChem A0965,9010 
peqGOLD 100bp DNA Ladder 50 µg PeqLab 25-2010 
peqGOLD 1kb DNA Ladder 5 x 50 µg PeqLab 25-2030 
Phenylmethylsulfonylfluorid, PMSF 5 g Sigma-Aldrich P-7626-5G 
Ponceau S, practical grade 50 g Sigma-Aldrich P3504-50G 
Protein G-Agarose 5 ml Roche 11243233001 
Protran® Nitrocellulose Transfer 
Membrane BA85, 0.45 μm 
 Whatman 10401196 
Precision Plus Protein  
Dual Color Standards 
500 µl Bio-Rad 161-0374 
RNAse away  Molecular Bioproducts 7000 
Rotiphorese Gel 30,  
Acrylamid/Bis-Acrylamid solution 
1 l Carl Roth 3029.1 
Rubidium chloride, >99%, p.a. 10 g Carl Roth 4471.1 
Select agar 250 g Sigma-Aldrich A5054-250G 
Sodium chloride, >98% 1 kg Sigma-Aldrich S3014-1KG 
Sodium dodecyl sulfate (SDS) 500 g Sigma-Aldrich L4390-500G 
Sodium fluoride 100 g Fluka 71519 
Sodium hydroxide pellets  Merck 106462 
Sodium orthovanadate 10 g Sigma-Aldrich 450243-10G 
TEMED 100 ml Sigma-Aldrich T9281 
Triton X-100, for molecular biology 100 ml Sigma-Aldrich T8787-100ML 
Trizma base 5 kg Sigma T1503-5KG 
Tween 20, BioChemica 500 ml AppliChem A1389,0500 
UltraPure™ Agarose 100 g ThermoFisher 16500100 
Table 27 | Overview on chemicals. 
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6.9 Cell culture media, reagents and supplements 
Article Quantity Company Order number 
D-MEM (HG) W/O NA PYR (CE) 500 ml ThermoFisher 41965-062  
Dimethyl sulfoxide (DMSO),  
Hybri-Max 
5 x 10 ml Sigma-Aldrich D2650 
HyClone FetalClone III Serum (FCS III) 
   Lot: AVL90602 
500 ml GE Healthcare 
Life Sciences 
SH30109.03 
L-Glutamine; 200 mM 100 ml ThermoFisher 25030024 
Lipofectamine reagent 1 ml ThermoFisher 18324012 
Dulbecco’s Phosphate  
Buffered Saline (PBS) 
500 ml Sigma-Aldrich D8537 
Penicillin/Streptomycin solution 100 ml ThermoFisher 15140122 
Poly-L-Lysine 50 ml Sigma-Aldrich P4707 
Trypan Blue solution (0.4%, sterile-
filtered, suitable for cell culture) 
100 ml Sigma-Aldrich T8154-100ML 
Trypsin-EDTA (0.05%) 100 ml ThermoFisher 25300054 
Water, sterile filtered, BioReagent, 
suitable for cell culture 
1 l Sigma-Aldrich W3500-1L 
Table 28 | Overview on cell culture media, reagents and supplements. 
 
 
6.10 Kits 
Kit Company Order number 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel REF 740609.50 
QIAGEN® OneStep RT-PCR Kit Qiagen 210210 
QIAGEN® Plasmid Maxi Kit (25) Qiagen 12163 
QIAprep® Spin Miniprep Kit (250) Qiagen 27106 
QuikChange® Site-Directed Mutagenesis Kit Stratagene 200518 
Table 29 | Overview on kits. 
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6.11 Equipment 
Article Company Order number 
ÄKTApurifier GE Healthcare Life Sciences  
Cell counting chamber  
(Neubauer, depth: 0.1 mm; 0.0025 mm2) 
Marienfeld-Superior 0640010 
Centrifuge, 5417 R, refrigerated Eppendorf  
Centrifuge, 5424 Eppendorf  
Centrifuge, Multifuge 1 s-r, refrigerated Heraeus 75004331 
Centrifuge, refrigerated, BC Avanti J-26 XP Beckman Coulter JXS 10 G30 
Centrifuge bottle, polycarbonate, 50 ml Beckman Coulter 357000 
Centrifuge bottle, polypropylene, 1000 ml Beckman Coulter 366752 
E-Box 3026 WL-26M (UV-Transilluminator) PeqLab  
Forma Orbital Shaker, 37°C Thermo Scientific  
Forma Orbital Shaker, refrigerated Thermo Scientific  
GeneQuant 1300 GE Healthcare Life Sciences 28-9182-13 
ImageQuant LAS 4000  GE Healthcare Life Sciences 28-9558-10 
JA-25.50 rotor for Avanti J-26 XP Beckman Coulter S/N 10E 2140 
JLA-8.1000 rotor for Avanti J-26 XP Beckman Coulter 969329 
High Load™ 16/60 Superdex 200 pg GE Healthcare Life Sciences 28989335 
Leica AF6000 LX Life Cell Imaging System Leica  
Mastercycler ep gradient S Eppendorf 5345 000.510 
Mini Trans-Blot® Cell Bio-Rad 170-3930 
PowerPac™ 300 Bio-Rad 165-5051 
PowerPac™ Basic Power Supply Bio-Rad 164-5050 
Spectrofluorometer, Fluoromax-4 Horiba, Jobin Yvon  
TissueRuptor Qiagen 9001272 
Water bath Memmert  
Table 30 | Equipment overview. 
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6.12 Disposable materials 
Article Company Order number 
Amicon Ultra, 30K, Centrifugal filters Millipore UFC803024 
Amicon Ultra-4, 50K, Centrifugal filters Millipore UFC805024 
Autoclave indicator tape (120°C) A. Hartenstein STKD 
Blotting papers, Grade 3 MM Chr Whatman 3030.917 
Cell culture dish (100 x 20 mm) Greiner Bio-One 664160 
Cell culture plate (6-well) Greiner Bio-One 657160 
Cellstar tubes, canonical (15 ml) Greiner Bio-One 188 271 
Cellstar tubes, canonical (50 ml) Greiner Bio-One 227 261 
CryoTube Vials (1 ml) Nunc 366656 
Microscope cover glasses, 15 mm A. Hartenstein DKR2 
Microscope slides, Menzel-Gläser,  
   Superfrost Plus 
Thermo Scientific J1800AMNZ 
Needles, BD Microlance 3, 20G x 1.5“ BD Biosciences 301300 
Parafilm® “M” Laboratory Film Pechiney Plastic Packaging PM-996 
Pasteur pipettes A. Hartenstein PP07 
PCR SoftTubes (0.2 ml) Biozym 710920 
Petri dishes (94 x 16 mm) A. Hartenstein PP90 
Pipette tips, blue (100-1000 μl) Axygen T-1000-B 
Pipette tips, white (0.5-10 μl) Axygen T-300 
Pipette tips, yellow (2-200 μl) Sarstedt 70.760.002 
Reaction tubes (1.5 ml) A. Hartenstein RK1G 
Reaction tubes (2.0 ml) A. Hartenstein RK2G 
Syringe (2 ml) BD Biosciences 237 
Syringe (10 ml) BD Biosciences 274 
Syringe with needle, 1 ml 26G x 3/8“, Luer BD Biosciences 300015 
T25 cell culture flask (25 cm2, 50 ml) Sarstedt 83.1810.002 
T75 cell culture flask (75 cm2, 250 ml) Sarstedt 83.1813.002 
Transfection tubes (5 ml, 75 x 12 mm) Sarstedt 55.476.013 
Ventilation cap tubes (14 ml) Sarstedt 62.515.006 
Videoprinter paper VWR   PEQRCD80E1091 
WillCo-Dish (Glass-bottom dish; 40 mm) WillCo Wells B.V. GWSt-5040 
Table 31 | Overview on disposables. 
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A 
aa · Amino acid 
AAA · ATPases Associated with Diverse Activities 
ABD · F-actin binding domain 
AcGFP · Aequorea coerulescens GFP 
ADF · Actin depolymerising factor 
ADP · Adenosine diphosphate 
AMPA · α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
Arf · ADP-ribosylation factor 
Arp2/3 · Actin-related protein 2/3 
ARPC · Arp complex protein 
ATP · Adenosine triphosphate 
B 
bp · Base pair 
Br · Brachydanio rerio 
BSA · Bovine serum albumine 
C 
Caax · Cysteine-aliphatic-aliphatic-arbitrary 
cAMP · Cyclic adenosine monophosphate 
Capu · Cappucino 
cDNA · Complementary DNA 
CIP · Calf intestinal alkaline phosphatase 
CMV · Cytomegalovirus 
Cobl · Cordon-bleu 
Co-IP · Co-immunoprecipitation 
Crag · Calmodulin-binding protein related to a Rab3 
GDP/GTP exchange protein 
CRISPR · Clustered Regularly Interspaced Short 
Palindromic Repeats 
CV · Column volume 
Cy5 · Cyanine dye 5 
D 
DENN · Differentially expressed in normal and neoplastic 
cells 
DFV · Discoidal/fusiform-shaped vesicle 
DLC2 · Dynein light chain 2 
DLIC · Dynein light intermediate chain 
DMEM · Dulbecco’s modified eagle’s medium 
Dm-MyoV · Drosophila myosin V 
DMSO · Dimethylsulfoxide 
dNTP · 2´-Desoxyribonucleosid-5´-triphosphate 
dRab11 · Drosophila Rab11 
DTE · 1,4-Dithioerythritol 
E 
EB · Elution buffer 
ECM · Extracellular matrix 
EDTA · Ethylenediaminetetraacetate 
EE · Early endosome 
EEA1 · Early endosome antigen 1 
EFBD · exon-F binding domain 
EGF · Epidermal growth factor 
eGFP · Enhanced GFP 
EHD1 · Eps-15-homology domain-containing protein 1 
EHD3 · Eps-15-homology domain-containing protein 3 
ER · Endoplasmatic reticulum 
ERM · Ezrin-radixin-moesin 
Evi5 · ecotropic viral integration site 5 protein 
F 
F-actin · Filamentous actin 
FCCS · Fluorescence cross-correlation spectroscopy 
FCS · Fluorescence correlation spectroscopy 
FCSIII · Fetal calf serum III 
FH · Formin-homology domain 
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FL · Full-length 
FLIM-FRET · Fluorescence lifetime microscopy-Förster 
resonance energy transfer 
FMN · Formin family formin 
FMN-2 · Formin-2 
FSI · Formin/Spir interaction sequence 
FYVE · Fab1, YOTB/ZK632.12, Vac1, EEA1 
G 
G-actin · Globular actin 
GAP · GTPase activating protein 
GDF · GDI displacement factor 
GDI · Guanine nucleotide dissociation inhibitor 
GDP · Guanosine diphosphate 
GEF · Guanine nucleotide exchange factor 
GFP · Green fluorescent protein 
Gg · Gallus gallus 
GluA1 · Glutamate ionotropic receptor AMPA type 
subunit 1 
GLUT4 · Glucose transporter type 4 
GS · Griscelli syndrome 
GST · Glutathione-S-transferase 
GTBM · Globular tail domain binding motif 
GTD · Globular tail domain 
GTP · Guanosine triphosphate 
H 
HCl · Hydrochloric acid 
HEK293 · Human embryonic kidney 293 cells 
HeLa · Human cervix carcinoma cells 
HIV · Human immunodeficiency virus 
HPLC · High pressure liquid chromatography 
HRP · Horse-radish-peroxidase 
Hs · Homo sapiens 
I 
IC · Intermediate compartment 
Ile · Isoleucine 
INF2 · Inverted formin 2 
IPTG · Isopropyl-β-D-thiogalactopyranoside 
IQ motif · Isoleucine glutamine motif 
J 
JMY · Junction-mediating and regulatory protein 
JNK · Jun N-terminal kinase 
K 
KCl · Potassium chloride 
kDa · Kilodalton 
KH2PO4 · Potassium dihydrogen phosphate 
KIF · Kinesin superfamily 
KIND · Kinase non-catalytic C-lobe domain 
KW · KIND-WH2 
KWM · KIND-WH2-GTBM 
L 
LALA · L408,409A 
LB0 · Lysogeny broth 
LE/MVB · Late endosome/multi-vesicular body 
Lmod · Leiomodin 
LTP · Long-term potentiation 
M 
mA · Milliampere 
MaxiPrep · Plasmid-Maxi-Purification 
MDa · Megadalton 
mDia1 · Mammalian Dia 1 
MgCl2 · Magnesium chloride 
MIN · Multifunctional Integrase 
MiniPrep · Plasmid-Mini-Purification 
MLPH · Melanophilin 
mM · Millimolar 
Mm · Mus musculus 
MMP · Matrix metalloproteinase 
mRNA · Messenger RNA 
MSF · GTBM-SB-FYVE 
MT-MMP · Membrane-type matrix metalloproteinase 
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MTOC · Microtubule organising centre 
Myo1E · Myosin 1E 
Myo1p · Myosin 1 (Yeast) 
Myo5p · Myosin 5 (Yeast) 
myoB · Myosin IB (Dictyostelium) 
myoC · Myosin IC (Dictyostelium) 
MyoIb · Myosin Ib 
MyoVa · Myosin Va 
MyoVb · Myosin Vb 
MyoVc · Myosin Vc 
MyRIP · Myosin and Rab interacting protein 
N 
Na2HPO4 · Sodium hydrogen phosphate 
Na3VO4 · Sodium orthovanadate 
NaCl · Sodium chloride 
NaF · Sodium fluoride 
Ncd · Nonclaret disjunctional 
NEB · New England Biolabs 
NPF · Nucleation promoting factor 
NT3 · Wash Buffer 
NTA · Nitrilotetraacetat 
NTI · Binding Buffer 
O 
oN · Over night 
P 
PAGE · Polyacrylamide gelelectrophoresis 
PBS · Phosphate buffered saline 
PBST · PBS/Tween20 
PCC · Pearson Correlation Coefficient 
PCR · Polymerase chain reaction 
PEM-5 · Posterior end mark-5 
Phe · Phenylalanine 
Pi · Inorganic phosphate 
PIP3 · Phosphatidylinositol-3,4,5-trisphosphate 
PMSF · Phenylmethylsulfonylfluoride 
PSD · Postsynaptic densities 
R 
Rab · Ras-like in brain 
Rab11-FIP · Rab11 family-interacting protein 
Ran · Ras-like nuclear 
Ras · Rat sarcoma 
RCP · Rab coupling protein 
RE · Recycling endosome 
REI-1 · RAB-11-interacting protein-1 
REP · Rab escort protein 
Rho · Ras homology 
Rip11 · Rab11-interacting protein 
RT · Room temperature 
RT-PCR · Reverse transcriptase PCR 
S 
SB · Spir-box 
SDS · Sodium dodecyl sulfate 
SEC · Size exclusion chromatography 
SEM · Standard error of mean 
SF · SB-FYVE 
SHD · Synaptotagmin homology domains 
She3 · Swi5-dependent HO expression 3 protein 
Slac-2a · Slp Homolog Lacking C2 Domains A 
Slac-2c · Slp Homolog Lacking C2 Domains C 
SNARE · Soluble NSF Attachment Protein Receptor 
Spir2-KW · Spir-2-KIND-WH2 
Spir2-KWM · Spir-2-KIND-WH2-GTBM 
Spir2-MSF · Spir-2-GTBM-SB-FYVE 
T 
TA · Annealing temperature 
TBC · Tre2/Bub2/Cdc16 
TBE · Tris-borate-EDTA 
tE · Elongation time 
TEV · Tobacco Etch Virus 
TGN · Trans-Golgi network 
TH1 · Tail homology 1 domain 
TIRF · Total internal refelction 
TLR4 · Toll-like receptor 4 
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Tm · Melting temperature 
TRITC · 5(6)-Tetramethylrhodaminisothiocyanat 
Tyrp1 · Tyrosinase-related protein 1 
Tyrp2 · Tyrosinase-related protein 2 
V 
Val · Valine 
Vangl2 · Vang-like protein 2 
Vrp1p · Verprolin 1 (Yeast) 
VSV · Vesicular stomatitis virus 
W 
WASP · Wiskott-Aldrich syndrome protein 
WAVE · WASP-family verprolin homology 
WH2 · Wiskott-Aldrich syndrome protein homology 2 
Wsp1p · Wiskott-Aldrich syndrome protein 1 (Yeast) 
X 
Xt · Xenopus tropicalis 
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